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1. INTRODUCTION 
 
1.1. ANTIDEPRESSANTS 
 
 Depression is the most common mental disorder that affects a large 
number of individuals in all countries. However, depression is under 
diagnosed and frequently under treated. [Audrius Sveikata et al., 2002]. 
Recent evidence suggests that depressive episodes, if left untreated, may 
heighten severity of subsequent episodes and may increase need for more 
health care resources. 
 
 The importance of depression as a major public health problem is 
emphasized by finding its place in the range of global burden of diseases. 
Depression was the fourth largest cause of disease worldwide in 1990, and by 
2020 it is expected to be the second largest cause of disease. [Lopcz AD et 
al., 1996]. This problem can become chronic or recurrent and lead to 
substantial impairments in an individual’s ability to take care of his/her 
everyday responsibility. At its worst, depression can lead to suicide, a tragic 
fatality associated with the loss of about 850 000 lives every year [WHO, 
2005] 
 
 As per World Health Organization,  
? Depression is common, affecting about 121 million people worldwide.  
? Depression occurs in persons of all genders and ages. 
? Depression is among the leading causes of disability worldwide. 
? Depression can be reliably diagnosed and treated in primary care. 
? Fewer than 25% of those affected have access to effective treatments. 
 
 Antidepressant medications and brief forms of psychotherapy are 
effective for 60 –80 % of those affected and can be delivered in primary care. 
However, fewer than 25% of those affected (in some countries fewer than 
10%) received such treatment. 
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 Over 10% of the population will have depression within their lifetime. 
The range of lifetime risk for major depressive disorder in community samples 
is from 10 to 25% for women and 5 to 12% for men. Some individuals have 
only a single episode with full return to premorbid functioning; however, 50 to 
85 % have recurrence of depression. 
 
 Antidepressants are the drugs which relieve the symptoms of major 
depressive disorders and may results in an increased output of behaviour. 
Antidepressants are as a class of psychotropic medication has the following 
broad range of indications [Janicak PG et al., 2001]. 
 
? Mood disorders:  
? Major depressive disorder, bipolar disorder, cyclothymic disorder,   
dysthymic disorder. 
? Psychotic disorders: 
? Substance-induced mood disorders: 
? Sleep disorders 
? Anxiety disorders 
? Eating disorders 
? Substance related disorders 
? Others: Pain syndromes, irritable bowel syndrome, enuresis, 
arrhythmia and some immune dysfunction. 
 
1.1.1. Classification of Antidepressants: 
 
 Contemporary antidepressant classification system is based on the 
mechanism of action, which is presumed to be responsible for their 
antidepressant effects. A pharmacodynamic system of classification has 
advantages because it incorporates the current theories of disease 
pathophysiology. This system can easily accommodate new agents as they 
become available because it is based on the established pharmacology of 
drugs. According to this the currently available antidepressant drugs are 
classified into the following categories. [Beers MH et al., 1999; Kent JM, 2000; 
Davis KL et al., 2002; Stahl SM 1998]. 
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[1] Non- selective antidepressants 
 
(a) Serotonin and noradrenaline reuptake inhibition with effects on multiple  
      receptors system and sodium conductance.  
 E.g. Tricyclic antidepressants [TCAs] 
(b) Monoamine oxidase inhibitors. [MAOIs] 
 
[2] Selective reuptake inhibitors 
 
(a) Selective serotonin reuptake inhibitors. [SSRIs] 
(b) Selective noradrenaline reuptake inhibitors. [NARIs] 
(c) Serotonin and noradrenaline reuptake inhibitors. [SNRIs] 
(d) Noradrenaline and dopamine reuptake inhibitors. [NDRIs] 
 
[3] Receptor blockers 
 
(a) Serotonin [5-HT2A, 5HT2C and 5HT3] receptor blockade with 
noradrenalin (alpha-2) receptor blockade [Noradrenergic and specific 
serotonergic antidepressant] (NaSSA) 
(b) Serotonin (5HT2A) receptor blockade with serotonin reuptake 
inhibitors. 
 
[4] Others 
 
 Clinically it seems that inhibitors of noradrenaline reuptake and 5-HT 
(5-Hydroxy Tryptamine, Serotonin) reuptake are equally effective as an 
antidepressant. From the pharmacological studies of reserpine, it was 
postulated that depression must be associated with decreased functional 
amine dependant synaptic transmission. This idea provided the basis for what 
become know as amine hypothesis of depression. While the amine 
hypothesis is undoubtedly too simplistic, it has provided the major 
experimental models for the discovery of new antidepressant drugs. As a 
result all currently available antidepressant drugs except bupropion are having 
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their primary action on the metabolism, reuptake, or selective receptor 
antagonism of noradrenaline, serotonin or both. 
 
[1] Non selective antidepressants   
 
 The history of antidepressant pharmacotherapy begins with the tricyclic 
antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). Both of 
these classes of antidepressants were successful and were discovered by 
chance. [Janicak PG et al., 2001]. The first antidepressant tricyclic and 
monoamine oxidase inhibitors became available in the late 1950s. 
 
(a) Tricyclic antidepressants (TCAs) 
 
Tricyclic antidepressants are an important group of antidepressants in clinical 
use. They are, however, far from ideal in practice. Most of the tricyclic 
antidepressants are derivatives of dibenzazepine or structurally related 
compounds. Structurally they are closely related to phenothiazine derivatives, 
which are one of the potential antipsychotic agents. Sulphur in aromatic 
linkages has been known to be isosteric to –CH=CH- . Replacement of 
sulphur of phenothiazine with –CH=CH- could give dibenzazepine system, 
with seven membered central ring and saturation of –CH=CH- to –CH2CH2-
could lead to the 10, 11- dihydro derivatives. Imipramine and clomipramine 
were found to be no use in schizophrenia but effective against depression. 
Similar changes to the structure of thioxanthene type antipsychotic drugs 
resulted in drugs such as amitriptyline. They differ from phenothiazine and 
thioxanthene principally in the incorporation of an extra atom in the central 
ring which twists the structure, so that molecule in no longer planner as in 
phenothiazine and thioxanthere. [Kadam SS et al., 2006]. All these 
compounds are tertiary amines, with two methyl groups attached to the basic 
nitrogen atom. They are quite rapidly demethylated in vivo, to corresponding 
secondary amines (desipramine, nortriptyline) which are themselve active 
other tricyclic derivatives with slightly modified bridge structures include 
doxapine, amoxapine and dithiapine. 
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(i) Phenothiazine      Dibenzazepine 
    (Antipsychotics)      (Antidepressants) 
 
N
S
N
Me
Me
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2
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Me
MeR
R
1
2
 
 
 
(ii) Thioxanthene       Dibenzocycloheptane 
     (Antipsychotics)      (Antidepressants) 
 
S
N
Me
Me
R
R1
2
  
N
Me
MeR
R
1
2
 
 
Mechanism of action: 
 
  Tricyclic antidepressants potentiate central noradrenergic and 
serotonergic function. They inhibit the reuptake of norepinephrine and 
serotonin by neuron terminals by competition for the binding site of transport 
protein. Synthesis of amines, storage in synaptic vesicles and release are not 
directly affected, though some TCAs appears to increase transmitter release 
indirectly by blocking alpha-2 adreno receptors. Most TCAs inhibit the 
reuptake of norepinephrine and 5-HT but much less effect on dopamine 
reuptake. It improves emotional symptoms mainly an enhancement of 5HT 
mediated transmission where as relief to biological symptoms results from 
facilitation of norepinephrine transmission. 
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  The choice of initial antidepressant legitimately varies 
considerably among clinicians and countries [Gelder MG et al., 2000]. 
 
(b) Monoamine oxidase inhibitors: 
 
The potential of monoamine oxidase inhibitors as an antidepressant was 
discovered accidentally. In 1951, isoniazid came to be recognized as an 
effective tuberculostatic agent. A year later its N-isopropyl derivative, 
iproniazid, was made available for treating tuberculosis. Amazingly, it was 
observed that iproniazid had mood elevating effects in patients. Soon after 
many hydrazine derivatives were found to be active as such. The action and 
use are very similar to tricyclic antidrepressants, i.e., they inhibit the reuptake 
of nor epinephrine and serotonin by neuron terminals. Monoamine oxidase 
inhibitors have been employed less often than the tricyclic antidepressants, 
probably because of the possibility of drug interaction and dietary precautions 
that are required to be observed.  
 
[2] Selective reuptake inhibitors 
 
(a) Selective serotonin reuptake inhibitors [SSRIs] 
 
 Selective serotonin reuptake inhibitors are so called, because they 
selectively inhibit the reuptake of serotonin [5-HT] from the synaptic gap. The 
simplified concept of selective serotonin reuptake inhibitors is usually used to 
describe how these agents work but it does not describe important features of 
the group as a whole and of the individual agents. An important consequence 
of increasing serotonin is the stimulation of post synaptic serotonergic 
receptors. There are many subtypes of serotonergic receptors. There is an 
opinion that stimulation of serotonin 2C [5HT-2C] receptors in the CNS is 
responsible for the increase of anxiety that is often associated with early 
stages of SSRIs therapy [Audrius sveikata et al., 2002]. Stimulation of 5HT3 
and 5HT4 receptors in the gut is thought to account for the nausea and 
gastrointestinal upset that may occur in the first few days or weeks. 
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1.1.2. Fluoxetine hydrochloride 
 
Introduction: 
 
  Fluoxetine hydrochloride is a selective serotonin reuptake 
inhibitor which is clinically effective for the treatment of depression [Stark P et 
al., 1985]. Fluoxetine and its major metabolite norfluoxetine act as neuronal 
inhibitors of serotonin reuptake and result in both increased serotonin 
concentration at the synaptic cleft and autoreceptor stimulation [Schmidt MJ 
et at., 1988; Wong DT et al., 1975]. Fluoxetine hydrochloride has been shown 
to have comparable efficacy to tricyclic antidepressants but with fewer 
anticholinergic side effect [Chouinard G, 1985; Lader M, 1988]. Fluoxetine 
hydrochloride has been primarily studied for the treatment of depression, but 
more recently has been studied for the treatment of bulimia and severe 
obesity [Ferguson JM et al., 1987; Levina LR et al., 1987]. 
 
Chemical Name: 
  
d,1-N-methyl-3-phenyl-3-[(α, α, α-trifluoro-p-tolyl)oxy]polyamine hydrochloride 
 
OR 
 
[(3RS)-N-Methyl-3-phenyl-3-(4-trifluoromethyl phenoxy) propan-1-amine] 
hydrochloride 
 
 
 
Structural formula: 
 
F3C
O N
H
CH3
H
HCl
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Emperical formula: C17H18F3NO HCl 
 
Molecular Weight: 345.79 
 
Appearance, color and odour: 
 
  Fluoxetine hydrochloride is a white to off white, crystalline, odorless 
powder. 
 
Melting Point: 158.4 to 158.9 0C 
 
Solubility: 
  Fluoxetine hydrochloride is freely soluble in methanol and 
ethanol; soluble in acetonitrile, chloroform and acetone; slightly soluble in 
ethyl acetate, dichloromethane and water (With sonication at pH: 1.2, 4.5 and 
7.0). The maximum solubility of fluoxetine obtained in water is 14 mg/ml. 
Fluoxetine is essentially insoluble in toluene, cyclohexane and hexane. 
 
Stability: 
  Fluoxetine hydrochloride is a very stable molecule under normal 
storage conditions. The only known degradation products are α-[2(methyl 
amino) ethyl] benzene methanol and p-trifluoromethyl phenol. They are 
formed under acidic stress conditions (3mg fluoxetine/1ml 0.1 N HCl refluxed 
for 48 hrs) [Donald SR et al., 1990] or when irradiated for five hrs with a 
mercury arc lamp [Souter RW et al., 1976]. Fluoxetine hydrochloride is stable 
as the bulk drug stored at 25 0C for five years and at 50 0C for two years. 
 
Metabolism: 
 
  The main metabolite of fluoxetine is norfluoxetine, an active 
metabolite with similar physiological activity as its parent compound. 
Metabolism occurs in the liver by N-demethylation [Lemberger L et al., 1985; 
Aronoff GR et al., 1984]. Studies in animals have shown that fluoxetine is also 
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metabolized into p-trifluoromethylphenol by O-dealkylation. Other known 
metabolites include glucuronides of both fluoxetine and norfluoxetine. 
 
Mechanism of Action: 
 
  Fluoxetine and its major metabolite norfluoxetine act as 
neuronal inhibitors of serotonin reuptake and result in both increased 
serotonin concentration at the synaptic cleft. Fluoxetine has significant activity 
at serotonin 2C [5HT-2C] receptors, and serotonin 2C receptors are 
presumed to be involved in the regulation of appetite and food intake. The 
affinity for serotonin 2C receptors might explain why fluoxetine is also the 
SSRI that gained approval for eating disorders. Blockade of the 5HT-2C 
receptors may be involved in the alleviation of psychosis [Boet JA et al., 
2001]. Fluoxetine has some activity with noradrenaline reuptake inhibition as 
well [Shilash R. et al., 2000]. Fluoxetine also binds to cytochrome P450 3AG 
and 206, this is important for drug interaction. 
 
1.1.3. Sertraline hydrochloride 
 
Introduction: 
 
  Sertraline hydrochloride is an antidepressant for oral 
administration. It is chemically unrelated to trycyclic, tetracyclic, or other 
available antidepressants. It is a novel inhibitor of serotonin reuptake in the 
brain [Koe BK et al., 1983]. 
 
Chemical Name: 
 
(1S-Cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-
naphthalenamine hydrochloride [CAS-79559-97-0] 
Preferred use name. 
 
 
OR 
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Cis-(1S,4S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-
naphthalenamine hydrochloride [J. Med. Chem. 1984, 27(11), 1508] 
 
OR 
 
Cis-(1S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-
naphthalenamine hydrochloride [US Patent 4,536,518] 
 
Structural Formula: 
 
N
CH3H
Cl
Cl
HCl
 
 
• Empirical Formula: C17H18NCl3 
 
• Molecular Weight: 342.7 
 
• Appearance, Color, Odour: 
 
  Sertraline hydrochloride is a white to off-white, crystalline 
powder having no odour. It is an irritant, contact with skin and eyes should be 
avoided. 
• Melting Point:  245-250 0C 
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• Solubitity: 
 
  Sertraline hydrochloride is freely soluble in ethanol, chloroform, 
methanol, dimethyl sulfoxide and N,N-dimethyl formamide. Soluble in 
acetone, acetonitrile, isopropyl alcohol. The solubility of a saturated solution of 
sertraline hydrochloride in distilled water at room temperature is 3 mg/ml. The 
pH of this saturated solution is 5.3. The solubility in water is pH dependent; in 
acidic pH (i.e. 0 to 7 pH) it is freely soluble. As the pH of solution increase 
from 7 to 12, the solubility decreases and above12 pH, it is almost insoluble 
[Bruce M et al., 1996] 
 
• Stability: 
 
  Sertraline hydrochloride is a very stable molecule under normal 
storage condition as well as a variety of challenge conditions. The only trace 
degradation product identified was the ketone, i.e. [4-5-(3,4-dichlorophenyl)-
3,4-dihydro-1(2H)-naphthalenone] which was obtained under extreme 
conditions only (i.e. refluxing with 5 N HCl or with 5 N NaOH for 3 hrs]. The 
molecule is stable at 30 0C for 60 months. 
 
• Metabolism: 
 
  Sertraline undergoes extensive first pass metabolism. The 
principal initial pathway of metabolism for setraline is N-demethylation. N-
demethyl setraline has a plasma terminal elimination half-life of 62 to 104 hrs. 
The N-demethyl setraline is substantially less active than parent molecule. 
Both sertraline and N-demethyl setraline undergo oxidative deamination and 
subsequent reduction, hydroxylation and glucuronide conjugation. [Tremaine 
LM et al., 1989] 
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• Mechanism of action: 
 
   The mechanism of action of setraline is presumed to be linked to 
its inhibition of CNS neuronal uptake of serotonin [5HT]. In vitro studies have 
shown that sertraline has no significant affinity for adrenergic (alpha 1, alpha 
2, beta), chlolinergic, GABA, dopaminergic, histaminergic and serotonergic 
(5HT 1A, 5HT 1B, 5HT 2) or benzodiazepine receptors. Sertraline does not 
inhibits monoamine oxidase. 
 
(b) Selective noradrenaline reuptake inhibitors [NARIs] 
 
 Some TCAs (e.g. desipramine, nortriptyline) block noradrenaline 
reuptake more potently than serotonin reuptake. These TCAs are not really 
selective noradrenaline reuptake blockers since they block other receptors 
like H1, acetylcholine – M and noradrenaline α-1 receptors as well. The first 
really selective noradrenergic reuptake inhibitor (NARI) is reboxetine. 
Reboxetine does not inhibit electrically excitable membranes and for this 
reason overdose of reboxetine should not couse significant risk of 
cardiotoxicity or seizures. [Janicak PG et al., 2001; Mucci M, 1997]. The 
efficacy of reboxetine in anxiety and panic, not predicted from the known 
psychopharmacology of noradrenaline suggests a role for the noradrenaline 
pathway in anxiety and panic [Bruncllo N et al., 2002]. 
 
(c) Serotonin and nordrenaline reuptake inhibitors [SNRIs] 
 
 These drugs block the reuptake of serotonin and noradrenaline (like 
TCAs such as amitriptyline) but differ from TCAs by their lack of receptor 
blocking activity at H1, acetylcholine – M and noradrinaline α-1 and α-2 
receptors. They should also lack membrane stabilizing activity. They should 
therefore not cause sedation or postural hypotension or fatality in overdose.. 
 
 
 
 
 12
_______________________________________________________Introduction____  
1.1.4. Duloxetine hydrochloride 
 
• Introduction: 
 
  Duloxetine and venlafaxine are the new drugs in this group, 
which inhibit first serotonin reuptake and later they inhibit noradrenaline 
reuptake as well [Gabbard GO, 2001]. Duloxetine is official as hydrochloride 
salt. 
 
• Chemical Name: 
 
(+) – (S)- N-methyl-γ-(1-naphthyloxy)-2-thiophene propylamine hydrochloride 
 
• Structural Formula: 
 
NH
CH3
S
O
HCl
 
 
• Empirical Formula: C18H19NOS HCl 
 
• Molecular Formula: 333.88 
 
• Appearance, Color, Odour: 
  
           Duloxetine hydrochloride is a white to slightly brownish white solid, and     
           odourless. 
 
• Melting Point: 163-167 oC 
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• Solubility: 
 
 Duloxetine hydrochloride is freely soluble in methanol, ethanol, 
chloroform and dimethyl sulphoxide. Soluble in acetonitrile, and acetone. 
Slightly soluble in water. 
 
• Stability: 
 
 Duloxetine hydrochloride degraded in acidic media. So it is available as 
enteric coated pellets which prevent degradation of drug in acidic environment 
of the stomach while overall stable compound. 
 
• Metabolism: 
 
 The major biotransformation pathways for duloxetine involve oxidation 
of the naphthyl ring followed by conjugation and further oxidation. Both 
CYP2D6 and CYP1A2 catalyse the oxidation of the naphthyl ring in vitro. 
Metabolites found in plasma include 4-hydroxy duloxetine glucuronide and 5-
hydroxy, 6-hydroxy duloxetine sulphate. Many additional metabolites have 
been identified in urine. Most of (more than 70%) the duloxetine dose appears 
in the urine as metabolites of duloxetine, about 20% is excreted in the feces 
and only trace (< 1% of dose) amounts of unchanged duloxetine are present 
in the urine. 
 
• Mechanism of Action: 
 
 The antidepressant and pain inhibitory action of duloxetine is believed 
to be related to its potentiation of serotonergic and noradrenergic activity in 
the CNS. Preclinical studies have shown that duloxetine is a potent inhibitor of 
neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of 
dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, 
adrenergic, cholinergic, histaminergic, opioid, glutamate and GABA receptors 
in vitro. Duloxetine does not inhibit monoamine oxidase (MAO). Duloxetine 
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undergoes extensinve metabolism, but the major circulating metabolites have 
not been shown to contribute significantly to the pharmacologic activity of 
duloxetine [Cymbalta, Eli Lilly and Company, 2004]. 
 
(d) Noradrenaline and dopamine reuptake inhibitors [NDRIs] 
 
 Bupropion is a relatively week inhibitor of dopamine reuptake, with 
modest effects on noradrenaline reuptake and no effects on serotonin 
reuptake. It does not appear to be associated with down regulation of 
postsynaptic beta adrenergic receptors. However, presumed mechanism of 
action of bupropion is based on inhibition of reuptake of dopamine and 
noradrenaline. Its weak affinity for these reuptake pumps has raised questions 
whether these mechanisms are relevant to its antidepressant activity. The 
combined plasma concentration of bupropion and its three active metabolites, 
hydroxybupropion, threohydrobupropion, erythrohydrobupropion are 
responsible for the inhibition of both these pumps [ Schatzberg AI; 2001] 
 
[3] Receptor Blockers 
 
(a) Noradrenergic and specific serotonergic antidepressant [NaSSA] 
 
 The novel antidepressant mirtazapine has dual mode of action, it is a 
noradrenergic and specific serotonergic antidepressants that acts by 
antagonizing central alpha-2 adrenergic auto and hetero receptors, as well as 
by blocking 5-HT2 and 5-HT3 receptors. Mirtazapine enhances noradrenergic 
and serotonergic neurotransmission. Bioavailability of mirtazapine is 
approximately 50% peak plasma concentration is reached within 2 hours. The 
elimination half-life ranges from 20 to 40 hours. Mirtazapine has linear 
pharmacokinetics. It is approximately 85% bound to protein in plasma. 
Blockade of presynaptic central alpha-2 adrenergic autoreceptors leads to 
enhanced noradrenergic neurotransmission via increased noradrenergic cell 
firing and noradrenaline release. The overall effect of these pharmacological 
action is increased noradrenergic and 5HT1A activity [Sami AK; 2001] 
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(b) Serotonin (5-HT2A) receptor blockade with serotonin reuptake 
inhibitors 
 
 Mefazodone has selective and unique effects on the serotonin system. 
Mefazodone blocks serotonin reuptake, while functioning as a 5-HT2A 
receptor antagonist. Mefazodone has some unusual pharmacological 
properties. Mefazodone is metabolized by CYP303/4 to form the active 
metabolite m-chlorophenylpiperazine, which is a potent serotonin agonist. 
This metabolite is a 5-HT 2C agonist and could paradoxically cause anxiety 
and stimulation instead of anxiety reduction and sedation. Mefazodone has 
nonlinear kinetics, which results in greater than proportional mean plasma 
concentration with higher doses. The elimination half-live is 2-4 hours for the 
parent compound. Mefazodone is extensively (about 99%) but loosely bound 
to proteins [Schatzberg AI; 2001] 
 
[4] Others: 
 
 Tianeptine the drug that has been found to be an effective 
antidepressant. Tianeptine actually increases the uptake of serotonin into 
nerve endings, an effect that is opposite to the standard selective serotonin 
inhibitors. Tianeptine decreases both serotonin transporter mRNA and that of 
binding site [Schatzberg AI; 2001] 
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1.2 Antihypertensive drugs and angiotention – II antagonist 
 
 Hypertension is a common disorder, which, if not effectively treated, 
results in a greatly increased probability of coronary thrombosis, strokes and 
renal failure. Until about 1950, there was no effective treatment, and the 
development of antihypertensive drugs, which greatly increase life 
expectancy, has been a major, but largely unsung, therapeutic success story 
[Cohen JN; 1996]. 
 
 There are a few recognizable and surgically treatable causes of 
hypertension, such as phaeochromocytoma, steroid secreting tumours of the 
adrenal cortex, renal artery stenosis and so on, but the great majority of cases 
involves no obvious causative factor, and is grouped as essential 
hypertension. The pathophysiology is intimately related to the kidneys and 
leads to narrowing of the lumen of systemic arterioles. The raised peripheral 
vascular resistance calls into play various physiological responses ivolving the 
cardiovascular system, nervous system and kidney. The following figure 
summarises major physiological mechanisms that control arterial blood 
pressure, and shows the sites at which some antihypertensive drugs act. 
 
 In hypertension, the small arterioles used for transferring blood from 
the arteries to the tissue capillaries and venus circulation get under excessive 
stimulation of sympathetic nervous system. This may result arteriole 
contraction and increase peripheral resistance to the flow of blood. As a result 
blood pressure increases. The agents used to reduce blood pressure are 
known as antihypertensive agents. 
 
 The World Health Organization (WHO) has defined “Hypertension” as a 
state in which systolic pressure is 150 mm of Hg or more and diastolic 
pressure is 95 mm of Hg or more. As per the statistical data given by WHO in 
1990, every year approximately 15 million people have died due to heart 
disease. The renal and cardiovascular complications resulting from this 
prolong elevation of blood pressure. The drug therapy reduce cardiac output / 
or and reduce total peripheral resistance without correcting the cause. 
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For practical guidance, most physicians classified. 
? Diastolic pressure if 90 to 110 mm of Hg is consider as mild 
hypertension. 
? Diastolic pressure if 110 to 130 mm of Hg is consider as moderate 
hypertension. 
? Diastolic pressure if more than 130 mm of Hg is consider as severe 
hypertension. 
 
1.2.1. Classification of antihypertensive agents: 
 
 All currently available antihypertensive drugs act mainly by interfering 
with normal hemostatic mechanisms and this provides a useful basis for the 
classification of these drugs. They are classified as [Rang HP et al., 2003; 
Bruntoni LL et al., 2005; Satoskar RS et al., 2003]. 
 
(i) Drugs acting centrally:  
 E.g. Clonidine hydrochloride, Guanabenz, Guanfacine, Methyldopa,   
             Methyl dopate 
(ii) Ganglion blocking agents:  
 E.g. Mecamylamine hydrochloride, Pentolinium tartarate, Trimethaphan 
             camsylate 
 
(iii) Drugs acting on the post ganglionic sympathetic nerve ending: 
(a) Adrenergic neurone blockers: e.g. Gaunethidine, Bethanidine, 
 Bretylium 
(b) Catecholamine depletors: e.g. Reserpine, Deserpine, 
Rescinnamine 
(iv)  Drugs acting on adrenergic receptors 
(a) α–adrenergic blocking agents: e.g. Phentolamine, Prazosin,  
 Phenoxybenzamine 
(b) β – adrenergic blocking agents: e. g. Propanolol, Atenolol 
(c) Mixed blockers: e.g. Labetalol 
(d) Imidazole receptor antagonist: e.g. Ritmanidine 
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(v) Drugs acting directly on the vascular smooth muscles 
           (Vasodilators) 
(a) Arterial vasodilators:  
 e.g. Hydrallazine, Diazoxide, Minoxidil, Sodium nitropruside 
(b) Calcium Channel Blockers:  
 e.g. Nifedipine, Amlodipine, Verapamil, Diltiazem 
(vi) Drugs acting on Renin Angiotensin System 
(a) Drug blocks rennin release: e.g. Propranolol, Clonidine 
(b) Angiotensin Converting Enzyme inhibitors: e.g. Captopril, 
Lisinopril, 
 Ramipril 
(c) Angiotensin – II antagonists: e.g. Saralasin 
(d) Angiotensin – II (Specific AT1) receptor blockers: e.g. Losartan,  
 Valsartan, Candesartan, Olmesartan, Irbesartan 
(e) Aldosterone antagonist: e.g. Spironolactone 
(vii) Diuretics: 
(a) Thiazides: e.g. Hydrochlorothiazide 
(b) Loop diuretics: e.g. Furosemide 
(c) Potassium sparing diuretics: e.g Triamterene, Amiloride 
(viii)  Drug act by reflex mechanism: e.g. Veratrum alkaloid 
 
1.2.2. Drugs acting on renin angiotensin system 
 
 Renin is a proteolytic enzyme having molecular weight 42000 and 
stored in the granules of the juxtaglomerular cell in the walls of the afferent 
arterioles of the kidney. Upon release into the renal arterial blood stream, 
rennin catalyses the conversion of angiotensinogen as per following chart. 
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Angiotensinogen (Plasma α2 – globulin)  
(An inactive precursor) 
 
            Renin 
 
Angiotensin – I (Decapeptide synthesize in liver) 
 
                                                               Angiotensin Coverting Enzyme (ACE) 
 
               Angiotensin – II (Octapeptide most potent vasoconstrictors) 
 
                                                                Aminopeptidase enzyme (Hydrolysis    
                                                                which lead to loss of one Amino acid) 
Angiotensin – III (Heptapeptide active intermediate) 
 
 
                                                                Aminopeptidase carboxypeptidase &  
                                                                andopeptidase 
 
Inactive peptide fragmets 
  
 The rennin angiotensin system is an important part of homeostatic 
mechanism in the body. It works to maintain the blood pressure at the normal 
level. It also regulates the electrolyte balance by controlling aldosterone 
biosynthesis and release from adrenal cortex. Similarly the juxtaglomerular 
cells are directly innerved by central sympathetic nerves. Hence under the 
conditions of strain and stress, the sympathetic stimulation may lead to 
hypertension due to the activation of rennin angiotensin system [Kadam SS et 
al., 2006] 
 
 The rennin angiotensin system plays a determinant role in the 
regulation of blood pressure. Angiotensins are potent vasoconstrictors. They 
tend to increase the peripheral vascular resistance. The octapeptide hormone 
angiotensin – II is the active product of rennin angiotensin system which 
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causes vasoconstriction when binds to AT1 receptor. The angiotensin induced 
release of aldosterone increases the sodium ion retention in plasma, resulting 
into an increase in plasma volume. The overall result of all these effects is 
hypertension. Hence one can expect that angiotensin antagonists would be 
effective antihypertensive agents. This expectation was proved to be correct 
by the development of saralasin (1971) and captopril (1977), each being the 
member of two distinct classes [Goodfriend TL et al., 1996]. 
 
 AT1 antagonists constitute the most recent class of them. They block 
the receptor in a competitive or insurmountable way so that angiotensin – II 
cannot bind at the active site. The discovery by Dufont group of a series of 
(biphenylmethyl) imidazoles as nonpeptidic potent and orally active 
angiotensin – II receptor (AT1 subtype) antagonists has opened up a 
completely new field in angiotensin – II antagonist research. Losartan is 
parent molecule of this class. A number of studies have appeared in which the 
imidazole moiety of losartan is successively replaced by other heterocycles 
indicating the AT1 receptor is quite permissive in accepting this region of the 
nonpeptide antagonist. This leads to the generation of more potent drugs 
valsartan, irbesartan, candesartan, olmesartan and eprosartan [Dzau VJ et 
al., 1993; Timmermans PB et al., 1993]. 
 
 
1.2.3. Valsartan 
 
• Introduction: 
 
 Valsartan, a specific angiotensin – II antagonist, is used alone or with 
other antihypertensive agents to treat hypertension. It is competitively blocks 
the binding of angiotensin – II to type I angiotensin (AT1) receptor and 
therefore block the effects of angiotensin more selectively than do the ACE 
inhibitors. It reduces the angiotensin induced vasoconstriction, sodium 
reabsorption and aldosterone release. It does not inhibit the breakdown of 
bradykinin. 
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• Chemical Name: 
  
N-(1-oxopentyl)-N-[{2-(1H-tetrazol-5-yl)- (1,1-biphenyl) -4-yl}methyl]-L-valine 
 
OR 
 
N-[p-(o-1H-Tetrazol-5-ylphenyl) benzyl]-N-valeryl-1-valine 
 
 
Structural formula: 
 
N
NN
NH
N
O
COOH
 
 
• Empirical Formula: C24H29N5O3 
 
• Molecular weight: 435.5 
 
• Appearance, Color and Odour: 
  
           A white or almost white practically odourless amorphous powder. 
 
• Melting Point: 108 – 110 0C  
 
• Solubility:  
 
 Valsartan is freely soluble in methanol, ethanol and chloroform. Soluble 
in water, phosphate buffer at pH 7.4 and in acid solution.  
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• Stability:  
 
 Valsartan is a very stable molecule under normal storage conditions. 
 
• Mechanism of Action: 
 
 Valsartan compete with angiotensin – II for binding at the AT1 receptor 
subtype. As angiotensin – II is a vasoconstrictor, which also stimulates the 
synthesis and release of aldosterone, blockage of its effects results in a 
decrease in systemic vascular resistance. AT1 receptor antagonists could be 
more effective than ACE inhibitors (e.g. captopril, enalepril, lisinopril etc.). AT1 
receptor antagonist does not cause the dry cough that is sometimes caused 
by ACE inhibitors. 
 
• Metabolism and Elimination: 
 
 Excretion of valsartan is rapid, with complete elimination demonstrable 
at 48 hrs. Valsartan is predominantly excreted unchanged in the bile and, to a 
lesser extent, in urine. The hepatic route constitutes the major route of 
excretion 94 – 96 % of the delivered dose may be recovered in the feces. 
Oxidation biotransformation of valsartan in the liver is slow and constitutes 
only a very small fraction of total drug elimination. Metabolites in the excreta 
include the tetra – N – glucose conjugate, the tetrazole biphenyl methanolic 
acid derivative in mice and the valeryl – 4 – hydroxyl valsartan derivative. 
Small amounts of other metabolites may also be detected in the liver, 
including an acylglucoride conjugate. Additional racemization does not occur 
in vivo when valsartan is administered orally [Hein L et al., 1995]. 
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1.3. ION PAIR COMPLEXES: 
 
Many amines and quaternary ammonium compounds can be 
determined in aqueous solution by forming a salt or ion pair between the 
positively charged or negatively charged nitrogenous compound and, an 
opposite charged dye or indicator molecule. This ion-pair formed is extracted 
into an organic solvent and concentration of extracted dye is measured 
spectrophotometrically. This technique is called ion pair extraction technique 
(Sethi PD; 1997).  
 
1.3.1. Types: 
 
There are two types of ion-pair extraction technique. 
 
1. Acid dye method 
 
 Here drug is positively charged and dye is acidic in nature and 
negatively charged as anionic form at given pH. 
 
2. Basic dye method 
 
 Here drug is negatively charged and dye is basic in nature and 
positively charged as cationic form at given pH. 
 
The acidic and basic dye techniques are important analytical application of 
phase transfer principle to the colorimetric determination of various amines 
(Kenneth A; 1982). 
 
1.3.2. Principle: 
 
Colorimetric analysis also can be based on molecular complex 
formation. Recall that charge-transfer complexation often is accompanied by 
the development of an intense charge-transfer absorption band and this can 
be put to analytical use for example, tertiary amines can be determined 
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spectrophotometrically by complexation with tetracyanoethylene. Many 
complex formation reactions are used in conjunction with or as the basis for a 
separation either by liquid-liquid extraction or chromatography (Alfonso R. 
Gennaro, 2000). 
 
 The acid-dye technique is an important analytical application of phase 
transfer principle for the colorimetric determination of amines (Higuchi, T. 
1961).  
 
 A weakly acidic acid-base indicator (the acid or basic dye) that ionizes 
to produce an anion is added to an aqueous solution of an amine, the pH 
being adjusted so the dye is predominantly in the ionized state. If, at this pH 
the amine is protonated, an ion pair is formed and this ion pair is extracted 
into an organic solvent, where the concentration of the extracted dye (which is 
equal to the concentration of the amine) is measured spectrophotometrically. 
The technique is also applicable to the determination of quaternary 
ammonium compounds. If the amine is not protonated, evidently an ion pair 
cannot be formed, but an extractable association complex may be formed 
from the anionic dye and the neutral amine (Kenneth A Connors, 1982). 
 
The equilibrium expression for ion-pair formation can be expressed as. 
 
A+ aq.  +   D- aq.   →   AD org. 
 
A+ aq. is the protonated amine in aqueous phase. D- aq. is the anionic pairing 
dye in aqueous phase and AD org. is the final ion-pair complex extractable 
into organic phase. Extracting the complex with aqueous acid or alkali 
depending on the anion pairing dye readily decomposes these complexes. 
(Sethi, P.D., 1997) 
Basic drug chlorpromazine makes ion-pair complex with acidic dye methyl 
orange (Zhou Z. et al., 1996).         
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NN
CH3
CH3
N SO3 -
Methyl orange (anionic dye) 
                                   + 
 
           S
N Cl
(CH2)3 N
+ CH3
H
CH3
            Chlorpromazine (cationic drug) 
                          
.
S
N Cl
(CH2)3
CH3
CH3
 
N
H
N N N SO3
 
+
_
 
                           Methyl orange                                       Chlorpromazine   
                          
(Neutral lipophilic ion-pair complex) 
 
The principle of the acid dye technique can be applied in a basic-dye                      
method in which the charge types are reversed. 
 
Amines in their anionic or protonated state form a complex with a 
cationic or anionic dye species respectively to form complexes, which are 
distinguished by their solubility in organic solvents such as chloroform, 
benzene, dichloromethane. Thus by using a pairing reagent, a colored 
complex is produced and the amines can thus be measured colorimetrically. 
The equilibrium expression for ion-pair formation can be expressed as 
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A-aq + D+aq      ADorg  
 
A-aq = anionic drug in aq. Phase 
D+aq = cationic dye in aq. Phase 
ADorg = ion-pair complex extractable into organic phase. 
 
For example the acidic component of glycyrrhiza (Glycyrrhetinic acid) was 
determined by extraction of its ion pair with the basic dye methylene blue 
(Habib, A.A.M., 1979 and Pesez, M., 1974) 
 
 
 
 
OH
O
COO
+
-
N
N
N
S
+
CH3
CH3
CH3
CH3
 
Glycyrrhetinic acid (anionic drug)          Methylene blue (cationic dye) 
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↓     
OH
O
COO
 
-
.
N
N
N
S
CH3
CH3
CH3
CH3
 
+
 
                    Glycyrrhetinic acid                                    Methylene blue   
 
                                (Neutral lipophilic ion-pair complex)  
The pH of aqueous phase is critical to the success of method. The pH should 
be usually being near or below pKa of the basic dye (Higuchi T. and Bodin 
J.I.1961). 
 
1.3.3: Theory: 
 
The relevant experimental conditions (pH of the buffer, extracting 
solvent and absorption maxima) for several reported compounds are given in 
Table 1.1. 
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 The success of the method is based on the condition that only the 
complexed form of the dye is extractable. So each molecule of amine results 
in the complexation of one molecule of dye and this is extracted into the 
organic phase. Whereas concentration of dye is an indirect measure of the 
amount of amine. In order to ensure the non extractability of the excess 
uncomplexed dye, a dye is used that is a neutral weak acid and the aqueous 
pH is controlled at a level above the pK of the dye thus converting it to its 
anionic form (Higuchi T. and Bodin J.I.1961). 
 
 Among the dyes that have been commonly used are bromocresol 
purple, methyl orange, thymol blue, etc (acidic dyes), safranin O, methylene 
blue, etc (basic dyes) and organic solvents generally used for extraction of 
drug-dye complex from aqueous phase are chloroform, dichloromethane and 
benzene. The indicator dye is added in excess and the pH of the aqueous 
solution is adjusted if necessary to a value where both the amine and dye are 
in the ionized forms. The ion-pair is separated from the excess indicator by 
extraction into the organic solvent, and the absorbance is measured at the 
λmax. The molar absorptivity of the ion-pairs formed between quaternary 
ammonium compounds and dyes are typically 0.9 x 104 to 4 x 104 in acid and 
base dye technique. So both the dye techniques provide more sensitive 
techniques for certain nitrogen containing compounds. The acid-dye 
technique is used officially in European Pharmacopoeia for the assay of 
formulations containing certain quaternary ammonium salts or amines, i.e., 
biperidine Lactate injection, clonidine hydrochloride injection and tablets, 
neostigmine methylsulphate injection, and benzhexol hydrochloride Tablets 
(Backett, A.H., 2002). 
 
 Some selectivity can be achieved by control of pH; for example the 
alkaloid berberine was determined in the presence of hydrastine and 
canadine by acid dye extraction (with bromocresol purple) at pH 7.2 (El-
Masry, S. and  Korany, M.A. 1980). 
  
 Theoretical condition which helps in choosing a rational system for a 
particular determination involves the knowledge of the dissociation constant of 
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acidic dye and the basic compound, or the basic dye and the acidic 
compound and the pH dependence of the partition characteristics of the two 
substances and their addition product between aqueous and organic solvent. 
Since dyes are used in excess one of the basic requirements of this technique 
is that unreacted dye must be wholly retained in aqueous phase at the pH 
employed. If the initial partition coefficient of the dye (in acid form) is high, the 
pH of the organic phase, pH of the buffer may not have much role. As pH has 
no significant influence on partition characteristics of the dye above its pT 
(The pH at which titration in presence of a given indicator is ended is 
sometimes known as its titration exponent, denoted by pT). (Alexeyev, V., 
1994), it is always advisable to explore the area between pK and pT (Table 
1.2.) to find out the most critical pH for a system i.e. the lowest pH at which 
the dye is wholly retained in the aqueous phase on shaking with an organic 
solvent. Most nitrogenous bases of pharmaceutical interest have pK between 
4 and 8. Thus at a particular pH, the extent to which any base will exist in its 
free form will depend on its pKa value. The condition required is that the 
medium may not be too acidic so as to retain the base in the aqueous phase. 
It is sometimes necessary to operate at a pH somewhat higher than the pT of 
the indicator (dye). General guideline is that pH of the buffer chosen should 
be some what above the pKa of the base to be estimated and then select the 
dye for which this pH is optimum. The sensitivity of this method depends 
primarily on molar extinction coefficient of the dye in the medium in which the 
absorbance is measured (Sethi, P.D., 1997).  
 
1.3.4:  Basic requirements for ion-pair technique: 
 
1. Drug and dye both are required to be soluble in the same solvent and 
ion-pair complex must be least soluble in aqueous solvent as compare 
to organic solvent used for extraction of complex. 
2. Stoichiometric ion pair must be formed between positively or negatively 
charged nitrogenous compound and corresponding acidic and basic 
dye respectively. 
3. This ion pair is quantitatively extractable in organic phase. 
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4. The unreacted dye molecules must not be extracted into the organic 
phase as they are insoluble in organic phase (Sethi PD; 1997). 
 
1.3.5:  Important factors: 
 
There are three major factors that significantly influence the success of 
method. 
a) Dye selection and its concentration 
b) pH of aqueous phase 
c) Solvent for extraction of ion-pair complex (Das Gupta. 1973 & 
Kenneth A. 1982) 
 
 
1.3.6: Advantages and Limitations: 
 
Advantages 
 
1. Ion-pair technique increase sensitivity of drugs that poorly absorbs in 
UV region. 
2. Method is highly specific in nature because complex between particular 
drug and dye only form if specific pH is provided. 
3. In most cases it has been proven that, no any excipient in the dosage 
form interferes with complex formation. So method can be used for 
routine analysis. (Sethi, P.D., 1997).     
 
Limitations: 
 
1. Absorption maximum is not sharp and difficult to locate. 
2. Reagent blanks sometimes very high due to impurities in dye. 
3. Formation of complex is pH dependent and presence of other 
substance can affect the pH (Sethi, P.D., 1997).    
 
 
 
 31
_______________________________________________________Introduction____  
1.3.7    Chemistry of dyes used as complexing agents 
1.3.7.1 Methyl orange (tropaeolin d) (Jeffery, G.H., 1989) 
                 
• Chemical Name:  
 
 Dimethylamino- phenyl azobenzene- sulphonic acid sodium salt. 
 
• Structural formula:                
                                    
NN
CH3
CH3
N SO3-
    (Base form, pH > 4.4, yellow) 
 
                          NaOH      HCl     
 
N
+
CH3
CH3
N N SO3-
H      (Acid form, pH < 2.9, red) 
 
• Molecular Formula: C14H14N3Na03S 
 
• Molecular Weight:  327.34 
  
• Appearance:  
 
 Orange- Yellow powder or crystalline scales. 
 
• Solubility:  
 
 Soluble in 500 parts water; more soluble in hot water, practically 
insoluble in alcohol. 
 
• Dissociation constant (pKind): 3.7 
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• pH range  
 
 (transition interval) and color change : 2.9 - 4.4  
 Red at pH< 2.9, pH> 4.4 yellow 
 
1.3.7.2 Safranin o (Jeffery, G.H., 1989)   
 
• Chemical name:  
  
 3,7-diamino-2, 8-dimethyl-5 phenylphenazinium chloride 
or 
3,7-diamino-2, 8, 16-trimethyl-5 phenylphenazinium chloride 
 
• Structure : 
          
 
N
N
+
NH2
CH3CH3
NH2
N
N
+
NH2
CH3CH3
NH2
CH3
Cl-
Cl-
           Dimethyl safranin    Trimehtyl safranin  
 
 
   
Dimethyl Safranin   
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• Molecular Formula: C20H19N4Cl (dimethyl) 
  C21H21N4Cl (trimethyl) 
 
• Molecular Weight:  350.8 (dimethyl) 
 364.9 (trimethyl) 
 
• Appearance:   
 Maroon red crystalline powder 
 
• Solubility:   
 5.45% in Water; 3.5% in Alcohol; 3.5% in Glycol and 0.0% in xylene 
 
• Dissociation constant (pKind):  7.9 
 
• pH range: 3.2 – 5.6 
 
1.3.7.3 Thymol blue (Jeffery, G.H. et.al., 1989) 
 
• Chemical Name: Thymolsulphophthalein 
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• Structural formula:  
 
C
S
O
O CH3
OH
CH3
CH3
CH3OH
CH3
CH3
O
          
C
S
O
O
CH3
CH3
CH3
CH3OH
CH3
CH3
O
O
 
 
      (Acid form, pH < 1.2, red)     (Base form, pH > 2.8, yellow) 
 
• Molecular Formula: C27H30O5 
 
• Molecular Weight : 466.60 
  
• Appearance:  
 
 Brownish-Green crystalline powder; characteristic odor 
 
• Solubility:  
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 Insoluble in water, soluble in alcohol and dilute alkali solutions. 
 
• Dissociation constant (pKind): 1.7 
 
• pH range  
 
 (transition interval)  and color change: 1.2 - 2.8 
      Red at pH< 1.2, pH> 2.8 yellow 
 
1.3.7.4 Bromo cresol green  (Jeffery, G.H. et.al., 1989) 
 
• Chemical Name: Tetrabromo-m-cresol sulphophthalein 
 
• Structural formula:  
 
C
S
O
O CH3
OH
Br
Br
CH3OH
Br
Br
O
                
C
S
O
O
CH3
Br
Br
OH
Br
Br
O
OCH3
 
 
    (Acid form, pH < 3.8, yellow)      (Base form, pH > 5.4, blue-green) 
 
 
• Molecular Formula : C21H14Br4O5S 
 
• Molecular Weight: 698.02 
  
• Appearance:  
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 Slightly yellow crystals from acetic acid 
 
• Solubility: 
 
 Sparingly soluble in water, readily soluble in alcohol, ether, ethyl 
acetate, fairly soluble in benzene 
 
• Dissociation constant (pKind):  4.7 
 
• pH range  
 
 (transition interval) and color change : 3.8 - 5.4 
      Yellow at pH< 3.8, pH> 5.4 Blue-Green 
 
1.3.7.5 Bromophenol blue (Jeffery, G.H. et.al., 1989) 
 
• Chemical Name:  
 
 Tetrabromophenol sulphophthalein 
 
• Structural formula: 
 
    
C
S
O
Br
Br
OH
OH
Br
Br
O
O
             
C
S
O
O
Br
Br
O
OH
Br
Br
O
 
 
       (Acid form, pH < 3.0, yellow)        (Base form, pH > 4.6, purple) 
 
• Molecular Formula: C19H10Br4O5S 
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• Molecular Weight:  669.97  
• Appearance:  
 
 Orange- Yellow powder or crystalline scales. 
 
• Solubility:  
 
 Soluble in water (about 0.4 gm/ 100ml), more soluble in methyl alcohol, 
ethyl alcohol and benzene. Freely soluble in NaOH solutions with the 
formation of a water-soluble sodium salt 
 
• Dissociation constant (pKind): 4.1 
 
• pH range 
 
 (transition interval) and color change : 3.0 - 4.6 
 Yellow at pH< 3.0, pH> 4.6 purple 
 
Table 1.1. pH of the buffer, extracting solvent and λmax for analysis of 
several nitrogenous drugs 
 
Sr. 
No 
Drug Dye pH 
(Buffer)
Extracting
Solvent 
λ max 
(nm) 
Reference 
1 Fluoxetine HCl MO 
TB 
4.0 
8.0 
Chloroform 433 
410 
Prabhakar 
A.H.  
et al.1999 
2 Trazodone 
HCl 
BPB 3.4 Chloroform 414 El-Gindy A.  
et al.,, 2001 
3 Chlorpromazine MO  6.0 Chloroform 424 Zhou Z. et 
al.,, 1996 
4 Strychnine and 
brucine 
MO 5.0 Chloroform 424 El-Masry S. 
et al. 1978 
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5 Meclizine HCl MO 2.8 (Mc 
Il vaine)
Chloroform 440 Hom FS. et 
al.,, 1977 
6 Ipeca alkaloids MO 5.0 Chloroform 460 
283 
Saleh MR. 
 et al.,, 
1979 
7 3-dimethyl 
amino 
methyl khellin 
MO 5.0 Chloroform 420 Abu-Shady 
H.,1978 
8 Protein BPB 1.0 Chloroform 595 Lin LY. et.  
al., 1989 
9 Enrofloxacin 
Pefloxacin 
BPB 
MO 
2.3-2.5 
3.6 
Chloroform
Chloroform
420 
424 
Mostafa S.  
et al.,, 2002 
10 Sulfur dioxide TB 
 
I2 + 
TB 
2.4 
 
3.0 
 
Chloroform
 
Chloroform
545 
 
430 
 
Gayathri N. 
et al.,, 2001 
11 Metho 
trimeprazine 
BPB 3.0 Chloroform 409 Kedor-
Hackmann 
ER. et al. 
2000 
12 Tilidine BCG
BPB 
3.5 Chloroform 415 
411 
Dobrila ZS.  
et al.,, 1990 
13 Ceterizine HCl BCP 
BPB 
2.64 
Walpole
Chloroform 409 
414 
Gowda BG. 
et al.,, 2001 
14 pH of fresh 
water 
BCP 
PR 
4.5-8.5 Chloroform 432,589 
433,558 
Yao w.  
et al.,, 2001 
15 Guanidino 
drugs 
BCP 3.8 Chloroform 415 Wahbi AA.  
et al.,, 1993 
16 Urinary albumin BPB 5.0 Chloroform 610 Schosinsky 
KH.  
et al.,, 1987 
17 Pilocarpine BCP 6.0 Chloroform 580 El-Masry S. 
et al. 1980 
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18 Sparfloxacin BTB 3.5 Chloroform 385 Marona HR. 
et al.,, 2001 
19 Bismuth MTB 5.5 Chloroform 548 Themellis 
DG.  
et al.,, 2001 
20 Ioperamide HCl TB 
BPB 
NBB
2.7 
2.8 
6.0 
Chloroform 414 
415 
627 
El-sherif 
ZA.  
et al., 2000 
21 Clonidine BCG 3.0 Chloroform 415 Zivanov-
Stakic D., et 
al. 
22 Methenamine BCG 5.0 Chloroform 412 Strom JG.  
et al.,, 1986 
23 Promethazine 
HCl 
BCG 2.7-2.8 Chloroform 415 Emami Khoi 
AA., 1983 
24 Amino 
qunioline 
BPB 1.5 
 
Chloroform 415-
420 
El-Ashry 
SM.  
et al.,, 1994 
       
25 
Piperazine 
HCl 
BPB 1.5 Chloroform 410 Abdel-
Gawad FM., 
1997 
26 Total steroid 
Bases in 
solanum 
species 
MO 4.7 Chloroform 420 Jan Birner, 
1969 
27 Hydrastis 
Alkloids 
BCP 7.2 Chloroform 590 
28 Berberine BCP 5.6 Chloroform
 
580 
Savsan El-
Masry,  
et al., 1980 
29 Hyoscyamine  BCP 6.6 Chloroform 420 Savsan El-
Masry, 
Saleh 
A.H.K. 1973
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Table 1.2. pK, pT, Appropriate extracting solvent and pH of buffer for 
several dyes 
 
Dye pK pT pH Organic Solvent 
Bromocresol purple 6.3 6.8 5.4 Benzene 
Bromothymol blue 7.0 7.6 5.0 Toluene 
Bromocresol green 4.7 5.4 6.6 Chloroform 
Bromo phenol blue 4.0 4.6 5.6 Chloroform 
Bromochlorophenol blue 4.2 4.8 4.0 Benzene 
Chlorophenol red 6.0 6.6 6.5 Benzene 
Methyl orange 3.8 4.4 5.0 
Ethylene dichloride,  
chloroform, benzene 
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2. LITERATURE REVIEW 
 
2.1 Antidepressants 
 
 Numerous analytical methods have been designed and developed for 
the determination of Fluoxetine, sertraline and Duloxetine in pharmaceutical 
dosage form and in biological fluids [Eap CB et al; 1996] are reviewed as 
follows: 
 
2.1.1 Fluoxetine hydrochloride 
 
Thin Layer Chromatography 
 
 A thin layer chromatographic technique can be used to determine the 
identity and purity of Fluoxetine hydrochloride. Precoated 20 x 20 cm silica gel 
60F254 TLC plates are used in combination with binary solvent system 
consisting of 90% methanol and 10% concentrated ammonium hydroxide. 
Visualization is performed by exposing the plate to iodine vapours prior to 
viewing under short UV light (254 nm) [Donald SR et al; 1990]. 
 
 A simple, rapid and accurate thin layer chromatographic method has 
been developed for determination of Fluoxetine and Paroxetine in dosage 
forms. The drugs were chromatographed on silica gel 60 F 254 plates in 
horizontal chambers with benzene-acetone-ethanol-25% aqueous ammonia 
[9+7+2+1 v/v] as a mobile phase. Densitometric detection was performed at 
218 nm and 293 nm for Fluoxetine and Paroxetine, respectively, video 
densitometric detection was performed at 254 nm for both drugs. The range of 
linearity was 2-10 μg per spot for Fluoxetine and 0.5 – 8 μg per spot for 
Paroxetine [Robert S, et al; 2003] 
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Table 2.1. Estimation of Fluoxetine hydrochloride by Thin Layer 
Chromatography 
 
Sr. 
No. 
Specifications Reference 
1 The identity and purity of Fluoxetine was 
determined by Thin Layer Chromatography 
Method 
Donald SR et al; 
1990 
2 Determination of Fluoxetine and Paroxetine in 
pharmaceutical formulations by densitometric 
and videodensitometric Thin Layer 
Chromatography method 
Robert S et al; 2003 
 
High Performance Liquid Chromatography 
 
 A High Performance Liquid Chromatographic method with fluorescence 
detector has been developed for the determination of Fluoxetine and nor 
Fluoxetine in human plasma. Sample was used after liq – liq extraction on a 
C8 column with a mixture of perchlorate buffer and acetonitrile as mobile 
phase. Fluoxetine, nor Fluoxetine and internal standard (Paroxetine) were 
eluted in less than 9 minutes. Response for both analytes was linearly 
obtained in a range 2.5 – 500 ng/ml [Raggi MA et al; 1999]. 
 
 Analysis by reversed phase liquid chromatography on a xterra MA C18 
column using a fast gradient. Fluoxetine, norFluoxetine and fluvoxamine 
(internal standard) were ionized using the turbolon spray interface operating in 
positive ion mode. The method is linear over the range 0.5 – 50 μg/ml [Green 
R et al; 2002]. 
 
 Simultaneous determination of Fluoxetine, Citalopram, Paroxetine, 
Venlafaxine in plasma by high performance liquid chromatography. The 
separation of the analytes was performed on a macherey – nagel C18 column, 
using water (Formic acid 0.6%, ammonium acetate 30 mmol/L)-acetonitrile 
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[35:65 v/v] as a mobile phase, with a flow rate of 0.85 ml/min. The compounds 
were ionized in the electrospray ionization mass spectrometry. The calibration 
curves were linear in the range of 5.0 – 1000 ng/ml for all compounds. [He J. 
et al; 2005] 
 
 A rapid and sensitive high performance liquid chromatographic method 
has been developed for determination of Fluoxetine and nor Fluoxetine in 
human plasma using Paroxetine as internal standard. The compounds were 
separated on a C18 column using acetonitrile-40 mM potassium di hydrogen 
phosphate buffer (pH 2.3) in the ratio of 31:69 (v/v) as the mobile phase. The 
quantification of both were made by fluorescence detector. The assay for 
each analyte was linear over the range of 1 – 39 and 0.9 – 36 μg/ml 
respectively. [Laurian V. et al; 2005]. 
 
 The High Performance Liquid Chromatographic method is described 
for determination of Fluoxetine and nor Fluoxetine in plasma via reversed 
phase column and UV detector. The limit of quantification was 14 nmol/L for 
both compounds [Ilerena A. et al; 2003]. 
 
 Selective liquid chromatographic method for determination of 
Fluoxetine in plasma was performed on novapak C18 column with an isocratic 
mobile phase consisting of phosphate buffer-acetonitrile – methanol – triethyl 
amine (58:30:10:2 v/v) adjusted to pH 7 using UV detector. The calibration 
curve was linear over the concentration range of 10 – 200 μg/ml. [Afshin Z et 
al; 2001] 
 
 Separation of Fluoxetine enantiomers on five chiral stationary phase 
[chiralcel OD-H, chiralcel OJ-H, chiralpak AD-H, cyclobond I 2000 DM and 
kromasil CHI-TBB] was investigated using hexane-isopropanol-diethyl amine 
as proportion of mobile phase. [Jie Z et al; 2007] 
 
 A simple, accurate and sensitive high performance liquid 
chromatographic technique was described for the determination of Fluoxetine 
in the capsule dosage form, human plasma and biological fluid. The 
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determination was performed with a reversed phase C18 column with UV 
detector. The isocratic mobile phase consists of acetonitrile and triethylamine 
buffer (48:52 v/v). The calibration curve was linear over the concentration 
range of 10-300 μg/L. [Mohamed AE et al; 2002] 
 
 A sensitive and selective liquid chromatographic – tandem mass 
spectrometric method was developed and validated for Paroxetine and 
Fluoxetine on a C18 analytical column. The retention time was 1.6 and 1.7 for 
Paroxetine and Fluoxetine respectively. [Massaroti P et al; 2005] 
 
 An official method for determination of Fluoxetine hydrochloride 
capsule by liquid chromatographic separation followed by UV detection was 
mention in British Pharmacopoeia – 2000 and United State Pharmacopoeia, 
XXIV edition – 2000 
 
 A reversed phase high performance liquid chromatographic method 
has been developed to determine Fluoxetine in pharmaceutical dosage forms. 
The mobile phase consists of acetonitrile-water-triethylamine (50:49:1 v/v). 
Water and triethylamine adusted to pH 6 with phosphoric acid, using DuPont 
Zorbax RX column. The flow rate is 1.0 ml/min and UV detection is at 260 nm. 
The method is linear over the range of 25-800 μg/ml and it is also applicable 
for determination of drugs and its active metabolite from serum. [Orsulak PJ et 
al; 1988] 
 
 
Table 2.2. Estimation of Fluoxetine hydrochloride by Liquid 
Chromatography 
 
Sr. 
No. 
Specification Reference 
01 Determination of Fluoxetine and norFluoxetine in 
human plasma using fluorescene detector.  
Linearily: 25 – 500 ng/ml 
Raggi MA et al; 
1999 
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02 Determination of Fluoxetine and norFluoxetine in 
human plasma by liquid spectrometry-tandem 
mass spectrometry. 
Linearity : 0.5 – 50 μg/ml 
Green R et al; 
2002 
03 Simultaneous determination of Fluoxetine, 
Citalopram, Paroxetine, Venlafaxine in plasma by 
High Performance Liquid Chromatography – 
electrospray ionization mass spectrometry. 
Linearity for all : 5.0 – 1000 ng/ml 
He J. et al; 2005
04 Determination of Fluoxetine and nor Fluoxetine in 
human plasma by High Performance Liquid 
Chromatography – fluorescene detector.  
Linearity for Fluoxetine : 1.0 – 39.0 μg/ml, nor 
Fluoxetine : 0.9 – 36 μg/ml   
Laurian V. et al; 
2005 
05 Determination of Fluoxetine and nor Fluoxetine in 
plasma by High Performance Liquid 
Chromatography, using UV detector. The limit of 
quantification was 14 nmol/L 
Ilerena Adrian 
et al; 2003 
06 Selective liquid chromatographic method was 
developed using UV detector for Fluoxetine in 
plasma. 
Linearity : 10 – 200 μg/ml 
Afshin Z et al; 
2001 
07 Comparision of performance of chiral stationary 
phase for separation of Fluoxetine enantiomers. 
Jie Z et al: 2007 
08 Sensitive HPLC technique is described for 
determination of Fluoxetine in capsule dosage 
form and in plasma using UV detector. Linearity : 
10 – 300 μg/L 
Mohamed AE et 
al; 2002 
09 Determination of Paroxetine and Fluoxetine by 
liquid chromatographic – tandem mass 
spectrophotometric method was developed and 
validated. 
Massaroti P et 
al; 2005 
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10 Determination of Fluoxetine hydrochloride capsule 
by High Performance Liquid Chromatography 
using UV detector. 
British 
Pharmacopoeia 
– 2000 Page 
No. 1961-1962 
11 Determination of Fluoxetine hydrochloride capsule 
by liquid chromatographic method using UV 
detector. 
United State 
Pharmacopoeia, 
XXIV, edition-
2000 page no. 
739-740 
12 Determination of Fluoxetine in pharmaceutical 
dosage form and serum by reversed phase High 
Performance Liquid Chromatography using UV 
detector. 
Orsulak PJ et 
al; 1988 
 
Gas Chromatography 
 
 Due to the reasonable thermal stability and the volatility of Fluoxetine, 
a gas chromatographic technique has been used to determine Fluoxetine.  
 
 A gas chromatographic method has been developed for determination 
of Fluoxetine in dosage forms, plasma and urine by using an HP Model 5713 
GC with electron capture detector. [Nash JF et al; 1982; and Lopez C et al; 
1989] 
 
 An electron capture gas chromatographic procedure was developed for 
the simultaneous analysis of the enantiomers of Fluoxetine and norFluoxetine. 
The assay involves basic extraction of these enantiomers from biological 
sample, followed by their conversion to diastereomers using the chiral 
derivatizing reagent (S)-(-)-N-trifluoroacetylpropyl chloride. [Torok-Both GA et 
al; 1992] 
 
 A simple and fast capillary gas chromatographic method using flame 
ionization detector was developed column head pressure (80 Kpa), injector 
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and detector temp (260 0C and 250 0C), time and temperature for the splitless 
step (0.75 min. and 60 0C), size and sample (2 μL) and oven temperature 
program, providing analysis time shorter than 10 min., recoveries between 
97.5 to 102.5 %. [Berzas Nevado JJ et al; 2000] 
 
Table 2.3. Estimation of Fluoxetine hydrochloride by Gas 
Chromatography 
 
Sr. 
No. 
Specifications Reference 
01 Determination of Fluoxetine in dosage form, 
plasma and urine by gas chromatographic 
method using electron capture detector. 
Nash JF et al; 1982 
and Lopes C et al; 
1989 
02 Simultaneous determination of Fluoxetine and 
norFluoxetine enantiomers in biological sample 
by gas chromatographic method using electron 
capture detector. 
Torok-Both GA et al; 
1992 
03 Determination of Fluoxetine, fluvoxamine and 
clomipramine in pharmaceutical dosage form by 
capillary gas chromatography using flame 
ionization detector. 
Berzas Nevado JJ et 
al; 2000 
 
Capillary Electrophoresis 
 
 A simple, rapid and sensitive procedure using non aqueous capillary 
electrophoresis to measure Fluoxetine and active metabolite norFluoxetine 
has been developed and validated optimum separation of Fluoxetine and 
norFluoxetine by measuring at 230 nm was obtained on a 60 cm X 75 μm 
capillary using a non aqueous solution system of 7:3 methanol – acetonitrile 
containing 15 mM ammonium acetate. Detection limits of 10 μg/ml were 
obtained. [Rogriguez FJ et al; 2005] 
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 A simple and rapid method for determination of Fluoxetine in 
pharmaceutical formulation by capillary electrophoresis method has been 
developed. A different capillary was used; the high sensitivity cell and the 
cyclodextrins in the BGE were not necessary. The detection wavelength was 
changed from 195 to 205 nm to obtain less noisy base line. Good linearity 
was found in the concentration range 0.25 – 50 μg/ml. [Mandrioli R et al; 
2002] 
 
Table 2.4. Estimation of Fluoxetine hydrochloride by Capillary 
Electrophoresis 
 
Sr. 
No. 
Specifications Reference 
01 Determination of Fluoxetine and nor Fluoxetine by 
non aqueous capillary electrophoresis in human 
urine. 
Rogriguez FJ et 
al; 2005 
02 Determination of Fluoxetine in pharmaceutical 
formulation by capillary electrophoresis method. 
Mandrioli R et al; 
2002 
 
Voltametric Method 
 
 The determination of Fluoxetine in pharmaceutical formulation using 
adsorptive square wave cathodic stripping voltametric method was developed. 
Linear calibration graphs were obtained in the range 0.52 – 5.2 μM. [Roque 
DS et al; 1999] 
 
 The oxidative behavior of Fluoxetine was studied at a glassy carbon 
electrode in various buffer systems and at different pH using differential pulse 
and square wave voltammetry. A new square wave voltametric method was 
developed for determination of Fluoxetine in pharmaceutical formulations 
using borate (pH 9) buffer solution as supporting electrolyte. Under the 
optimized conditions, a linear response was obtained in the range 10 to 16 μM 
with a detection limit of 1.0 μM. [Rui PL et al; 2006] 
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 Electroanalytical methods based on square wave adsorptive-stripping 
voltammetry and flow injection analysis was developed for Fluoxetine. The 
method was based on the reduction of Fluoxetine at a mercury drop electrode 
at 1.2 V versus Ag/AgCl, in a phosphate buffer at pH 12. This method was 
successfully applied in the quantification of Fluoxetine in pharmaceutical 
formulation, serum and in drug dissolution studies. The presence of dissolved 
oxygen did not interfere significantly with the analysis. [Henri PA et al; 2007] 
 
Table 2.5 Estimation of Fluoxetine hydrochloride by Voltammetry  
 
Sr. 
No. 
Specifications Reference 
01 Determination of Fluoxetine in pharmaceutical 
formulation using square wave adsorptive 
cathodic stripping voltametry. 
Roque DS et al; 
1999 
02 Voltametric quantification of Fluoxetine in 
pharmaceutical formulation using differential 
pulse and square wave voltametry. 
Rui PL et al; 2006 
03 Electroanalytical method based on square wave 
adsorptive stripping voltametry and flow injection 
analysis for Fluoxetine. 
Harri PA et al; 
2007 
 
Spectrophotometric method  
 
 Spectrophotometric technique was developed for determination of 
Fluoxetine and sertraline in bulk and pharmaceutical formulations. The 
methods are based mainly on charge transfer complexation reaction of drugs 
with either п acceptor [Chloranil and 2,3-dichloro-5,6-dicyanobenzoquinone] 
or σ acceptor [Iodine]. The colour produced is quantified 
spectrophotometrically at 550, 450 and 263 nm for Fluoxetine and 450, 455 
and 290 nm for sertraline respectively. The method determined the cited 
drugs in concentration ranges of 80 – 640, 16 – 112 and 7.5 – 60 μg/ml with 
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mean percentage recoveries of 99.83, 99.76 and 100 %. [Bebawy LI et al; 
1999] 
 
 A rapid, sensitive and economical spectrophotometric method was 
developed for the determination of Fluoxetine in bulk and its dosage form. The 
method was based on the formation of yellow ion pair complex due to the 
action of methyl orange and thymol blue in acidic (pH 4) and basic (pH 8) 
medium respectively under optimum condition it shows an absorption maxima 
at 433 nm (MO) and 410 nm (TB). In both cases Beer’s law is obeyed at 1 – 
20  μg/ml with MO and 4 – 24 μg/ml with TB. [Prabhakar AH et at; 1999] 
 
 A rapid, simple and accurate spectrophotometric method was 
presented for the determination of Fluoxetine by batch and flow injection 
method. The method is based on complexation of drug with phenolphthalein-
β-cyclodextrin (PHP-β-CD) inclusion complex and measured at 554 nm. The 
linearity was observed between 7.0 x 10-6 – 24 x 10-4 mol/L. [Abbas A et al; 
2006] 
 
 Fluvoxamine and Fluoxetine react with eriochrom cyanine R to form 
pink-ion association compound. These compounds are insoluble in water but 
fairly soluble in organic solvents. Addition of methyl cellulose affects the 
solubility of compounds and increase the absorbance of the solution. It gives 
good linearity in the concentration ranges 0.6-15 and 0.3-5 μg/ml respectively. 
[Barbara S.; 2001] 
 
 Simple and sensitive spectrophotometric methods were developed and 
validated for the determination of Fluoxetine, sertraline and Paroxetine in their 
pharmaceutical dosage forms. These methods were based on the reaction of 
the N-alkylvinylamine formed from the interaction of the free secondary amino 
group in the drugs and acetaldehyde with each of three haloquinone, i.e. 
chloranil, bromanil and 2,3-dichloronaphtho quinone, to give coloured vinyl 
amino substituted quinone, which measured at 665, 655 and 580 nm 
respectively. The linearity was observed in the range 4 – 120 μg/ml. [Ibrahim 
AD; 2005] 
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 A new simple and sensitive spectrophotometric method was developed 
for determination of Fluoxetine in bulk and its dosage form in UV region and 
measured at 225 nm. The Beer’s Law obeyed in the concentration range of 
2.5 – 25 μg/ml. [Sujatha K et al; 2004] 
 
 A simple, fast and precise extractive spectrophotometric method was 
developed for the determination of Fluoxetine in pharmaceutical formulations. 
The method is based on formation of coloured complex with bromothymol 
blue and measured at 412 nm. The method obeyed Beer’s Law in the range 
of 1.5 – 20 μg/ml. [Naik MT et al; 1999] 
 
Spectrophotometric method for the determination of Fluoxetine in bulk 
and dosage form was developed. The method is based on the formation of 
yellow ion-pair complex with methyl orange in phthalate buffer pH 4.0 and 
thymol blue in phosphate buffer pH 8.0. [Anandkumari HP et al; 1999] 
 
Table 2.6. Estimation of Fluoxetine hydrochloride by Spectrophotometry 
 
Sr 
No. 
Specifications Reference 
01 Spectrophotometric determination of Fluoxetine 
and sertraline using chloranil, 2,3-dichloro-5,6-
dicyanobenzoquinone and iodine. 
Bebawy LI et al; 
1999 
02 Spectrophotometric determination of Fluoxetine 
in bulk and pharmaceutical formulation using 
methyl orange and thymol blue. 
Prabhakar AH et 
al; 1999 
03 Spectrophotometric determination of Fluoxetine 
by batch and flow injection method using PHP-
β-CD inclusion complex. 
Abbas A et al; 
2006 
04 Spectrophotometric determination of 
fluvoxamine and Fluoxetine using eriochrom 
cyanine R to form pink-ion association 
compound. 
Barbara S.; 2001 
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05 Development and validation of 
spectrophotometric methods for determination 
of Fluoxetine, sertraline and Paroxetine using 
various haloquinone. 
Ibrahim AD; 2005 
06 Spectrophotometric method for determination 
of Fluoxetine in UV region. 
Sujatha K et at; 
2004 
07 Spectrophotometric method for determination 
of Fluoxetine by formation of coloured complex 
with bromothymol blue. 
Naik MT et al; 
1999 
08 Spectrophotometric determination of Fluoxetine 
using methyl orange and thymol blue to form 
ion pair complex. 
Anandkumari HP 
et al; 1999 
 
Spectrofluorimetric method 
 
 A simple, rapid and sensitive method for determination of Fluoxetine in 
pharmaceutical dosage form has been developed. Fluorescene emission 
intensity was measured at 293 nm, while exciting at 230 nm. The linearity was 
observed in the concentration range 0.25 – 5.0 μg/ml. [Mandrioli R et al; 2002] 
 
Table 2.7. Estimation of Fluoxetine hydrochloride by Spectrofluorimetry  
 
Sr 
No. 
Specifications Reference 
01 Spectrofluorimetric method for determination 
of Fluoxetine in bulk and pharmaceutical 
dosage form. 
Mandrioli R et al; 
2002 
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2.1.2 Sertraline hydrochloride 
 
High Performance Liquid Chromatography 
 
 A sensitive stereo specific high performance liquid chromatographic 
method for the determination of Sertraline in bulk, tablets and capsules was 
developed. The composition of mobile phase was aqueous 170 mM 
phosphate buffer, pH 3.0 (adjusted with 85% phosphoric acid) containing 18 
mM hydroxypropyl-β-cyclodextrine-acetonitrile (68:32 v/v) at a flow rate of 1.0 
ml/min. The UV detection was set at 225 nm. Calibration curve was linear in 
the range of 1 – 120 μg/ml. [Chen D et al; 2004] 
 
 Micellar electrokinetic chromatographic method has been developed 
for separation of cis-trans isomers and enantiomers of sertraline. An optimum 
separation was achieved using a buffer (pH 11.5) of 35 mM sodium borate 
containing 30 mM sodium deoxycholate and 20 mM hydroxy-β-cyclodextrine. 
The measurement was carried out at 210 nm by UV detector. This method 
was successfully applied for the detection of sertraline in bulk and various 
dosage forms. [Deving C et al; 2004] 
 
 A high performance liquid chromatographic method was developed and 
validated for the determination of sertraline & nefazodone in bulk and 
pharmaceutical formulations. The samples were chromatographed on a 
supercosil RP-18 column using methanol-phosphate buffer pH 4.5 (20:80 v/v) 
& methanol-acetonitrile-phosphate buffer at pH 5.5 (10:50:40 v/v) respectively 
measured at 270 nm (sertraline) and 265 nm (nefazodone). [Nevin ERK; 
2003] 
 
 A fully automated turbulent flow liquid chromatography – tandem mass 
spectrometry technique was developed for monitoring 13 different 
antidepressants in human serum. The calibration curves for all antidepressant 
were found in the range 10 to 500 ng/ml. [Sauvage FL et al; 2006] 
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 A sensitive, simple and rapid method was developed for determination 
of paroxatine, sertraline and fluvoxamine using LC/MS and LC/MS/MS, where 
dextro methorphan was used as internal standard. The samples of biological 
fluid were mixed with formic acid and directly subjected to LC/MS. The 
calibration curves were linear in the range 5 – 80 ng/ml. [Hattori H et al; 2005] 
 
 A simple and sensitive method was developed for the determination of 
sertraline in bulk and formulation using isocratic reversed phase high 
performance liquid chromatography. Wales Nova Pak C18 column and 
acetonitrite-methanol-0.05 M acetic acid and 0.02 M triethylamine buffer 
(45:15:40 v/v) mobile phase was used. The UV detection was made at 254 
nm. [Bruce MJ et al; 1996] 
 
  High performance liquid chromatographic method was developed to 
measure sertraline and its metabolites in biological fluid using radiolabeled 
drug and radioactivity detector and /or a variable wavelength UV detector. 
Waters C18 μBondapak column and acetonitrile-50 mM sodium phosphate (pH 
4.5)-acetonitrile-50 mM ammonium acetate (pH 5.0) was used as the mobile 
phase. [Tremain LM et al; 1989] 
 
 Estimation of high performance liquid chromatographic technique has 
been reported for measuring sertraline and desmethyl sertraline in mouse 
cerebral cortex using versapack C18 column and acetonitrile-0.25 potassium 
phosphate (pH 2.7) 30:70 v/v mobile phase. The detection was carried out at 
235 nm in UV detector. [Weiner HL et al; 1990] 
 
 Determination of sertraline in bulk and pharmaceutical formulation 
using high performance liquid chromatography technique has officially been 
reported. 
 
 The method of determination of sertraline and desmethyl sertraline in 
human serum was developed. A new solid phase extraction method 
employing the dual functionality clean screen cartidge followed by reverse 
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phase liquid chromatographic analysis. The response was linear over the 
concentration range 0.01 – 25 mg/l for both. [Rogowsky D et al; 1994] 
 
 A new rapid and sensitive high performance liquid chromatographic 
method has been developed for determination of 11 most commonly 
prescribed antidepressants [Fluoxetine, sertraline, Paroxetine, citalopram, 
fluvoxamine, meclobemide, mirtazapine, milnacipram, toloxatone, venlafaxine, 
viloxazine] and two active metabolite norFluoxetine and desmethyl 
venlafaxine. It involves liquid – liquid extraction followed by liquid 
chromatography coupled to photodiode array UV detection. [Duvemeuil et al; 
2003] 
 
 Sertraline hydrochloride was determined by high performance liquid 
chromatography – UV detection technique at 270 nm. The sample was 
chromatographed on a supercosil RP – 18 columns. The mobile phase were 
methanol:phosphate buffer pH 4.5. [Erk N; 2003]   
 
Table 2.8. Estimation of Sertraline hydrochloride by High Performance 
Liquid Chromatography  
Sr. 
No. 
Specification Reference 
01 Determination of sertraline in bulk and formulation 
by high performance liquid chromatography with 
UV detector. 
Chen D et al; 
2004 
02 Optimized separation of Cis-trans isomers and 
enantiomers of sertraline by micellar electrokinetic 
chromatography. 
Deving C et al; 
2004 
03 Determination of sertraline and nefazodone in 
pharmaceutical formulations by high performance 
liquid chromatography with UV detector. 
Nevin ERK; 2003 
04 Liquid chromatography-tandem mass 
spectrophotometric technique is developed for 
monitoring antidepressant in human serum. 
Sauvage FL at at; 
2006 
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05 Rapid, sensitive and simple determination of 
selective serotonin inhibitor in human serum by 
liquid chromatography-MS and LC/MS/MS. 
Hattori H et al; 
2005 
06 Determination of sertraline in bulk and formulation 
using isocratic reverse phase high performance 
liquid chromatography – UV detection system. 
Bruce MJ et al; 
1996 
07 Determination of sertraline in biological fluid using 
High Performance Liquid Chromatography 
variable wavelength UV detector. 
Tremain LM et al; 
1989 
08 Determination of sertraline in mouse cerebral 
cortex using high performance liquid 
chromatography – UV detector. 
Weiner HL et al; 
1990 
09 Determination of sertraline in pharmaceutical 
dosage form using high performance liquid 
chromatography – UV detection technique. 
B. P. – 2000 & 
USP – XXIV 
2000. 
10 Determination of sertraline and desmethyl 
sertraline from human serum using reverse phase 
liquid chromatography. 
Rogowsky D et al; 
1994 
11 A high performance liquid chromatographic – 
photodiode array UV detection for therapeutic 
drug monitoring of 11 most commonly prescribed 
antidepressants in human plasma. 
Duvemeuil et al; 
2003 
12 Sertraline was determined by high performance 
liquid chromatography – UV detection method. 
Erk N.; 2003 
 
Gas Chromatography 
 
 Various analytical methods using gas chromatographic technique has 
been developed. The determination of sertraline in biological fluid in which 
sertraline is extracted from plasma and derivatized with 
trifluoroaceticanhydride. The derivative is chromatographed using either a 
mass spectrometric detector [Fouda HG et al; 1987] or a 63 Ni electron 
capture detector. [Tremaine LM et al; 1989] 
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 The determination of sertraline and desmethyl sertraline was 
developed using gas chromatographic method and mass spectrometric 
detector. [Rogowsky D et al; 1994] 
 
 A gas chromatographic method was developed for estimation of 
plasma concentration of citalopram, Paroxetine, sertraline and their 
pharmacologically active N-desmethyl metabolites using mass spectrometric 
detector. [Eap CB et al; 1998] 
 
 A rapid and sensitive gas chromatography-mass spectrometry, with the 
selected ion monitoring mode for the determination of sertraline in human 
serum was developed. The linear response was obtained in the range of 0.2 – 
10.0 ng/ml. [Kim KM et al; 2002] 
 
 Rapid and sensitive determination of sertraline in human plasma was 
developed using gas chromatography-mass spectrophotomeric method. [Mee 
KK et al; 2002] 
 
Table 2.9. Estimation of Sertraline hydrochloride by Gas 
Chromatography  
 
Sr. 
No. 
Specification Reference 
01 Determination of sertraline in biological fluid by 
Gas Chromatography using mass spectrometric 
detector or electron capture detector. 
Fouda HG et al; 
1987 & Tremaine 
LM et al; 1989 
02 Determination of sertraline and desmethyl 
sertraline by gas chromatographic – mass 
spectrometric system. 
Rogowsky D et al; 
1994 
03 Simultaneous determination of human plasma 
levels of citalopram, Paroxetine, sertraline and 
their metabolite by gas chromatography – mass 
spectrometry. 
Eap CB et al; 
1998 
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04 Rapid and sensitive determination of sertraline in 
human plasma using GC – MS. 
Kim KM et al; 
2002 
05 Rapid and sensitive determination of sertraline in 
human plasma using GC – MS. 
Mee KK et al; 
2002 
 
 
Spectrophotometric method 
 
 Rapid and simple method for quantitative analysis of sertraline 
hydrochloride was carried out with first derivative spectrophotometry and 
measured its first derivative signal at 271.6 – 275.5 nm. The linear response 
was observed in the range of 8.0 – 46 μg/ml. [Erk N.; 2003] 
 
 Spectrophotometric method was developed and validated for 
determination of sertraline, Fluoxetine and Paroxetine in pharmaceutical 
dosage forms. The method was based on reaction of the N-alkylvinyl amine 
[Formed by interaction of drugs and aldehyde] with haloquinone (chloranil, 
bromanil and 2,3-dichloro naphthoquinone) to give coloured vinyl amino 
substituted quinones and measured at 665, 655 and 580 nm with chloranil, 
bromanil and 2,3-dichloronaphthoquinone respectively and observed good 
linearity. [Darwish IA; 2005] 
 
 A spectrophotometric procedure was reported for determination of 
Fluoxetine and sertraline. The method is based on charge transfer 
complexation reaction of drugs with either п acceptor (chloranil and 2,3-
dichloro-5,6 dicyano benzoquinone] or σ acceptor (Iodine). The colour 
produced was measured at 450, 455 and 290 nm for sertraline with chloranil, 
DDQ and iodine respectively. [Bebawy LI et al; 1999] 
 
 A simple and accurate first derivative spectrophotometric method was 
developed for nafazodone and sertraline in pharmaceutical dosage form. The 
measurement was carried out of their first derivative signals at 241.8 – 256.7 
nm and 271.6 – 275.5 nm (Peak to peak amplitude) respectively. The 
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calibration graphs were established for 10 – 42.0 μg/ml and 8 – 46 μg/ml 
respectively. [Nevin ERK; 2003] 
 
 A simple and reproducible spectrophotometric method has been 
developed for determination of sertraline, Fluoxetine and venlafaxine in 
pharmaceutical formulation. The method is based on reaction of drugs and ion 
pair agents (bromothymol blue, bromocresol green or bromophenol blue) to 
produce yellow coloured ion pair complexes in acidic buffers and extracted in 
chloroform and measured at optimum wavelength. Beer’s Law was obeyed 
within the concentration range from 1 – 15 μg/ml. [Armagan D et al; 2006] 
 
 Spectrophotometric determination of sertraline in bulk and 
pharmaceutical dosage form was developed. Solution of drug was prepared in 
methanolic hydrochloric acid and was measured at 275 nm. [Bruce MJ et al; 
1996] 
 
 
Table 2.10. Estimation of Sertraline hydrochloride by Spectrophotometry  
 
Sr. 
No. 
Specification Reference 
01 Rapid and simple spectrophotometric method was 
developed for determination of sertraline 
hydrochloride. 
Erk N.; 2003 
02 Development and validation of spectrophotometic 
method for determination of sertraline, Fluoxetine 
and Paroxetine in pharmaceutical dosage form. 
Darwish IA; 2005 
03 Spectrophotometric determination of Fluoxetine 
and sertraline using chloranil, 2,3-dichloro-5,6- 
dicyano benzoquinone and iodine. 
Bebawy LI et al; 
1999 
04 Determination of nafazodone and sertraline in 
pharmaceutical formulation using first derivative 
spectrophotometic method. 
Nevin ERK; 2002 
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05 Spectrophotometric determination of certain 
antidepressants using ion pair reagents to form 
ion pair complexes. 
Armagan D et al; 
2006 
06 U. V. spectrophotometric determination of 
sertraline hydrochloride was carried out in 
methanolic hydrochloric acid solution. 
Bruce MJ et al; 
1996 
 
Voltametric method 
 
 An electro analytical method for determination of sertraline was 
developed. A flow injection wave cathodic stripping voltametric method has 
been used for determination of sertraline in bulk and pharmaceutical dosage 
forms. The method shows linearity between peak current intensity and 
sertraline concentration. [Henri PA et al; 2005] 
 
 
Table 2.11. Estimation of Sertraline hydrochloride by Voltammetry  
 
Sr. 
No. 
Specification Reference 
01 Determination of sertraline in bulk and 
pharmaceutical dosage forms using a flow 
injection wave cathodic stripping voltametric 
method. 
Henri PA et al; 
2005 
 
Capillary Electrophoresis 
 
 A method for the analysis of sertraline and its main metabolite N-
desmethyl sertraline in human plasma was developed using capillary 
electrophoretic method with LIF detection (λ = 488nm). After pretreatment of 
biological fluid, followed by derivatization step in which reboxetine was used 
as a internal standard. The electrophoretic run is completed in 7.5 min. 
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Linearity was observed in the plasma concentration range of 3.0 to 500 μg/ml. 
[Alessandro M. et al; 2007] 
 
Table 2.12. Estimation of Sertraline hydrochloride by Capillary 
Electrophoresis 
 
Sr. 
No. 
Specification Reference 
01 Capillary Electrophoretic determination of 
sertraline and N-desmethyl sertraline in human 
plasma by CE with LIF detection. 
Alessandro M. et 
al; 2007 
 
 
2.1.3 Duloxetine hydrochloride 
 
High Performance Liquid Chromatographic Method 
 
 A rapid and sensitive liquid chromatography – mass spectrometric 
(LC/MS) method for determination of Duloxetine in human plasma using 
flupentinol as an internal standard was developed and validated. Sample 
preparation of the plasma involved deprotination with acetonitrile followed by 
high performance liquid chromatography using thermo hypersil – hypurity C18 
column. A single quadrupole mass spectrometer in the selected ion – 
monitoring mode to detect the [M + H]+ ions at 298 m/z for Duloxetine and at 
435 m/z for internal standard. [Ma N et al; 2007] 
 
 A determination of Duloxetine in pharmaceutical dosage form by high 
performance liquid chromatography – spectrophotometric technique using 
inertsil CN3 column was developed. 1% triethylamine solution (adjusted to pH 
6 by phosphate buffer) – acetonitrile (30:70 v/v) was used as mobile phase. 
The detection was carried out at 290 nm. The range of linearity was 0.06 – 
0.96 µg/ml. [Chang G et al; 2007] 
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 A sensitive bioanalytical method for the determination of two major 
metabolites of Duloxetine (4-hydroxy Duloxetine glucuronide and 5-hydroxy-4-
methoxy Duloxetine sulphate) in plasma was reported using liquid 
chromatography – tandem mass spectrometric method. [Satonin DK et al; 
2007] 
 
 A high performance liquid chromatographic method was developed and 
validated for Duloxetine and desmethyl Duloxetine in human plasma. The 
human plasma was adjusted to pH 10 with 1.0 M sodium carbonate and 
extracted with hexane which contain 2% isopropylalcohol. The concentrated 
extract was derivatized with dansyl chloride (500 µg/ml) and was separated 
using phenomenon primesphere 5C18HC column followed by fluorescene 
detection with excitation and emission wavelength at 285 nm and 525 nm 
respectively. The linearity was observed between 2 to 64 ng/ml for both. 
[Jason TJ et al; 1996] 
 
 High performance liquid chromatography – tandem mass spectroscopy 
was developed for the determination of Duloxetine in pharmaceutical dosage 
form. Good result was obtained in the range of 5 – 100 ng/ml. [Michael HS et 
al; 2004] 
 
 A rapid, sensitive and accurate liquid chromatographic–tandem mass 
spectrometry (LC–MS–MS) method is described for the determination of 
Duloxetine in human plasma. Duloxetine was extracted from plasma using 
methanol and separated on a C18 column. The mobile phase consisting of a 
mixture of acetonitrile and 5 mM ammonium acetate (45:55, v/v, pH 3.5) was 
delivered at a flow rate of 0.3 ml/min. Atmospheric pressure ionization (API) 
source was operated in positive ion mode. Multiple reaction monitoring (MRM) 
mode using the transitions of m/z 298.1 → m/z 44.0 and m/z 376.2 → m/z 
123.2 were used to quantify Duloxetine and internal standard (I.S.), 
respectively. The linearity was obtained over the concentration range of 0.1–
50.0 ng/ml and the lower limit of quantitation (LLOQ) was 0.1 ng/ml. [Selvan 
PS et al; 2007] 
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  A rapid and sensitive high-performance liquid chromatographic method 
was developed for Duloxetine analysis in human plasma. The assays were 
carried out using a C8 reversed-phase column and a mobile phase composed 
of 60% aqueous phosphate buffer containing triethylamine at pH 3.0 and 40% 
acetonitrile. The UV detector was set at 230 nm and loxapine was used as the 
internal standard. An original pre-treatment of plasma samples was 
developed, based on solid-phase extraction (SPE) with mixed-mode reversed 
phase—strong cation exchange cartridges (30 mg, 1 mL). The extraction 
yields values were higher than 90%. Linearity was found in the 2–200 ng mL−1 
Duloxetine concentration range; the limit of quantitation was 2.0 ng mL−1 and 
the limit of detection was 0.7 ng mL−1. [Raggi MA et al; 2007] 
 
 A new high-performance liquid chromatographic method is presented 
for the determination of 10 frequently prescribed tricyclic and nontricyclic 
antidepressants: imipramine, amitriptyline, clomipramine, Fluoxetine, 
sertraline, Paroxetine, citalopram, mirtazapine, moclobemide and Duloxetine. 
The simple and accurate sample preparation step, consisted of liquid:liquid 
extraction with recoveries ranging between 72% and 86%, except for 
moclobemide (59%). Separation was obtained using a reverse phase Select B 
column under isocratic conditions with UV detection (230 nm). The mobile 
phase consisted of 35% of a mixture of acetonitrile/methanol (92:8, v/v) and 
65% of 0.25 mol L−1 sodium acetate buffer, pH 4.5. The standard curves were 
linear over a working range of 2.5–1000 ng mL−1 for moclobemide, 5–
2000 ng mL−1 for citalopram, Duloxetine, Fluoxetine, 10–2000 ng mL−1 for 
sertraline, imipramine, Paroxetine, mirtazapine and clomipramine. The intra-
assay and inter-assay precision and accuracy were studied at three 
concentrations (50, 200, and 500 ng mL−1). The intra-assay coefficients of 
variation (CVs) for all compounds were less than 8.8%, and all inter-CVs were 
less than 10%. Limits of quantification were 2.5 ng mL−1 for moclobemide, 
5 ng mL−1 for citalopram, Duloxetine and amitriptyline, and 10 ng mL−1 for 
mirtazapine, Paroxetine, imipramine, Fluoxetine, sertraline, and clomipramine. 
No interference of the drugs normally associated with antidepressants was 
observed. The method has been successfully applied to the analysis of real 
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samples, for the drug monitoring of ten frequently prescribed tricyclic and non-
tricyclic antidepressant drugs. [Regina HCQ et al; 2007] 
 
 A simple reversed-phase high-performance liquid chromatographic 
method employing C-18 column has been developed for simultaneous 
analysis of three intermediates in the synthesis of S-Duloxetine, the 
antidepressant drug, viz., 2-acetyl thiophene (AT), N,N-dimethyl-3-keto-(2-
thienyl)-propanamine (DKTP) and (S)-N,N-dimethyl-3-hydroxy-(2-thienyl)-
propanamine (DHTP). Good separations were achieved by employing an 
isocratic system using acetonitrile and 0.05 M phosphate buffer (pH 7.0) 
containing 0.02% diethylamine. The detection was carried out at 241 nm. The 
method was validated for linearity, range, accuracy and precision. The 
developed method was applied for monitoring the progress of chemical 
synthesis of DKTP from AT followed by the biocatalytic reduction of DKTP to 
DHTP as the disappearance of the substrate and formation of the product can 
be monitored simultaneously by the present method. [Pankaj S et al; 2005] 
 
Table 2.13. Estimation of Sertraline hydrochloride by High Performance 
Liquid Chromatography 
 
Sr. 
No. 
Specification Reference 
01 Determination of Duloxetine in human plasma 
using liquid chromatography – mass spectrometric 
method was developed. 
Ma N et al; 2007 
02 High Performance Liquid Chromatography – UV 
Spectrophotometric determination of Duloxetine in 
pharmaceutical formulation was developed. 
Chang G et al; 
2007 
03 Development and validation of liquid 
chromatography – tandem mass spectrometric 
method for determination of Duloxetine in human 
plasma. 
 
Satonin DK et al; 
2007 
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04 High Performance Liquid Chromatographic method 
was developed for determination of Duloxetine and 
desmethyl Duloxetine in human plasma. 
Jason TJ et al; 
1996 
05 High Performance Liquid Chromatography – 
tandem mass spectroscopy was developed for 
determination of Duloxetine. 
Michael HS et al; 
2004 
06 Determination of Duloxetine in human plasma by 
liquid chromatography with atmospheric pressure 
ionization–tandem mass spectrometry and its 
application to pharmacokinetic study 
Selvan PS et al; 
2007 
 
07 HPLC analysis of the novel antidepressant 
Duloxetine in human plasma after an original solid-
phase extraction procedure 
Raggi MA et al; 
2007 
08 Reliable HPLC method for therapeutic drug 
monitoring of frequently prescribed tricyclic and 
nontricyclic antidepressants 
Regina HCQ et 
al; 2007 
09 High-performance liquid chromatographic method 
for the simultaneous estimation of the key 
intermediates of Duloxetine
Pankaj S et al; 
2005 
 
Spectrophotometric Method 
 
 A simple, sensitive and accurate ultra violet spectrophotometric method 
was developed for the determination of Duloxetine in raw material and 
capsules validation of the method yielded good results concerning range, 
linearity, precision and accuracy. The absorbance was measured at 290 nm. 
The linearity range was found to be 5 – 50 µg/ml. [Kamila MH et al; 2007] 
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Table 2.14. Estimation of Sertraline hydrochloride by Spectrophotometry 
 
Sr. 
No. 
Specification Reference 
01 A simple, sensitive and accurate UV 
Spectrophotometric method was developed for 
Duloxetine in pharmaceutical formulation. 
Kamila MH et al; 
2007 
 
Capillary Gas Chromatographic Method 
 
 A capillary gas chromatographic method for the determination of 
residual organic solvents in Duloxetine was developed. [Jian OL et al; 2006] 
 
Table 2.15. Estimation of Sertraline hydrochloride by Capillary Gas 
Chromatography 
 
Sr. 
No. 
Specification Reference 
01 A residual organic solvent was determined from 
Duloxetine by capillary gas chromatographic 
technique. 
Jian OL et al; 
2006 
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2.2 Antihypertensive agents 
 
2.2.1 Valsartan 
 
High Performance Liquid Chromatographic Method 
 
 A high performance liquid chromatographic method for the 
determination of Valsartan in human plasma was developed. The assay is 
based on protein precipitation with methanol and reversed phase liquid 
chromatography with fluorometric detection. The liquid chromatography was 
performed on an octadecyl silica column using acetonitrile – 15mM 
dihydrogen potassium phosphate, pH 2 (45:55 v/v) as the mobile phase. The 
fluorimetric detection was operated at 234/374 nm (excitation / emission 
wavelength). The limit of quantification was 98 ng/ml. [Macek J et al; 2006] 
 
 A sensitive liquid chromatography – tandem mass spectrometry 
method for the determination of Valsartan in human plasma was developed 
and validated. [Nozomu K et al; 2007] 
 
 A simple and fast method for the simultaneous determination of 
Valsartan and its metabolite in human plasma using high performance liquid 
chromatographic – UV and fluorimetric methods. The separation was 
performed on an RP C18 Atlantis column using acetonitrile – trifluoroacetic 
acid and phosphate buffer (5 mM, pH=2.5) [50:50 v/v] as the mobile phase. 
The eluent was monitored with fluorescence detector at 234 and 378 nm 
excitation and emission wavelength respectively and at 254 nm using 
photometric detector. [Gorka I et al; 2007] 
 
 A rapid and specific high performance liquid chromatographic method 
was developed and validated for the simultaneous determination of 
ketoprofen, Valsartan and pantoprazol in human plasma. The separation was 
performed using chromasil C18 column and 0.02 M sodium dihydrogen 
phosphate buffer (pH 3.15) – acetonitrile (58:42 v/v) used as the mobile 
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phase. The detection was carried out using diode array detector. [Kocyigit B 
et al; 2006] 
 
 A rapid high performance liquid chromatographic method was 
developed for the determination of Valsartan in pharmaceutical dosage form. 
The separation was performed on C18 column using acetonitrile – phosphate 
buffer as mobile phase, where losartan is used as an internal standard. The 
detection was carried out at 265 nm with a UV detector. The assay was linear 
over the concentration range 1.0 – 5.0 µg/ml. [Tatar S et al; 2002] 
 
 A high performance liquid chromatographic – UV spectrometric method 
was developed for the determination of Valsartan and hydrochlorthiazide 
simultaneously in combined dosage forms. The separation was carried out on 
a reversed phase column using 0.02 M phosphate buffer (pH 3.2) – 
acetonitrile (55:45 v/v) mobile phase for the separation of Valsartan and 
hydrochlorthiazide. The linearity were observed in concentration range 0.06 – 
1.8 µg/ml and 0.07 – 0.5 µg/ml respectively. [Satana E et al; 2001] 
 
 Several angiotensin II receptor antagonists were analysed from human 
plasma and urine. Under optimized extraction condition, the protein 
component of the biological sample was flushed through the monolithic 
capillary, while the analytes were successfully trapped coupled to HPLC with 
fluorescence detection. This on line in tube solid – phase micro extraction 
(SPME) method was successfully applied for the determination of 
candesartan, losartan, irbesartan, valsartan, telmisartan, and their detection 
limit were found to be 0.1 – 15.3 ng/ml and 0.1 – 15.2 ng/ml in human plasma 
and urine respectively. The method was linear over the range of 0.5 – 200 
ng/ml for telmisartan, 5 – 2000 ng/ml for candensartan and irbesartan, 10 – 
2000 ng/ml for Valsartan and 50 – 5000 ng/ml for losartan with correlation co-
efficient being above 0.9985 in plasma and above 0.9994 in urine sample. 
[Jing H et al; 2005] 
 
 A method for the simultaneous determination of the β-blockers 
(Atenolol, Sotalol, metoprolol, Bisoprolol, Propranolol and Carvedilol), the 
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calcium channel antagonists (diltiazem, amlodipine and verapamil), the 
angiotensin – II antagonists (Losartan, Irbesartan, Valsartan, Telmisartan) and 
the antiarrythmic drug (Flecainide), in whole blood samples was developed. 
Sample clean – up was achieved by precipitation and solid phase extraction 
with mixed mode column. Quantification was performed by reversed phase 
high performance liquid chromatography with positive electrospray ionization 
mass spectrometric detection. The method has been developed and 
robustness tested by systematically searching for satisfactory conditions using 
good linearity was observed. [Lena K et al; 2007] 
 
 A rapid, sensitive and accurate liquid chromatographic –tandem mass 
spectrometric method is described for the simultaneous determination of 
nebivolol and Valsartan in human plasma. Nebivolol and Valsartan were 
extracted from plasma using acetonitrile and separated on a C18 column. The 
mobile phase consisting of a mixture of acetonitrile and 0.05mM formic acid 
(50:50 v/v, pH 3.5) was delivered at a flow rate of 0.25 ml/min. Atmospheric 
pressure ionization (API) source was operated in both positive and negative 
ion mode for nebivolol and valsartan, respectively. Selected reaction 
monitoring mode (SRM) using the transitions of m/z 406.1 ----> m/z 150.9; m/z 
434.2 ----> m/z 179.0 and m/z 409.4 ----> m/z 228.1 were used to quantify 
nebivolol, Valsartan and internal standard (IS), respectively. The linearity was 
obtained over the concentration range of 0.01 – 50.0 ng/ml and 1.0 – 2000.0 
ng/ml and the lower limits of quantitation were 0.01 ng/ml and 1.0 mg/ml for 
nebivolol and valsartan, respectively. This method was successfully applied to 
the pharmacokinetic study of fixed dose combination (FDC) of nebivolol and 
Valsartan formulation product after an oral administration to healthy human 
subjects. [Selvan PS et al; 2007] 
 
 A selective, accurate and precise high-performance liquid 
chromatographic assay coupled to fluorescence detection was developed for 
the detection of some angiotensin II receptor antagonists (ARA II): Losartan, 
Irbesartan, Valsartan, Candesartan cilexetil and its metabolite Candesartan 
M1. The analytes and the internal standard (bumetanide, a high-ceiling 
diuretic) were extracted from plasma under acidic conditions by means of 
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solid-phase extraction using C8 cartridges. This procedure allowed recoveries 
close to 80% for all these drugs excluding Candesartan cilexetil (70%) which 
presented adsorption processes on glass and plastic walls. The analytes and 
potential interferences were separated on a reversed-phase column, 
μBondapak C18, at room temperature. A gradient elution mode was used to 
carry out the separation, the optimal mobile phase being composed of 
acetonitrile–5 mM acetate buffer, pH 4, at variable flow-rates (from 1.0 to 1.2 
ml/min). Fluorescence detector was set at an excitation wavelength of 250 nm 
and an emission wavelength of 375 nm. Intra- and inter-day relative standard 
deviations for all the compounds were lower than 8% except for Losartan 
(12%) and the method assesses a quite good accuracy (percentage of 
relative error 6% in most of the cases). The limit of quantitation for these 
compounds was 3 ng/ml for Candesartan cilexetil and M1, 16 ng/ml for 
Losartan and 50 ng/ml for Irbesartan and Valsartan, which allows their 
determination at expected plasma concentration levels. This assay method 
has been successfully applied to plasma samples obtained from hypertensive 
patients under clinical studies after oral administration of a therapeutic dose of 
some of these ARA II compounds. [Alonso RM et al; 2002] 
 
 A stereospecific HPLC method for the quantitation of CGP 49309 in 
samples of its corresponding enantiomer Valsartan has been developed and 
validated. The enantiomeric separation was achieved on a 5 μm silica-bonded 
α1-acid glycoprotein column (Chiral AGP) with a phosphate buffer, pH 7, 
containing 2% (v/v) 2-propanol as a mobile phase. The linearity was 
established in the range 0.1–4% (r>;0.999). The limit of quantitation was 0.1% 
and the limit of detection was 0.04%. The accuracy of the method was found 
to be 96.7% (average). For the precision (repeatability), a relative standard 
deviation value of 2.4% was found. Similarly, a stereoselective HPLC method 
was also developed and validated for the quantitation of the enantiomer of the 
starting material used for the synthesis of valsartan, namely (R)- valinebenzyl 
ester tosylate. Baseline resolution of the enantiomers of valinebenzyl ester 
tosylate could be achieved on the chiral crown ether column Crownpak CR 
(Daicel) at 50°C using water-methanol-trifluoroacetic acid (850:150:1, v/v) as 
a mobile phase. The linearity was established in the range 0.5-5% (r>;0.999). 
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The accuracy of the method was found to be 100.5% (average). For the 
precision (repeatability), a relative standard deviation value of 3.4% was 
found. Both methods were found to be suitable for the analysis of the 
respective analytes. [Eric F et al; 1996] 
 
Table 2.16. Estimation of Valsartan by High Performance Liquid 
Chromatography 
Sr. 
No. 
Specification Reference 
01 Rapid determination of Valsartan in human plasma 
by protein precipitation and high performance liquid 
chromatographic method was developed. 
Macek J et al; 
2006 
02 Development and validation of a method for 
quantitative determination of Valsartan in human 
plasma was developed by liquid chromatography – 
tandem mass spectrometry. 
Nozomu K et al; 
2007 
03 Biovalidation of high performance liquid 
chromatography – UV – fluorescence method was 
developed for Valsartan and its metabolite in 
human plasma. 
Gorka I et al; 
2007 
04 Determination and validation of Ketoprofen, 
Pantoprazole and Valsartan together in human 
plasma was developed using HPLC. 
Kocyigit B et al; 
2006 
05 Determination of Valsartan in pharmaceutical 
formulation using HPLC – UV Spectrophotometric 
method. 
Tatar S et al; 
2002 
06 Determination of Valsartan in pharmaceutical 
formulation using HPLC – UV Spectrophotometric 
method. 
Satana E et al; 
2001 
07 Biocompatible in tube solid – phase micro 
extraction coupled to HPLC for the determination of 
angiotensin II receptor antagonists in human 
plasma and urine was developed. 
Jing N et al; 
2005 
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08 Simultaneous determination of 6 β-blockers, 3 
calcium channel blockers, 4 angiotensin – II 
antagonists and one antiarrhythmic drug in post 
mortem whole blood by automated solid phase 
extraction and liquid chromatography mass 
spectrometry was developed. 
Lena K et al; 
2007 
09 Simultaneous determination of fixed dose 
combination of Nebivolol and Valsartan in human 
plasma by liquid chromatographic – tandem mass 
spectrometric method was developed. 
Selvan PS et al; 
2007 
10 Fast screening method for the determination of 
angiotensin II receptor antagonists in human 
plasma by high-performance liquid chromatography 
with fluorimetric detection  
Alonso RM et al; 
2002 
11 Development and validation of chiral high-
performance liquid chromatographic methods for 
the quantitation of Valsartan and of the tosylate of 
valinebenzyl ester.
Eric F et al; 1996
 
High Performance Thin Layer Chromatographic Method 
 
 A new, simple, accurate, and precise high-performance thin-layer 
chromatographic (HPTLC) method has been established for simultaneous 
analysis of Valsartan and hydrochlorothiazide in tablet formulations. Standard 
and sample solutions of Valsartan and hydrochlorothiazide were applied to 
precoated silica gel G 60 F254 HPTLC plates and the plates were developed 
with chloroform-ethyl acetate-acetic acid, 5:5:0.2 v/v, as mobile phase. UV 
detection was performed densitometrically at 248 nm. The retention factors of 
Valsartan and hydrochlorothiazide were 0.27 and 0.56, respectively. The 
linear range was 800 – 5600 ng per spot for Valsartan and 125 – 875 ng per 
spot for hydrochlorothiazide; the correlation coefficients, r, were 0.9998 and 
0.9988, respectively. The method was validated in accordance with the 
requirements of ICH guidelines and was shown to be suitable for purpose. 
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The method was successfully used for determination of the drugs in tablets. 
Tablets excipients did not interfere with the chromatography. [Kadam BR et 
at; 2007] 
 
Table 2.17. Estimation of Valsartan by High Performance Thin Layer 
Chromatography 
 
Sr. 
No. 
Specification Reference 
01 Determination of Valsartan and 
hydrochlorothiazide in tablets was developed 
using high performance thin layer chromatography 
with ultraviolet absorption densitometry.  
Kadam BR et al; 
2007 
 
Spectrophotometric Method 
 
 A simple, sensitive and rapid method for the determination of Valsartan 
was developed using ultra violet spectrophotometric method. The 
measurement was carried out at 205.6 nm. The linearity was observed in the 
range of 2.0 – 10 µg/ml while in second method, the distance between two 
extreemum value (peak to peak amplitude) 221.6 and 231.2 nm were 
measured in the second order derivative spectra of standard solution. [Tatar S 
et al; 2002] 
 
 First derivative UV Spectrophotometric method was developed for 
simultaneous determination of Valsartan and hydrochlorothiazide in combined 
dosage forms. The derivative procedure was based on the linear relationship 
between the drug concentration and the first derivative amplitude at 270.6 and 
335 nm for Valsartan and hydrochlorothiazide respectively. The calibration 
graph were linear in the range of 12 – 36.1 µg/ml and 4 – 12.1 µg/ml for 
Valsartan and hydrochlorothiazide respectively. [Satana E et al; 2001] 
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 The two new method for the simultaneous determination of Valsartan 
and hydrochlorothiazide in pharmaceutical dosage forms have been 
developed. The first method, based on compensation technique is presented 
for derivative Spectrophotometric determination of binary mixtures with 
overlapping spectra by using ratio of derivative maxima or the derivative 
minimum, the exact compensation of either component in the mixture can be 
achieved followed by its determination. The second method, differential 
derivative spectrophotometry, comprised of measurement of the difference 
absorptivities derivatised in the first order of a tablet extract in 0.1 N NaOH 
relative to that of an equimolar solution in methanol at wavelength of 227.8 
and 276.5 nm respectively. [Nevin E; 2002] 
 
 Two new spectral approach (graphical and chemometric techniques) 
were applied for resolution of a binary mixture of Valsartan (VST) and 
hydrochlorothiazide (HCT) in tablets without a separation procedure. In the 
ratio derivative spectrophotometry, analytical derivative amplitudes were 
measured at 231.5 and 260.5 nm for VST and at 270.6 nm for HCT in the first 
derivative of the ratio spectra. The calibration graphs follow Beer’s law in the 
ranges of 8 – 24 µg/ml for VST and 2 -10 µg/ml for HCT. The prepared 
calibrations for the first technique were tested for the synthetic binary mixtures 
and 1.76 % for VST, 102.5 % and 2.41 % for HCT, respectively. In the inverse 
least square technique, absorbances matrix were produced by measurements 
in the spectral range from 225 to 280 nm of the interval of Δλ = 5 nm at 12 
wavelengths in zero order spectra of the various binary mixtures. The 
prepared calibration set for the absorbance and concentration values were 
used to predict the concentration of VST and HCT in their binary mixtures and 
tablets. The “Maple V” software was used for the numerical calculations. For 
this technique, mean recoveries and relative standard derivations were found 
as 101.2 % and 1.58 % for VST and 96.2 % and 2.35% for HCT. Both 
techniques were successfully applied for the determination of these two drugs 
in tablets. [Erdal D et al: 2005] 
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Table 2.18. Estimation of Valsartan by Spectrophotometry 
 
Sr. 
No. 
Specification Reference
01 UV and second derivative spectrophotometric method 
have been developed for Valsartan in pharmaceutical 
formulations.   
Tatar S et 
al; 2002 
02 Simultaneous determination of Valsartan and 
hydrochlorothiazide using first derivative UV 
spectrophotometric method was developed. 
Satana E 
et al; 2001 
03 Spectrophotometric determination of Valsartan and 
hydrochlorothiazide in pharmaceutical dosage forms was 
developed. 
Nevin E; 
2002 
04 Spectral resolution of binary mixture containing Valsartan 
and hydrochlorothiazide in tablets by ratio spectra 
derivative and inverse least square techniques were 
developed. 
Erdal D et 
al; 2005 
 
Spectrofluorimetric Method 
 
 A spectrofluorimetric method has been developed for the determination 
of two angiotensin II receptor antagonists (ARA II): Losartan and Valsartan. A 
fractional factorial design and a central composite design were used. The key 
factors considered in the optimization process were pH, temperature and 
emission slit width. Maximum fluorescent intensity was established as 
response for each experiment. The response surfaces confirmed the 
robustness of the method. A clean-up procedure was used for urine samples 
that consisted of a solid-phase extraction using C8 cartridges. The total 
analysis time was lower than 30 min. This method proved to be accurate (RE, 
8%), precise (intra- and inter-day coefficients of variation were lower than 8% 
and sensitive enough (LOQ c.a. 0.5 μg ml−1) to be applied to the 
determination of Losartan and Valsartan in urine samples. [Alonso RM et al; 
2001] 
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Table 2.19. Estimation of Valsartan by Spectrofluorimetry 
 
Sr. 
No. 
Specification Reference
01 Experimental design methodologies to optimise the 
spectrofluorimetric determination of Losartan and 
Valsartan in human urine  
Alonso RM 
et al; 2001 
 
Micellar Electrokinetic Capillary Chromatographic Method 
 
 Micellar electrokinetic capillary chromatographic method was 
developed for the separation of six angiotensin-II-receptor antagonists (ARA-
IIs): candesartan, eprosartan mesylate, irbesartan, losartan potassium, 
telmisartan, and valsartan. A face-centred central composite design was 
applied to study the effect of the pH, the molarity of the running buffer, and the 
concentration of the micelle-forming agent on the separation properties. A 
combination of the studied parameters permitted the separation of the six 
ARA-IIs, which was best carried out using a 55-mM sodium phosphate buffer 
solution (pH 6.5) containing 15 mM of sodium dodecyl sulfate. The same 
system can also be applied for the quantitative determination of these 
compounds, but only for the more stable ARA-IIs (candesartan, eprosartan 
mesylate, losartan potassium, and valsartan). Some system parameters 
(linearity, precision, and accuracy) were validated. [Hillaert S et al; 2003] 
 
Table 2.20. Estimation of Valsartan by Micellar Electrokinetic Capillary 
Chromatography 
 
Sr. 
No. 
Specification Reference
01 Optimization and validation of a micellar electrokinetic 
chromatographic method for the analysis of several 
angiotensin-II-receptor antagonists  
Hillaert S 
et al; 2003 
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Capillary Zone Electrophoretic Method 
 
 A capillary zone electrophoretic method was developed for separation 
of six angiotensin-II-receptor antagonists (ARA-IIs): candesartan, eprosartan, 
irbesartan, losartan potassium, telmisartan, and valsartan. A three-level, full-
factorial design was applied to study the effect of the pH and molarity of the 
running buffer on separation. Combination of the studied parameters 
permitted the separation of the six ARA-IIs, which was best carried out using 
60 mM sodium phosphate buffer (pH 2.5). The same system can also be 
applied for the quantitative determination of these compounds, but only for the 
more soluble ones. Some parameters (linearity, precision and accuracy) were 
validated. [Hillaert S et al; 2002] 
 
 
Table 2.21. Estimation of Valsartan by Capillary Zone Electrophoresis 
 
Sr. 
No. 
Specification Reference
01 Optimization and validation of a capillary zone 
electrophoretic method for the analysis of several 
angiotensin-II-receptor antagonists  
Hillaert S 
et al; 2002 
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2.3 Ion pair complexes 
 
 A spectrophotometric procedure for the determination of terfenadine 
and a number of its pharmaceutical preparations has been developed that 
offers advantages of simplicity, rapidity, sensitivity and stability indication over 
the official USP (1995) method. The proposed method is based on the 
formation of ion-pairs by the reaction of terfenadine with some chromotropic 
acid mono- and bis-azo dyes. Different variables affecting the ion-pair 
formation were studied and optimized. At the maximum absorption of 557, 
521, 592 and 543 nm, Beer's law is obeyed in the range 0.2–18.6, 0.2–16.4, 
0.2–25.0 and 0.2–22.2 µg ml–1 on using reagents I, II, III and IV, respectively. 
The stoichiometric ratio and stability of each ion-pair were estimated and the 
mechanism of the reaction is discussed. The molar absorptivity and Sandell 
sensitivity of the produced ion-pairs were calculated in addition to Ringbom 
optimum concentration ranges. Statistical treatment of the experimental 
results indicates that the procedures are precise and accurate. Excipients 
used as additives in pharmaceutical formulations did not interfere in the 
proposed procedures. The reliability of the methods was established by 
parallel determination against the official USP method. The procedures 
described were successfully applied to the determination of the bulk drug and 
its pharmaceutical formulations by applying the standard addition technique. 
[Amin AS et al; 1999] 
 
 Simple, sensitive, and accurate visible spectrophotometric methods are 
described for the determination of Paroxetine hydrochloride (PA) in tablets. 
Among them, the first 3 methods are based on the ion-pair complexes of PA 
formed with bromothymol blue (BTB), bromophenol blue (BPB), and 
bromocresol green (BCG) in aqueous acidic buffers. The complex species 
extracted into chloroform were quantitatively measured at 414 nm with BTB 
and BCG and at 412 nm with BPB. Beer's law was obeyed over the 
concentration ranges of 2–20, 2–16, and 2–16 μg/mL, respectively. The fourth 
method described is based on a coupling reaction between PA and 7-chloro-
4-nitrobenzofurazon (NBD-Cl) in borate buffer, pH 8.5, in which a yellow 
reaction product that was measured at 478 nm was formed. The Beer's law 
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range for this method was 2–10 μg/mL. The last method developed describes 
the interaction of PA base, as an n-electron donor, with 7,7,8,8-
tetracyanoquinodimethane (TCNQ), as a π-acceptor, in acetonitrile to give 
blue-colored TCNQ− radical anion with absorption maxima at 750 and 845 
nm. Measured at 845 nm, the absorbance–concentration plot was rectilinear 
over the range of 1.5–15 μg/mL. The new methods developed were 
successfully applied to the determination of PA in tablets without any 
interference from common tablet excipients. The results of the methods were 
in good agreement with those obtained with an official liquid chromatographic 
method. This report describes first colorimetric methods for the determination 
of PA. [Armagan O et al; 2005] 
 
 Extractive spectrophotometric methods are described for the 
determination of lercanidipine (LER) either in pure form or in pharmaceutical 
formulations. The methods involve formation of coloured chloroform 
extractable ion-pair complexes with bromothymol blue (BTB) and bromocresol 
green (BCG) in acidic medium. The extracted complexes showed absorbance 
maxima at 417 and 416 nm for BTB and BCG, respectively. The optimization 
of the reaction conditions was investigated. Beer's law is obeyed in the 
concentration ranges 6.0-42.0 µg/ml(-1) or 7.1-43.8 µg/ml(-1) with BTB or 
BCG, respectively. The composition of the ion-pairs was found to be 1:1 by 
Job's method. The specific absorptivities, molar absorptivities, Sandell 
sensitivities, standard deviations and percent recoveries were evaluated. 
Also, LER was determined by measurement of its first derivative signals at 
245 nm. Calibration graph was established for 4.2-58.0 µg/ml(-1) of LER. The 
methods have been applied to the determination of drug in commercial 
tablets. Results of analysis were validated. No interferences were observed 
from common pharmaceutical adjuvants. [Erk N; 2003] 
 
 A simple, extraction-free spectrophotometric method is proposed for 
the analysis of some β-blockers, namely atenolol, timolol and nadolol. The 
method is based on the interaction of the drugs in chloroform with 0.1% 
chloroformic solutions of acidic sulphophthalein dyes to form stable, yellow-
coloured, ion-pair complexes peaking at 415nm. The dyes used were 
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bromophenol blue (BPB), bromothymol blue (BTB) and bromocresol purple 
(BCP). Under the optimum conditions, the three drugs could be assayed in 
the concentration range 1-10 µg/ with correlation coefficient (n=5) more than 
0.999 in all cases. The stoichiometry of the reaction was found to be 1:1 in all 
cases and the conditional stability constant (K"F) of the complexes have been 
calculated. The free energy changes were determined for all complexes 
formed. The interference likely to be introduced from co-formulated drugs was 
studied and their tolerance limits were determined. [Al-Ghannam SM; 2006] 
 
 A spectrophotometric method is described for the determination of 
oxiconazole in raw material and in topical lotion. This method is based on the 
reaction of the oxiconazole with methyl orange in buffered aqueous solution of 
citric acid at pH 2.3. The chromogen, being extractable with dichloromethane, 
could be measured quantitatively with maximum absorption at 427 nm. The 
Lambert-Beer law was obeyed in the concentration range of 4.0-14.0 µg/ml. A 
prospective validation of the method showed that the method was linear 
(r=0.9995), precise (intra-day: CV=1.57% and inter-day: CV=1.50%) and 
accurate (mean recoveries: 99.69%). [Milano J. et al; 2005] 
 
 A sensitive method for determining ethambutol (20-100 g) in aqueous 
solutions and tablets is described, using bromthymol blue as a complex-
forming agent. Extraction of the complex in chloroform as well as in methylene 
chloride or ethylene dichloride is accomplished readily at an optimum pH 7. A 
stoichiometric relationship of 1:2 between ethambutol and the acid dye is 
proved. Cycloserine, isoniazid, and sodium aminosalicylate do not interfere 
with the assay. The reineckate precipitation method for ethambutol 
determination is compared and its direineckate derivative is identified. [Girgis 
EH et al; 1974] 
 
 Three simple, sensitive and accurate spectrophotometric methods 
have been developed for the determination of oxomemazine hydrochloride in 
bulk and pharmaceutical formulations. These methods are based on the 
formation of yellow ion-pair complexes between the examined drug and 
bromocresol green (BCG), bromocresol purple (BCP), and bromophenol blue 
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(BPB) as sulphophthalein dyes in acetate-HCl buffer of pH 3.6, 3.4, and 4.0, 
respectively. The formed complexes were extracted with dichloromethane and 
measured at 405 nm for all three systems. The best conditions of the 
reactions were studied and optimized. Beer's law was obeyed in the 
concentration ranges 2.0-12, 2.0-13, and 2.0-14 g mL-1 with molar 
absorptivities of 3.2 × 104, 3.7 × 104, and 3.1 × 104 L mol-1 cm-1 for the BCG, 
BCP, and BPB methods, respectively. Sandell's sensitivity, correlation 
coefficient, detection and quantification limits are also calculated. The 
proposed methods have been applied successfully for the analysis of the drug 
in pure form and in its dosage forms. No interference was observed from 
common pharmaceutical excipients. Statistical comparison of the results with 
those obtained by HPLC method shows excellent agreement and indicates no 
significant difference in accuracy and precision. [Akram ME; 2005] 
 
 Two simple, quick and sensitive spectrophotometric methods are 
described for the determination of enrofloxacin and Pefloxacin. The methods 
are based on the reaction of these drugs with bromophenol blue (BPB) and 
methyl orange (MO) in buffered aqueous solution at pH 2.3–2.5 in case of 
bromophenol blue and at pH 3.6 with MO to give highly coloured complex 
species, extractable with chloroform. The coloured products are quantitated 
spectrophotometrically at 420 and 424 nm for BPB and MO, respectively. 
Optimisation of the different experimental conditions is described. Beer's law 
is obeyed in the concentration ranges 2–12 and 2–18 μg ml−1 with BPB and in 
the ranges 1–12 and 4–40 μg ml−1with MO for enrofloxacin and pefloxacin, 
respectively. The proposed methods are applied for determination of Enroxil 
oral solution, Peflacine tablets and Peflacine ampoules with mean percentage 
accuracies 99.5±0.99, 99.39±1.05 and 100.02±0.895, respectively, with BPB 
and 100.30±0.89, 100.25±0.98 and 100.20±0.72, respectively, with MO. 
[Mostafa S et al; 2002] 
 
 It has been established that the antibiotic pefloxacin (Abaktal) 
methane-sulphonate reacts with Fe(III) at pH 1.00–8.00 to form a water-
soluble complex with maximum absorbance at 360 nm. The composition of 
the complex, determined spectrophotometrically by the application of Job's, 
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molar-ratio and Bent—French's methods, was pefloxacin: Fe(III) = 1:1 (pH = 
2.50; λ = 360 nm; μ = 0.1 M). The relative stability constant, obtained by the 
methods of Sommer and Asmus was 105.02 (pH = 2.50; λ = 360 nm; μ = 0.1 
M). The molar absorptivity of the complex at 360 nm was found to be 4.8 × 
103 l mol−1 cm−1, Beer's law was followed for pefloxacin concentrations of 
2.15–85.88 μg ml−1. The lower sensitivity limit of the method was 2.15 μg ml−1. 
The relative standard deviation (n = 10) was 0.57–1.07%. The method can be 
applied to the rapid and simple determination of pefloxacin in aqueous 
solutions and tablets. [Jelikic SM et al; 1989] 
 
 A direct, extraction-free spectrophotometric method has been 
developed for the determination of cinnarizine in pharmaceutical preparations. 
The method is based on ion-pair formation between the drug and three acidic 
(sulphonphthalein) dyes; namely bromocresol green (BCG), bromocresol 
purple (BCP) and bromophenol blue (BPB) which induces an instantaneous 
bathochromic shift of the maximum in the drug spectrum. Conformity to Beer's 
law enabled the assay of dosage forms of the drug. Compared with a 
reference method, the results obtained were of equal accuracy and precision. 
A more detailed investigation of the cinnarizine-BCG ion pair complex was 
made with respect to its composition, association constant and free energy 
change. In addition, this method was also found to be specific for the analysis 
of cinnarizine in the presence of some of the co-formulated drugs, such as 
pyridoxine hydrochloride and digoxin. [Abdine H et al; 2002] 
 
 Two simple, rapid and sensitive extractive spectrophotometric methods 
have been developed for the assay of trazodone hydrochloride (TRH) in pure 
and pharmaceutical formulations. These methods are based on the formation 
of chloroform soluble ion-association complexes of TRH with bromothymol 
blue (BTB) and with bromocresol purple (BCP) in KCl–HCl buffer of pH 2.0 
(for BTB) and in NaOAc–AcOH buffer of pH of 3.6 (for BCP) with absorption 
maximum at 423 nm and at 408 nm for BTB and BCP, respectively. Reaction 
conditions were optimized to obtain the maximum color intensity. The 
absorbance was found to increase linearly with increase in concentration of 
TRH, which was corroborated by the calculated correlation coefficient values 
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(0.9996, 0.9945). The systems obeyed Beer's law in the range of 0.2—14.5 
and 0.2—14.1 μg/ml for BTB and BCP, respectively. Various analytical 
parameters have been evaluated and the results have been validated by 
statistical data. No interference was observed from common excipients 
present in pharmaceutical formulations. The proposed methods are simple, 
accurate and suitable for quality control applications. [Ramanaboyina SK et al; 
2006] 
 
 A simple extractive spectrophotometric method has been developed for 
the estimation of sildenafil citrate in both pure and pharmaceutical dosage 
forms. The method is based on the formation of ion-pair complexes of the 
drug with three acid dyes namely bromothymol blue (BTB), bromocresol 
green (BCG), bromophenol blue (BPB) in acidic buffer solutions followed by 
their extraction in organic solvent (chloroform). The absorbance of the organic 
layer was measured at their respective wavelength of maximum absorbance 
against the corresponding reagent blank. The method has been statistically 
evaluated and is found to be precise and accurate. [Reddy MN et al; 2002] 
 
 Two new rapid, sensitive and economical spectrophotometric methods 
are described for the determination of Fluoxetine hydrochloride in bulk and in 
pharmaceutical formulations. Both methods are based on the formation of a 
yellow ion-pair complex due to the action of methyl orange (MO) and thymol 
blue (TM) on Fluoxetine in acidic (pH 4.0) and basic (pH 8.0) medium, 
respectively. Under optimised conditions they show an absorption maxima at 
433 nm (MO) and 410 nm (TB), with molar absorptivities of 2.12×10−4 and 
4.207×10−3 l mol−1 cm−1 and Sandell’s Sensitivities of 1.64×10−2 and 0.082 μg 
cm−2 per 0.001 absorbance unit for MO and TB, respectively. The colour is 
stable for 5 min after extraction. In both cases Beer’s Law is obeyed at 1–20 
μg mol−1 with MO and 4–24 μg mol−1 with TB. The proposal method was 
successfully extended to pharmaceutical preparations—capsules. The results 
obtained by both the agreement and E.P. (3rd edition) were in good 
agreement and statistical comparison by Student’s t-test and variance ratio F-
test showed no significant difference in the three methods. [Prabhakar AH et 
al; 1999] 
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 Three methods are described for the determination of trazodone 
hydrochloride in pharmaceutical tablets. The spectrophotometric method was 
based on the formation of yellow ion pair complex between the basic nitrogen 
of the drug and bromophenol blue at pH 3.4. The formed complex was 
extracted with chloroform and measured at 414 nm. The spectrofluorimetric 
method was based on measurement of the native fluorescence of the drug in 
50% acetic acid upon excitation at a maximum of 320 nm and the emission 
wavelength is 435 nm. The third method was based on the high performance 
liquid chromatographic determination of trazodone hydrochloride using a 
reversed phase, ODS column, with a mobile phase of acetonitrile--phosphate 
buffer at pH 4.5 (60:40, v/v). Quantization was achieved with UV detection at 
250 nm based on peak area. The three methods were simple, accurate and 
suitable for quality control application. [El-Gindy A. et al; 2001] 
 
 A rapid method is presented for determining strychnine and brucine in 
liquid galenicals. At pH 5.0, both strychnine and brucine are complexed with 
methyl orange. After treatment with 0.1N NaOH, the liberated alkaloids are 
determined spectrophotometrically, using the 2-wavelength method of 
analysis. The method has been successfully applied to the analysis of 4 
batches of nux vomica tincture, nux vomica acid, and nux vomica alkaline 
mixtures. The method has a relative standard deviation of 0.52%. [El-Massy 
S. et al; 1978] 
 
 An acid-dye colormetric method was described for the determination of 
chlorpromazine hydrochloride in the compound preparation. The method was 
based on the reaction of chlorpromazine hydrochloride with methyl orange, to 
form a yellow complex, which then was extracted by chloroform and exhibited 
a maximum absorption at 424 nm. The optimal conditions for determination 
were selected by orthogonal design test. The linear range of this method was 
20-120 µg/ml (r = 0.9997). The average recovery of the three sample 
solutions of different concentrations was 99.72% +/- 0.46% (n = 6). The other 
ingredients of preparation do not interfere with chlorpromazine determination. 
This method is more sensitive and accurate and can be used for quality 
control of this compound preparation. [Zhou Z. et al; 1996] 
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 A method, based on ion-pair extraction, is described for the 
quantification of meclizine hydrochloride in various pharmaceutical dosage 
forms, for content uniformity determination, and for concentration monitoring 
in dissolution and bioavailability studies. Methyl orange, dissolved in pH 2.8 
MacIlvaine buffer, gave excellent recovery of meclizine after its isolation from 
aqueous solutions of gelatin, urine, and blood serum. The chloroform-
extracted molecular species appeared to be a 1:1 ion-pair. Beer's law was 
obeyed for a wide concentration range. Because the extracted species 
seemed well defined and stable and since a surface or an interphase 
adsorption phenomenon was not a problem, the reported method is 
considered sensitive, accurate, precise, rapid, and simple. [Hom FS et al; 
1977] 
 
 A simple method, requiring no chromatographic separation, is 
presented for the determination of the total and non-phenolic alkaloids in 
ipeca and its preparations. The complex formed between the alkaloid and 
methyl orange at pH 5.0 is extracted with chloroform and treated with 0.1N 
NaOH. The liberated dye, determined at 460 nm, is a measure of the total 
alkaloids. The chloroform phase remaining is treated with 0.1N H2SO4, and 
the acid extract is measured at 283 nm for the non-phenolic alkaloids, 
calculated as emetine. The proposed method was successfully applied to 
samples of ipeca powder, ipeca tincture, and 3 British Pharmaceutical Codex 
mixtures containing ipeca tincture, namely, ipecacuanha mixture, pediatric; 
ipecacuanha and ammonia mixture, pediatric; and belladonna and 
ipecacuanha mixture, pediatric. The proposed method compares favorably 
with the Egyptian Pharmacopoeia, British Pharmacopoeia, and USP methods 
and has a relative standard deviation of 1.54%. The present procedure is less 
time-consuming and requires about 45 and 90 min for the assay of ipeca 
tincture and powder, respectively. Only a small sample (0.2 mL tincture of 1.0 
g powder) is required. [Saleh MR et al;1980] 
 
 Seven colorimetric methods (Biuret, Lowry, a modified Lowry technique 
using bicinchoninic acid, Coomassie brilliant blue G (CBBG) dye-binding in 
phosphoric acid, perchloric acid or hydrochloric acid, and bromophenol blue 
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dye-binding) were evaluated for determination of protein concentration in 
human whole saliva. Using bovine serum albumin (BSA), mucin, and 
thyroglobulin as protein standards to calculate salivary protein concentration 
gave different results among the assays used and even with the different 
standards of the same method. Among the seven methods used, the CBBG 
dye-binding assay in hydrochloric acid appeared to provide the most accurate 
estimation of protein concentration in human saliva. Using BSA as a standard, 
the mean values of human salivary proteins from 39 healthy individuals 
ranged from 0.72 to 2.45 mg/ml. The optimum conditions for the CBBG dye-
binding assay in hydrochloric acid are: (1) the absorbance at 595 nm was 
measured between 15 to 30 minutes after addition of reagent. (2) the optimum 
concentration of dye in hydrochloric acid was 0.06-0.12% (w/v) for the assay. 
(3) the dye reagent was stable within one month. [Lin LY et al; 1989] 
 
 A simple and sensitive spectrophotometric method was developed for 
the determination of trace amounts of sulfur dioxide. The method is based on 
the reaction of SO2 with a known excess of ICI as the oxidant. The unreacted 
ICI iodinates thymol blue under acidic conditions. The λmax of thymol blue is 
at 545 nm under acidic conditions, and on lodination λmax shifts to 430 nm. 
This shift results in a decrease in the absorbance at 545 nm. The amount of 
uniodinated thymol blue present depends on the concentration of unreacted 
ICI, which in turn depends on the SO2 concentration. The system obeys 
Beer's law in the range 0-30 microg SO2 in a final volume of 25 mL, having a 
molar absorptivity of 3.2 x 10(4) L/mol cm with a relative standard deviation 
(RSD) of 2% at 24 µg SO2 (n = 10). The uniodinated dye can be extracted 
into 5 mL isoamyl alcohol under acidic conditions for measurement of 
absorbance. The extraction method obeys Beer's law in the range 0-5 µg SO2, 
having a molar absorpitivity of 4.16 x 10(4) L/mol x cm with an RSD of 1.9% at 
4 µg SO2 (n = 10). The method has been successfully applied to the 
determination of atmospheric SO2. [Gayathri N. et al; 2001] 
 
 A spectrophotometric method is described for determination of 
methotrimeprazine (levomepromazine). The aim of this work was to develop a 
simple, rapid, precise, and accurate visible spectrophotometric method for 
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determination of methotrimeprazine in tablet, oral solution, and injection. The 
method is based on methotrimeprazine reaction with bromophenol blue, 
resulting in a stable, light yellow-green ion-pair complex that, after extraction 
with chloroform, presented maximum absorption at 409 nm. Beer's law was 
obeyed in the concentration range from 5.0 to 25.0 μg/ml. The proposed 
standardized method was applied to commercially available dosage forms. 
The accuracy of the method was confirmed by recovery tests. [Kedor-
Hackmann ERM et al; 2000] 
 
 A spectrophotometric method is described for the determination of 
tilidine in its dosage forms (injection, drops, suppositories). The method is 
based on ion-pair extraction with chloroform at pH 3.5 using bromocresol 
green or bromophenol blue as the ion-pairing reagents. The 
spectrophotometric measurements are carried out at the absorption maxima 
at 415 and 411 nm, respectively. [Dobrila ZS et al; 1990] 
 
 Two simple, rapid and sensitive extractive spectrophotometric methods 
have been developed for the assay of ceterizine hydrochloride (CTZH) in bulk 
drug and in pharmaceutical preparations. These methods are based on the 
formation of chloroform soluble complexes between CTZH with bromocresol 
purple (BCP) or bromophenol blue (BPB) in Walpole buffer of pH 2.64 with an 
absorption maximum at 409 nm and at 414 nm for BCP and BPB, 
respectively. Reaction conditions were optimised to obtain the maximum 
colour intensity. The absorbance was found to increase linearly with increase 
in concentration of CTZH, which was corroborated by the calculated 
correlation coefficient value (0.9991-0.9995). The system obeyed Beer's law 
in the range of 1-16 and 1.5-21 µg/ml(-1) for BCP and BPB, respectively. The 
various analytical parameters have been evaluated. The results obtained by 
the proposed methods were statistically compared by means of students t-test 
and by the variance ratio, F-test with those of the reported method and have 
shown to be in excellent agreement with the reported method. [Gowda BG et 
al; 2001] 
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 The dissociation constants (KI = [H+][I2-]/[HI-]) of two sulfonephthalein 
indicators (bromocresol purple and phenol red) were determined as function 
of temperature (10-30 degrees C) at zero ionic strength. Freshwater pH, on 
the free hydrogen ion concentration scale (molal units), can be precisely 
calculated from measurements of indicator absorbance ratios 
(lambda2A/lambda1A) using the following equations: pH = pKI + log((R - 
e1)/(e2 - Re3)) and pKI = pKI(degrees) - AdeltaZ2(mu1/2 /(1 + mu1/2) - 0.3 
mu), where R = lambda2A/lambda1A, pKI = -log KI, mu is the ionic strength, 
deltaZ2 = 4, and values of A for 283 less than or = T less than or = 303 can be 
estimated from the equation: A = 0.5092 + (T-298.15) x 8.5 x 10(-4). For 
bromocresol purple (lambda1 = 432 nm, lambda2 = 589 nm), pKI(degrees) = 
5.226 + 378.1/T, e1 = 0.00387, e2 = 2.858, and e3 = 0.0181. For phenol red 
(lambda1 = 433 nm, lambda2 = 558 nm), pKI(degrees) = 5.798 + 666.7/T, e1 
= 0.00244, e2= 2.734, and e3 = 0.1075. These two indicators can be used to 
make accurate pH measurements of freshwaters (river water, lake water, 
groundwater, rainwater, etc) within the range 4.5 less than or =pH less than or 
=8.5. The precision of pH measurements using phenol red in well-buffered 
freshwaters is on the order of +/-0.001 or better. [Yao W., et al; 2001] 
 
 Two simple, sensitive and accurate spectrophotometric methods for the 
determination of loperamide hydrochloride (lop. HCl) are described. The first 
method is based on the formation of ion-pair association complex (1:1) with 
bromothymol blue (BTB), bromophenol blue (BPB) and naphthol blue black B 
(NBB). The coloured products are extracted into chloroform, and measured 
spectrophotometrically at 414 (BTB), 415 (BPB) and 627 nm (NBB). Beer’s 
law was obeyed in the ranges of 5–35, 5–30 and 0.8–11.2 μg ml−1 for BTB, 
BPB and NBB methods, respectively. The method was found to be specific for 
the analysis of the drug in presence of its degradation products which can be 
detected by HPLC procedure. The second method is based on the reaction of 
the basic loperamide with iodine in chloroform to give molecular charge-
transfer complex with intense bands at 295 and 363 nm. Beer’s law was 
obeyed in the ranges 2.5–17.5 and 2.5–22.5 μg ml−1 for the method at 295 
and 363 nm, respectively. Optimization of the different experimental 
conditions are described for both methods. The proposed methods have been 
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applied successfully for the analysis of the drug in pure form and in its dosage 
forms. The methods have the advantage of being highly sensitive and simple 
for the determination of a small dose drug, which is also a weak UV-absorbing 
compound. [El-sherif ZA et al; 2000] 
 
 A simple and sensitive method for the determination of clonidine in 
dosage forms is presented. The method is based on colour reaction of 
clonidine with bromocresol green, whereby a yellow coloured ion pair is 
formed. [Zivanov SD et al; 1990] 
 
An ion-pair extraction technique is described for separating 
methenamine, a urinary tract antibacterial agent, from formaldehyde in human 
urine samples. Separation conditions are developed from extraction constants 
for the methenamine-bromocresol green ion-pair. The technique involves 
adsorption of the ion-pair on to a silica cartridge and elution with methylene 
chloride:1-pentanol (95:5). Methenamine is freed from the ion-pair by the 
addition of excess tetrabutylammonium iodide and converted to formaldehyde 
(determined spectrophotometrically) by reaction with ammonia and 
acetylacetone. Linear standard plots were obtained from urine containing 
methenamine which was diluted to 10-160 µg/ml. The lower limit of detection 
was 6 µg/ml of methenamine. Absolute recovery from urine was greater than 
or equal to 94.5%. The precision (CV) of detection of methenamine in the 
presence of formaldehyde was less than 2%, and less than or equal to 4.5% 
for the detection of formaldehyde in the presence of methenamine. No 
interferences were noted. The applicability of the method was demonstrated 
by analysis of human urine levels of both methenamine and formaldehyde 
following oral administration of a methenamine salt to a volunteer. [Strom JG 
Jr et al; 1986] 
 
 A spectrophotometric method was developed for determining 
promethazine hydrochloride (I) complexed with bromcresol green and then 
extracted with chloroform. The complex in chloroform showed maximum 
absorption at 415 nm and obeyed Beer's law over 1.2-8.5 µg/ml. The complex 
molar absorptivity was 1.93 X 10(4) M. Complex formation and extraction 
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were complete and quantitative over pH 2.7-2.8. The promethazine 
hydrochloride-bromcresol green molar ratio was 1:1. Excipients, coloring 
matter, flavoring agents, and other substances likely to be present in 
promethazine preparations did not interfere in the determination. Direct 
determination in tablet, syrup, and injection preparations were carried out 
satisfactorily. [Emami Khoi AA; 1983] 
 
 Simple and sensitive spectrophotometric methods are described for the 
assay of three piperazine derivatives; ketoconazole, piribedil and prazosin 
hydrochloride based on charge-transfer and ion-pair complexation reactions. 
The first method is based on the reaction of the basic drug with 2,3-dichloro-
5,6-dicyano-p-benzoquinone (DDQ) in acetonitrile. The orange-red colour 
formed due to the formation of charge-transfer complex showed maximum 
absorbance at 460 nm. The second method is based upon the interaction of 
the basic drug in dry chloroform with bromophenol blue (BPB) in the same 
solvent to produce a stable yellow ion-pair complex which absorbs at 410 nm. 
Beer's law was obeyed for both methods and the relative standard deviations 
were found to be less than 1%. The two methods can be applied to the 
analysis of tablets, with no evidence of interference from excipients. A more 
detailed investigation of the complex was made with respect to its 
composition, association constant and free energy change. [Abdel-Gawad 
FM; 1997] 
 
 A simple and rapid colorimetric method for the assay of amodiaquine 
hydrochloride, chloroquine phosphate and primaquine phosphate is 
described. The method is based on the interaction of the drug base with 
bromophenol blue to give a stable ion-pair complex. The spectra of the 
complex shows a maxima at 415-420 nm with high apparent molar 
absorptivities. Beer's law was obeyed in the concentration range 1-8, 2-10 
and 2-12 µg/ml for amodiaquine hydrochloride, primaquine phosphate and 
chloroquine phosphate respectively. The proposed method was applied to the 
determination of these drugs in certain formulations and the results were 
favourably comparable to the official methods. [El-Ashry SM et al; 1994] 
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 Hydrastine, canadine, and berberine were determined by the acid-dye 
technique. At pH 5.6, both the tertiary and the quaternary hydrastis alkaloids 
formed ion-pairs with bromcresol purple. The liberated hydrastine and 
canadine from the alkaloid-dye complexes were determined 
spectrophotometrically in the presence of berberine by the three-wavelength 
method of analysis. However, berberine could not be assayed successfully by 
this method due to significant partitioning in the aqueous phase during 
extraction. At pH 7.2, only berberine could ion-pair with bromcresol purple to 
form a chloroform-extractable complex. Consequently, the berberine content 
was analyzed selectively through the colorimetric determination of the 
combined dye at 580 nm. The suitability of the proposed methods was 
examined through the analyses of synthetic mixtures of hydrastis alkaloids 
and samples of hydrastis tincture and liquid extract. Percentage recoveries 
were 98.2-101.4 for the synthetic mixtures and 98.4-101.7 for the tincture and 
liquid extract spiked with berberine. [El-Masry S et al; 1980] 
 
 Two spectrophotometric methods are described for the determination 
of guanethidine sulphate (I), guanfacine hydrochloride (II), guanoclor sulphate 
(III), guanoxan sulphate (IV) and debrisoquine sulphate (V). The first method 
involves ion-pair formation of the selected compounds (I–V) with bromocresol 
purple at pH 3.8. The yellow ion pair is extracted with chloroform and the 
absorbance is measured at about 415 nm. The second method is based on 
the reaction of the basic guanidino compounds (I, III–V) with iodine in 
chloroform to give molecular charge-transfer complexes with maximum 
absorbance at 292 and 345 nm. Beer's law was obeyed for both methods and 
the relative standard deviations were found to be less than 2%. The apparent 
molar absorptivities were found to be 2.1 × 104 to 6.9 × 104 l mol−1 cm−1 using 
bromocresol purple and 0.7 × 104 to 2.4 × 104 l mol−1 cm−1 using iodine. The 
investigated drugs were assayed in tablets. The mean percentage recoveries 
were found to be 99.8–100.8% by the acid-dye method and around 100.4% 
by the charge-transfer complexation method. [Wahbi AAM et al; 1993] 
 
 This procedure for routine quantification of albumin in urine is based on 
the dye-binding properties of albumin with bromphenol blue. The absorbance 
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of 100 microL of urine mixed with 3 mL of color reagent is measured against 
blank reagent at 610 nm after 30 s. Results vary linearly with albumin 
concentration up to 6 g/L. The reaction is pH independent in the physiological 
range. It is not subject to substantial interference by uric acid, creatinine, 
calcium, sodium chloride, or bilirubin. The presence of globulins produces a 
small positive error. Within-run precision (CV) was 4.8, 1.5, and 0.9%, and 
day-to-day precision was 11.2, 2.0, and 1.9%, for samples containing albumin 
at about 0.1, 1.0, and 6.0 g/L, respectively. Results by a radial-
immunodiffusion method (x) correlated well with those by the proposed 
method (y): r = 0.986; y = 0.98x + 0.096; n = 64. The method can also be 
used to detect globulins, such as Bence Jones protein, by measuring the ratio 
of the absorbance at 30 min to that at 30 s. [Schosinsky KH et al;1987] 
 
 A quick method for the determination of pilocarpine in eye drops in the 
presence of decomposition products is described. The method involves 
complexation of the alkaloid with bromocresol purple at pH 6. After treatment 
with 0.1N NaOH, the liberated dye is measured at 580 nm. The method has a 
relative standard deviation of 1.99%, and has been successfully applied to the 
analysis of 2 batches of pilocarpine eye drops. The recommended method 
was also used to monitor the stability of a pilocarpine nitrate solution in 0.05N 
NaOH at 65 degrees C. The BPC method failed to detect any significant 
decomposition after 2 h incubation, but the recommended method revealed 
87.5% decomposition. [El-Masry S. et al; 1980] 
 
 A visible light spectrophotometric method is described for the 
determination of sparfloxacin in tablets. The procedure is based on the 
complexation of bromothymol blue 0.5% and sparfloxacin to form a compound 
of yellow colour with maximum absorption at 385 nm. The Lambert–Beer law 
was obeyed in the concentration range of 2–12 mg/l. The present study 
describes a sensitive and accurate method for the determination of the 
concentration of sparfloxacin in tablets. It was also found that the excipients in 
the commercial tablet preparation did not interfere with the assay. [Marona 
HRN et al; 2001] 
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 A new simple and rapid flow injection method is reported for the direct 
determination of bismuth in pharmaceutical products. Methylthymol Blue 
(MTB) was used as a chromogenic reagent and the absorbance of the colored 
Bi(III)-MTB complex produced was monitored at 548 nm. The various 
chemical and physical variables were optimized and a study of interfering ions 
was also carried out. Linear calibration graphs were obtained from 0 to 100 
mg l-1 Bi(m) (120 injections per hour). The precision was very good (sr = 
1.3%) and the limit of detection was cL = 0.150 mg l-1. The average accuracy 
was also very good (er = 0.75%) and was evaluated by comparison of the 
results obtained with those claimed by the manufacturers. The method was 
found to be adequately selective, considering the ions that the samples 
contain. [Themelis D G et al; 2001] 
 
 
 
Table 2.22. Estimation of drugs using ion pair complex methods 
 
Sr. 
No. 
Specification Reference 
01 Utility of the ion-pair formation for spectrophotometric 
determination of Terfenadine in pure form and in 
some pharmaceutical formulations  
Amin AS et al; 
1999 
02 Spectrophotometric Methods for the Determination of 
the Antidepressant Drug Paroxetine Hydrochloride in 
Tablets 
Armagan O et 
al; 2005 
03 Extractive spectrophotometric methods for 
determination of Lercanidipine.  
Erk N;2003 
04 A simple spectrophotometric method for the 
determination of α, β-blockers in dosage forms  
Al-Ghannam 
SM; 2006 
05 Spectrophotometric determination of Oxiconazole in 
topical lotion using methyl orange. 
Milano J. et al; 
2005 
06 Ion-pair extraction and precipitation methods for 
Ethambutol determination 
Girgis EH et al; 
1974 
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07 Extractive Spectrophotometric Methods for the 
Determination of Oxomemazine Hydrochloride in 
Bulk and Pharmaceutical Formulations Using 
Bromocresol Green, Bromocresol Purple and 
Bromophenol Blue 
Akram ME; 
2005 
08 Spectrophotometric determination of enrofloxacin and 
pefloxacin through ion-pair complex formation  
Mostafa S et 
al; 2002 
09 Spectrophotometric determination of pefloxacin in 
pharmaceutical preparations 
Jelikic SM et 
al; 1989 
10 Simple spectrophotometric determination of 
cinnarizine in its dosage forms. 
Abdine H et al; 
2002 
11 Sensitive Extractive Spectrophotometric Methods for 
the Determination of Trazodone Hydrochloride in 
Pharmaceutical Formulations 
Ramanaboyina 
SK et al; 2006 
12 Extractive spectrophotometric determination of 
sildenafil citrate in pharmaceutical dosage forms  
Reddy MN et 
al; 2002 
13 Spectrophotometric determination of Fluoxetine 
hydrochloride in bulk and in pharmaceutical 
formulations  
Prabhakar AH 
et al; 1999 
14 Spectrophotometric, spectrofluorimetric and LC 
determination of trazodone hydrochloride. 
El-Gindy A. et 
al; 2001 
15 Spectrophotometric determination of strychnine and 
brucine in liquid galenicals. 
El-Massy S. et 
al; 1978 
16 Determination of content of chlorpromazine 
hydrochloride in compound metamizole sodium 
microenema by acid-dye colorimetric method 
Zhou Z. et al; 
1996 
17 Determination of meclizine hydrochloride by ion-pair 
extraction with methyl orange. 
Hom FS et al; 
1977 
 
18 Determination of meclizine hydrochloride by ion-pair 
extraction with methyl orange. 
Saleh MR et 
al; 1980 
19 Determination of protein concentration in human 
saliva 
Lin LY et al; 
1989 
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20 Spectrophotometric determination of sulfur dioxide in 
air, using thymol blue. 
Gayathri N. et 
al; 2001 
21 Determination of methotrimeprazine in 
pharmaceutical preparations by visible 
spectrophotometry 
Kedor-
Hackmann 
ERM et al; 
2000 
22 Spectrophotometric determination of tilidine using 
bromocresol green and bromophenol blue. 
Dobrila ZS et 
al; 1990 
23 Extractive spectrophotometric determination of 
ceterizine HCl in pharmaceutical preparations. 
Gowda BG et 
al; 2001 
24 Spectrophotometric determination of freshwater pH 
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3. AIM OF PRESENT WORK 
 
 Rapid strides have been made in the area of analysis of 
pharmacologically active molecules. Recent advancements in the area of 
modern analytical techniques include HPLC, LC – MS, GLC, GC – MS, 
HPTLC, and Ion pair chromatography. These methods are time consuming 
and require sophisticated instruments and chemicals, which are too costly to 
afford especially by small – scale industries.  
Selective serotonin reuptake inhibitors and angiotensin II receptor 
antagonists are prime drugs in the field of antidepressants and 
antihypertensive therapy. A very few analytical methods have been reported. 
Therefore it was thought of interest to develop spectrophotometric method for 
the estimation of these drugs. 
 The proposed research project is aimed at developing accurate, 
precise, and reliable methods for the estimation of selective serotonin 
reuptake inhibitors and angiotensin II receptor antagonists in their 
pharmaceutical dosage forms. The major approach taken into consideration 
was to develop chromophore using acid – dye and basic – dye technique and 
planned to develop simple UV – visible spectrophotometric methods for the 
estimation of pharmaceutical dosage forms. 
  
The project work was planned considering following steps: 
 
1. A simple colorimetric acid dye technique was developed and validated. 
2. The proposed method was applied for the analysis of market formulations. 
3. A simple colorimetric basic dye technique was developed and validated. 
4. The developed method was applied for analysis of valsartan tablets and its 
combined dosage forms. 
5. Dissolution profile study of pharmaceutical formulations (Fluoxetine 
hydrochloride and Sertraline hydrochloride) was carried out using 
developed acid dye technique. 
6. The developed basic dye technique was applied to study the dissolution 
profile of valsartan.  
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GLIMPESES OF THE RESEARCH PROJECT WORK 
 
1. Fluoxetine hydrochloride 
(a) A simple colorimetric acid dye technique for the estimation of 
fluoxetine hydrochloride in pharmaceutical dosage forms. 
(b) Dissolution profile and in – vitro evaluation of dosage form 
containing fluoxetine hydrochloride. 
______________________________________________________________ 
 
2. Sertraline hydrochloride 
(a) A colorimetric acid dye technique for the estimation of sertraline 
hydrochloride in pharmaceutical dosage forms. 
(b)  Dissolution profile and in – vitro evaluation of dosage form 
containing sertraline hydrochloride. 
______________________________________________________________ 
 
3. Duloxetine hydrochloride 
(a) A colorimetric acid dye technique for the estimation of duloxetine 
hydrochloride in pharmaceutical dosage forms. 
 
______________________________________________________________ 
 
4. Valsartan  
(a) A colorimetric basic dye technique for the estimation of valsartan. 
(b) Determination of valsartan in combined dosage form with 
hydrochlorthiazide using basic dye technique. 
(c) Determination of valsartan in combined dosage form with S-
Amlodipine using basic dye technique. 
(a) Dissolution profile and in – vitro evaluation of valsartan in various 
pharmaceutical dosage form. 
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4. EXPERIMENTAL 
 
4.1. Apparatus. 
 
? Double beam spectrophotometer (Shimadzu, model UV – 1601 with 
1.0 cm matched quartz cells was employed for spectral 
measurements.) 
? pH meter (Systronic) 
? Monopan balance (Sartorius) 
? Sonicator (Frontline, model FS – 4) 
? Cyclomixer (Remi) 
? Distillation assembly (Janaki Impex Pvt. Ltd.) 
? Constant temperature water bath (Cintex) 
 
4.2. Reagents and Materials. 
 
? Fluoxetine hydrochloride (Gift sample from Torrent Pharmaceuticals 
Limited, Ahmedabad) 
? Sertraline hydrochloride (Gift sample from Restac Pharmaceuticals, 
Ahmedabad) 
? Duloxetine hydrochloride (Gift sample from Sun Pharma, Baroda) 
? Valsartan (Gift sample from Torrent Pharmaceuticals Limited, 
Ahmedabad) 
? S – Amlodepine besylate (Gift sample from Cadila Pharmaceuticals, 
Ahmedabad) 
? Hydrochlorothiazide (Gift sample from Astron pharmaceuticals, 
Ahmedabad) 
? Ethanol  (Baroda chemical Ind. Ltd. Dabhoi) 
? Safranin O (BDH chemicals Ltd., England) 
? Methyl orange, Anhydrous sodium sulphate, Chloroform, Sodium 
hydroxide, Potassium di hydrogen phosphate, Potassium hydrogen 
phthalate, Potassium chloride, Methanol (SD’s Fine Chemicals Pvt. 
Ltd.) 
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? Whatman filter paper no. 42 
? Double Distilled water. 
? The dosage forms of all the drugs were procured from local market. 
 
4.3. Spectrophotometric determination of Fluoxetine hydrochloride. 
 
4.3.1. Preparation of 0.1N Hydrochloric acid. 
 
 Hydrochloric acid (8.5 ml) was diluted to 1000 ml with distilled water.  
 
4.3.2. Preparation of standard solution of Fluoxetine hydrochloride. 
   
 Accurately weighed Fluoxetine hydrochloride (50.0 mg) was transferred 
into 100 ml volumetric flask, dissolved in ethanol (10.0 ml) and diluted to 
100.0 ml with 0.1N Hydrochloric acid. The solution (25.0 ml) was diluted 
further to 100 ml with 0.1N Hydrochloric acid to give a solution having strength 
of 125.0 μg/ml. 
   
4.3.3. Preparation of methyl orange solution. 
 
 Accurately weighed methyl orange (50.0 mg) was transferred into 100 
ml volumetric flask, dissolved in ethanol (40.0 ml) and diluted to 100 ml with 
distilled water to give 0.05 % w/v solution of methyl orange. 
 
Washing of the methyl orange solution 
 
 The above dye solution was washed by 3 X 10 ml of chloroform to 
remove chloroform soluble impurities and minimize absorption value of 
reagent blank. 
 
4.3.4. Preparation of buffer solution.  
  
 The various buffer solutions (pH 1.0 – 8.0) were prepared (Table 4.1) 
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Table 4.1. Preparation of buffer solutions (pH 1.0 – 8.0) [http://delloyd] 
 
pH Method of preparation 
1.0 0.2M potassium chloride (50.0 ml) + 0.2M HCl (134.0 ml) 
2.0 0.2M potassium chloride (50.0 ml) + 0.2M HCl (13.0 ml) 
3.0 0.1M potassium hydrogen phthalate (100.0 ml) + 0.1M HCl      
(44.6 ml) 
4.0 0.1M potassium hydrogen phthalate (100.0 ml) + 0.1M HCl (0.2 ml)
5.0 0.1M potassium hydrogen phthalate (100.0 ml) + 0.1M NaOH  
(45.2 ml) 
6.0 0.1M potassium di hydrogen phosphate (100.0 ml) + 0.1M NaOH 
(11.2 ml) 
7.0 0.1M potassium di hydrogen phosphate (100.0 ml) + 0.1M NaOH 
(58.2 ml) 
8.0 0.1M potassium di hydrogen phosphate (100.0 ml) + 0.1M NaOH 
(93.4 ml) 
 
4.3.5. Determination of wavelength of maximum absorbance of 
          Fluoxetine hydrochloride. 
 
 Standard solution of Fluoxetine hydrochloride (0.5 ml) was transferred 
into a glass stoppered tube containing 2.0 ml of methyl orange dye solution. 
The volume was adjusted to 5.0 ml with 0.1N Hydrochloric acid. Chloroform 
(5.0 ml) was added and Mixed well for one minute using cyclomixer. The drug 
– dye ion pair complex was extracted in chloroform. The chloroform layer was 
separated out, dried over anhydrous sodium sulphate (1.0 gm). The 
absorbance of the colored solution was scanned on spectrophotometer in  the 
range of 400 – 800 nm against reagent blank. The blank was prepared 
similarly in which volume of standard solution of fluoxetine hydrochloride was 
replaced by an equal volume of 0.1N hydrochloric acid.  
 
Maximum absorbance was obtained at 426.0 nm (Fig. 5.1). 
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4.3.6. Calibration curve for Fluoxetine hydrochloride. 
 
 Standard solutions of Fluoxetine hydrochloride (0.2, 0.4, 0.6, 0.8, 1.0 
and 1.2ml) were transferred into a series of glass stoppered tubes, each 
containing 2.0 ml of methyl orange solution. The volumes were adjusted to 5.0 
ml with 0.1N Hydrochloric acid and analysed as described under 4.3.5. The 
absorbance of the colored solutions was measured at 426.0 nm against 
reagent blank.  
 
 The Lambert – Beer’s law was obeyed in the concentration range of 
5.0 – 30.0 μg/ml (Table 5.1, Fig. 5.4).   
 
4.3.7. Factors affecting the development of color. 
 
4.3.7.1. Effect of pH in buffer and 0.1 N hydrochloric acid. 
 
  Standard solutions of Fluoxetine hydrochloride (0.5 ml) was transferred 
in to a series of glass stoppered tubes containing 2.0 ml of methyl orange 
solution. The volumes were adjusted with buffer solution (5.0 ml) having pH 
1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0 8.0 and 0.1N hydrochloric acid respectively and 
analysed as described under 4.3.5. The absorbance of the reaction mixtures 
were measured at 426.0 nm against reagent blank. 
   
  Maximum absorbance was obtained in presence of 0.1N hydrochloric 
acid and 1 to 4 pH buffer. (Table 5.4, Fig. 5.7) 
   
4.3.7.2. Effect of Concentration of methyl orange solution. 
 
  Standard solution of Fluoxetine hydrochloride (0.5 ml) was transferred 
into a series of glass stoppered tube containing (0.5, 1.0, 1.5, 2.0, 2.5, 3.0 ml) 
of methyl orange solution. The volumes were adjusted to 5.0 ml with 0.1N 
Hydrochloric acid and analysed as described under 4.3.5. The absorbance of 
the reaction mixtures were measured at 426.0 nm against reagent blank.  
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  Maximum absorbance was obtained in presence of 2.0 ml of methyl 
orange solution (Table 5.5, Fig. 5.8). 
 
4.3.7.3. Color Stability. 
 
 Standard solution of Fluoxetine hydrochloride (0.5 ml) was transferred 
into a glass stoppered tube containing 2.0 ml of methyl orange solutions. The 
volume was adjusted to 5.0 ml with 0.1N Hydrochloric acid and analysed as 
described under 4.3.5. The absorbance of the colored solution was measured 
at 426.0 nm against reagent blank at (1, 2, 3, 4, 8, 12, 24, 36, and 48 hours) 
time interval.  
 
  The color remained stable for 48 hours (Table 5.6, Fig. 5.9). 
 
4.3.8. Validation of Proposed method 
 
4.3.8.1. Linearity 
 
  It is the ability of the method within a given range to obtain best result, 
which is directly proportional to the concentration of analyte in the sample. 
 
  The absorbance value obtained at 426.0 nm of different concentration 
of fluoxetine hydrochloride was used to plot a calibration curve. The linearity 
range for fluoxetine hydrochloride was found to be 5.0 – 30.0 μg/ml and 
correlation coefficient was found to be 0.9991 (Table 5.1, Fig. 5.4).   
  
4.3.8.2. Accuracy 
 
  The accuracy of the analytical method is closeness of the result 
obtained by that method to the true value. Accuracy may often be expressed 
as percent recovery by the assay of known, added amount of analyte. 
Accuracy is a measure of the exactness of the analytical method. 
 
 104
____________________________________________________Experimental___  
Accuracy data of Fluoxetine hydrochloride 
  
Pre analyzed sample solution (A) = 125 μg/ml 
Standard drug solution (B) = 125 μg/ml 
Sample solutions were prepared from above solutions. 
 
1) 0.2ml of solution A + 0.0ml of solution B 
2) 0.2ml of solution A + 0.2ml of solution B 
3) 0.2ml of solution A + 0.4ml of solution B 
4) 0.2ml of solution A + 0.6ml of solution B 
5) 0.2ml of solution A + 0.8ml of solution B 
 
  The above series of solutions (1 to 5) were transferred in to glass 
stoperred tubes. Methyl orange (2.0 ml) was added and the volumes were 
adjusted to 5.0 ml with 0.1N Hydrochloric acid and analysed as described 
under 4.3.5. The absorbance of the colored solutions was measured at 426.0 
nm against reagent blank.    
             
           The % recovery experiment revealed good accuracy. The % recovery 
of fluoxetine hydrochloride was found to be 99.68 % – 101.88 % (Table 5.7). 
 
4.3.8.3. Precision 
 
  Precision is the measure of either the degree of reproducibility or 
repeatability of the analytical method. It is expressed as the standard 
deviation or relative standard deviation (co-efficient of variance). 
 
4.3.8.3.1. Repeatability of measurement of absorbance 
 
           Standard solutions of Fluoxetine hydrochloride (0.2, 0.4, 0.6, 0.8, 1.0 
and 1.2ml) were transferred into a series of glass stoppered tubes, each 
containing 2.0 ml of methyl orange solution. The volumes were adjusted to 5.0 
ml with 0.1N Hydrochloric acid. The drug – dye ion pair complex were 
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extracted similarly as described under 4.3.5. The absorbance of the colored 
solutions was measured at 426.0 nm against reagent blank. The absorbance 
of the same solutions was measured seven times and % CV was calculated 
(Table 5.10). 
 
4.3.8.3.2. Intra day and Inter day precision 
 
           Variation of results within the same day is called intra day variation, 
and variation of results within days is called inter day variation. Intra day 
precision was determined by analyzing drug as per the procedure described 
in 4.3.5 for three times in the same day. The inter day precision was 
determined by analyzing the fluoxetine hydrochloride as per the procedure 
described in 4.3.5 daily for three days (Table 5.13). 
 
4.3.8.4. Limit of detection (LOD) 
 
           It is the lowest concentration of analyte in a sample that can be 
detected, but not necessarily be quantified under the stated experimental 
condition. 
           Different concentrations of standard drug solution were used and 
minimum detectable limit was found. LOD value was calculated from the 
calibration curve using equation LOD = 3.3 SD / b. (Where, SD = Standard 
Deviation and b = Slop of corresponding calibration curve). The LOD was 
found to be 0.9803 (Table 5.20) 
 
4.3.8.5. Limit of quantitation (LOQ) 
 
  It is the lowest concentration of analyte in the sample that can be 
determined with the acceptable precision and accuracy under stated 
experimental condition. LOQ value was calculated from the calibration graph 
using equation LOQ = 10 SD / b (Where, SD = Standard Deviation and b = 
Slop of corresponding calibration curve). The LOQ was found to be 2.9707 
(Table 5.20). 
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4.3.8.6. Specificity 
 
 It is the ability of the developed analytical method to detect analyte 
quantitatively in the presence of other component, which are expected to be 
present in the sample matrix or other related substances. 
 
4.3.8.7. Job’s method for determination of Stoichiometry 
 
 Job’s method, also called the method of continuous variation, is a 
simple and effective approach to the determination of chemical reaction at 
stoichiometry. In Job’s continuous method equimolar solutions of drug and 
dye are used. 
 
Preparation of working standard drug solution 
 The working standard solution of Fluoxetine hydrochloride 125 μg/ml 
was used. Its concentration was equal to 3.615 X 10-7 M/ml. 
 
Preparation of Methyl orange solution:  3.615 × 10-7 M/ml 
 Accurately weighed quantity of methyl orange (11.833 mg) was 
transferred into 100 ml volumetric flask, dissolved in ethanol (40.0 ml) and 
diluted to 100 ml with distilled water.   
 
Procedure  
 
 Standard solutions Fluoxetine hydrochloride (0.0, 0.2, 0.4, 0.5, 0.6, 0.8, 
and 1.0ml) were transferred in a series of glass stoppered tube. The volume 
of each glass stoppered tube was adjusted up to 1.0 ml with methyl orange 
solution to get mole fraction of Fluoxetine hydrochloride as 0.0, 0.2, 0.4, 0.5, 
0.6, 0.8, and 1.0. The volumes were adjusted to 5.0 ml with 0.1N Hydrochloric 
acid and analysed as described under 4.3.5. 
 
 It was found that Fluoxetine hydrochloride formed 1:1 complex with 
methyl orange (Table 5.16, Fig. 5.10). 
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4.3.8.8. Analysis of marketed formulations 
 
 For tablets: Twenty tablets were accurately weighed and powdered.  
For capsules: Twenty capsules were weighed and removed powder 
from shell. Then shell were weighed and the weight of the powder obtained by 
deducting weight of the shell from weight of capsules.  
 
 A quantity of the powder equivalent to 50.0 mg of Fluoxetine 
hydrochloride was transferred into 100 ml volumetric flask containing ethanol 
(10.0 ml) and sonicated for five minutes. Volume was adjusted to 100 ml with 
0.1N hydrochloric acid and filtered through Whatman filter paper no. 42. 
 
 The solutions (0.5 and 0.8 ml) were transferred into glass stoppered 
tubes containing 2.0 ml methyl orange solution. The volume was adjusted to 
5.0 ml with 0.1N Hydrochloric acid and analysed as described under 4.3.5. 
The absorbance of the colored solutions was measured at 426.0 nm against 
reagent blank. 
 
 The amount of Fluoxetine hydrochloride was determined by 
referring to calibration curve (Table 5.17). 
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4.4. Spectrophotometric determination of Sertraline hydrochloride. 
 
4.4.1. Preparation of 0.1N Hydrochloric acid. 
 
 As described under 4.3.1. 
 
4.4.2. Preparation of standard solution of Sertraline hydrochloride. 
   
 Accurately weighed Sertraline hydrochloride (50.0 mg) was transferred 
into 100 ml volumetric flask, dissolved in ethanol (10.0 ml) and diluted to 
100.0 ml with 0.1N Hydrochloric acid. The solution (10.0 ml) was diluted 
further to 100 ml with 0.1N hydrochloric acid to give a solution having strength 
of 50.0 μg/ml. 
 
4.4.3. Preparation of methyl orange solution. 
 As described under 4.3.3. 
 
4.4.4. Preparation of buffer solution.  
 As described under 4.3.4. 
 
4.4.5. Determination of wavelength of maximum absorbance of Sertraline 
          hydrochloride. 
 
 Standard solution of Sertraline hydrochloride (0.5 ml) was transferred 
into a glass stoppered tube containing 2.0 ml of methyl orange dye solution. 
The volume was adjusted to 5.0 ml with 0.1N Hydrochloric acid. Chloroform 
(5.0 ml) was added and Mixed well for one minute using cyclomixer. The drug 
– dye ion pair complex was extracted in chloroform. The chloroform layer was 
separated out, dried over anhydrous sodium sulphate (1.0 gm). The 
absorbance of the colored solution was scanned on spectrophotometer in  the 
range of 400.0 – 800.0 nm against reagent blank The blank was prepared 
similarly in which volume of standard solution of sertraline hydrochloride was 
replaced by 0.1 N hydrochloric acid. 
 Maximum absorbance was obtained at 425.0 nm (Fig. 5.2). 
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4.4.6. Calibration curve for Sertraline hydrochloride 
 
 Standard solutions of Sertraline hydrochloride (0.2, 0.4, 0.6, 0.8, 1.0 
1.2 and 1.4ml) were transferred into a series of glass stoppered tubes, each 
containing 2.0 ml of methyl orange solution. The volumes were adjusted to 5.0 
ml with 0.1N Hydrochloric acid and analysed as described under 4.4.5. The 
absorbance of the colored solutions was measured at 425.0 nm against 
reagent blank.  
 
 The Lambert – Beer’s law was obeyed in the concentration range of 
2.0 – 14.0 μg/ml (Table 5.2, Fig. 5.5).  
 
4.4.7. Factors affecting the development of color. 
 
4.4.7.1. Effect of pH in buffer and 0.1 N hydrochloric acid. 
 
   Standard solutions of Sertraline hydrochloride (0.5 ml) was 
transferred in to a series of glass stoppered tubes containing 2.0 ml of methyl 
orange solution. The volumes were adjusted with buffer solution (5.0 ml) 
having pH 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0 8.0 and 0.1N hydrochloric acid 
respectively and analysed as described under 4.4.5. The absorbance of the 
reaction mixtures were measured at 425.0 nm against reagent blank. 
   
  Maximum absorbance was obtained in presence of 0.1N hydrochloric 
acid and at 1.0 pH buffer (Table 5.4, Fig. 5.7). 
 
4.4.7.2. Effect of concentration of methyl orange solution 
 
 Standard solution of Sertraline hydrochloride (0.5 ml) was transferred 
in to a series of glass stoppered tube containing (0.5, 1.0, 1.5, 2.0, 2.5, 3.0 
and 3.5ml) of methyl orange solutions. The volumes were adjusted to 5.0 ml 
with 0.1N Hydrochloric acid and analysed as described under 4.4.5. The 
absorbance of the reaction mixtures were measured at 425.0 nm against 
reagent blank.  
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 Maximum absorbance was obtained in presence of 2.0 ml of methyl 
orange solution (Table. 5.5, Fig. 5.8). 
 
4.4.7.3. Color Stability. 
 
  Standard solution of Sertraline hydrochloride (0.5 ml) was transferred 
into a glass stoppered tube containing 2.0 ml of methyl orange solutions. The 
volume was adjusted to 5.0 ml with 0.1N Hydrochloric acid and analysed as 
described under 4.4.5. The absorbance of the colored solution was measured 
at 425.0 nm against reagent blank at interval of (1, 2, 3, 4, 8, 12, 24, 36, and 
48 hours).  
 
The color intensity remained constant for 48.0 hours (Table. 5.6, Fig. 5.9). 
 
4.4.8. Validation of Proposed method. 
 
4.4.8.1. Linearity. 
 
  It is the ability of the method within a given range to obtain best result, 
which is directly proportional to the concentration of analyte in the sample. 
 
 The absorbance value obtained at 425.0 nm of different concentration of 
Sertraline hydrochloride was used to plot a calibration curve. The linearity 
range for Sertraline hydrochloride was found to be 2.0 – 14.0 μg/ml and 
correlation coefficient was found to be 0.9985 (Table. 5.2, Fig. 5.5).   
  
4.4.8.2. Accuracy 
 
 The accuracy of the analytical method is closeness of the result obtained 
by that method to the true value. Accuracy may often be expressed as 
percent recovery by the assay of known, added amount of analyte. Accuracy 
is a measure of the exactness of the analytical method. 
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Accuracy data of Sertraline hydrochloride 
  
Pre analyzed sample solution (A) = 50 μg/ml 
Standard drug solution (B) = 50 μg/ml 
Sample solutions were prepared from above solutions. 
 
1) 0.2ml of solution A + 0.0ml of solution B 
2) 0.2ml of solution A + 0.2ml of solution B 
3) 0.2ml of solution A + 0.4ml of solution B 
4) 0.2ml of solution A + 0.6ml of solution B 
5) 0.2ml of solution A + 0.8ml of solution B 
 
  The above series of solutions (1 to 5) were transferred in to glass 
stoperred tubes. Methyl orange (2.0 ml) was added and the volumes were 
adjusted to 5.0 ml with 0.1N Hydrochloric acid and analysed as described 
under 4.4.5. The absorbance of the colored solutions was measured at 425.0 
nm against reagent blank.    
             
           The % recovery experiment revealed good accuracy. The % recovery 
of Sertraline hydrochloride was found to be 98.48 % to 101.78 % (Table 5.8). 
 
4.4.8.3. Precision. 
 
 Precision is the measure of either the degree of reproducibility or 
repeatability of the analytical method. It is expressed as the standard 
deviation or relative standard deviation (co-efficient of variance). 
 
4.4.8.3.1. Repeatability of measurement of absorbance 
 
  Standard solutions of Sertraline hydrochloride (0.2, 0.4, 0.6, 0.8, 1.0, 1.2 
and 1.4ml) were transferred into a series of glass stoppered tubes, each 
containing 2.0 ml of methyl orange solution. The volumes were adjusted to 5.0 
ml with 0.1N Hydrochloric acid. The drug – dye ion pair complex were 
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extracted similarly as described under 4.4.5. The absorbance of the colored 
solutions was measured at 425.0 nm against reagent blank. The absorbance 
of the same solutions was measured seven times and % CV was calculated 
(Table 5.11).  
 
4.4.8.3.2. Intra day and Inter day precision 
 
 Variation of results within the same day is called intra day variation, and 
variation of results within days is called inter day variation. Intra day precision 
was determined by analyzing drug as per the procedure described in 4.1.4.4. 
For three time in the same day. The inter day precision was determined by 
analyzing the Sertraline hydrochloride as per the procedure described in 
4.1.4.4. daily for three days (Table 5.14). 
 
4.4.8.4. Limit of detection (LOD) 
 
 It is the lowest concentration of analyte in a sample that can be detected, 
but not necessarily be quantified under the stated experimental condition. 
  
 Different concentrations of standard drug solution were used and 
minimum detectable limit was found. LOD value was calculated from the 
calibration curve using equation LOD = 3.3 SD / b. (Where, SD = Standard 
Deviation and b = Slop of corresponding calibration curve). The LOD was 
found to be 0.9803 (Table 5.20) 
 
4.4.8.5. Limit of quantification (LOQ) 
 
   It is the lowest concentration of analyte in the sample that can be 
determined with the acceptable precision and accuracy under stated 
experimental condition. LOQ value was calculated from the calibration curve 
using equation LOQ = 10 SD / b (Where, SD = Standard Deviation and b = 
Slop of corresponding calibration curve). The LOQ was found to be 2.9707 
(Table 5.20). 
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4.4.8.6. Specificity. 
 It is the ability of the developed analytical method to detect analyte 
quantitatively in the presence of other component, which are expected to be 
present in the sample matrix or other related substances. 
 
4.4.9. Job’s method for determination of Stoichiometry. 
 
 Job’s method, also called the method of continuous variation, is a 
simple and effective approach to the determination of chemical reaction at 
stoichiometry. In Job’s continuous method equimolar solutions of drug and 
dye are used. 
 
Preparation of working standard drug solution 
  The working standard solution of Sertraline hydrochloride 50 
μg/ml was used. Its concentration was equal to 1.459 X 10-7 M/ml. 
 
Preparation of Methyl orange solution: 1.459 × 10-7 M/ml 
 Accurately weighed methyl orange (5.324 mg) was transferred into 100 
ml volumetric flask, dissolved in ethanol (40.0 ml) and diluted to 100 ml with 
distilled water.   
 
Procedure  
 
 Standard solutions Sertraline hydrochloride (0.0, 0.2, 0.4, 0.5, 0.6, 0.8, 
and 1.0ml) were transferred in a series of glass stoppered tube. The volume 
of each glass stoppered tube was adjusted up to 1.0 ml with methyl orange 
solution to get mole fraction of Sertraline hydrochloride as 0.0, 0.2, 0.4, 0.5, 
0.6, 0.8, and 1.0. The volumes were adjusted to 5.0 ml with 0.1N Hydrochloric 
acid and analysed as described under 4.4.5. 
 
 It was found that Sertraline hydrochloride form 1:1 complex with methyl 
orange (Table. 5.16, Fig. 5.10). 
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4.4.10. Analysis of marketed formulation 
 
 Twenty tablets were accurately weighed and powdered. A quantity of 
the powder equivalent to 50.0 mg of Sertraline hydrochloride was transferred 
into 100 ml volumetric flask containing ethanol (10.0 ml) and sonicated for five 
minutes. Volume was adjusted to 100 ml with 0.1N hydrochloric acid and 
filtered through Whatman filter paper no.42. The solution (10.0 ml) was diluted 
further to 100 ml with 0.1N Hydrochloric acid. Aliquots (0.5 and 0.8 ml) were 
transferred into glass stoppered tubes containing 2.0 ml methyl orange 
solution. The volumes were adjusted to 5.0 ml with 0.1N Hydrochloric acid 
and analysed as described under 4.4.5. The absorbance of the colored 
solutions was measured at 425.0 nm against reagent blank. 
 
 The amount of Sertraline hydrochloride was determined by referring 
to the calibration curve (Table. 5.18). 
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4.5. Spectrophotometric determination of Duloxetine hydrochloride 
 
4.5.1. Preparation of Phthalate Buffer (pH 2.2 - 4.0) 
 
 Potassium hydrogen phthalate, 0.2M (50 ml) was transferred into 
200 ml volumetric flask, specified volume of 0.2M hydrochloric acid was 
added as per following table. The final volume was adjusted up to the mark 
with distilled water (IP 1996: A-144). 
  
Table 4.2. Preparation of phthalate buffer (pH 2.2 – 4.0) 
 
pH Hydrochloric acid. 0.2M 
(ml) 
2.2 49.5 
2.4 42.2 
3.0 22.3 
3.2 15.7 
3.6 6.3 
4.0 0.1 
 
4.5.2. Preparation of standard solution of Duloxetine hydrochloride 
 
 Accurately weighed Duloxetine hydrochloride (50.0 mg) was 
transferred into 100 ml volumetric flask, dissolved in ethanol (10.0 ml) and 
diluted to 100.0 ml with Phthalate buffer (pH 3.0). The solution (10.0 ml) was 
diluted further to 100.0 ml with the same solvent to give a stock solution 
having strength of 50.0 μg / ml.   
 
4.5.3. Preparation of methyl orange solution. 
 
 As described under 4.3.3. 
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4.5.4. Determination of wavelength of maximum absorbance of 
Duloxetine hydrochloride 
 
 Standard solution of Duloxetine hydrochloride (0.5 ml) was transferred 
into a glass stoppered tube containing 2.0 ml of methyl orange dye solution. 
The volume was adjusted to 5.0 ml with Phthalate buffer (pH 3.0). Chloroform 
(5.0 ml) was added and Mixed well for one minute using cyclomixer. The drug 
– dye ion pair complex was extracted in chloroform. The chloroform layer was 
separated out, dried over anhydrous sodium sulphate (1.0 gm). The 
absorbance of the colored solution was scanned on spectrophotometer in the 
range of 400 – 800 nm against reagent blank. The blank was prepared 
similarly in which volume of standard solution of duloxetine hydrochloride was 
replaced by an equal volume of phthalate buffer (pH 3.0).  
 
Maximum absorbance was obtained at 426.0 nm (Fig. 5.3).  
 
4.5.5. Calibration curve for Duloxetine hydrochloride 
 
 Standard solutions of Duloxetine hydrochloride (0.2, 0.4, 0.6, 0.8, 1.0 
and 1.2 ml) were transferred into a series of glass stoppered tubes, each 
containing 2.0 ml of methyl orange solution. The volumes were adjusted to 5.0 
ml with Phthalate buffer (pH 3.0) and analysed as described under 4.5.4. The 
absorbance of the colored solutions was measured at 426.0 nm against 
reagent blank.  
 
 The Lambert – Beer’s law was obeyed in the concentration range of 
2.0 – 12.0 μg/ml (Table. 5.3, Fig. 5.6).  
   
4.5.6. Factors affecting the development of color 
 
4.5.6.1. Effect of pH of Buffer 
 
 Standard solutions of Duloxetine hydrochloride (0.5 ml) was transferred 
in to a series of glass stoppered tubes containing 2.0 ml of methyl orange 
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solution. The volumes were adjusted to 5.0 ml with phthalate buffer having pH 
(2.2, 2.6, 3, 3.2, 3.6 and 4.0) and analysed as described under 4.5.4. The 
absorbance of the reaction mixtures were measured at 426.0 nm against 
reagent blank. 
  Maximum absorbance was obtained in presence of phthalate buffer 
(pH 3.0) (Table. 5.4, Fig. 5.7). 
 
4.5.6.2. Effect of Concentration of methyl orange solution 
 
  Standard solution of Duloxetine hydrochloride (0.5 ml) was transferred 
into a series of glass stoppered tube containing (0.5, 1.0, 1.5, 2.0, 2.5, 3.0 and 
3.5ml) of methyl orange solutions. The volumes were adjusted to 5.0 ml with 
Phthalate buffer (pH 3.0) and analysed as described under 4.5.4. The 
absorbance of the reaction mixtures were measured at 426.0 nm against 
reagent blank.  
 
  Maximum absorbance was obtained in presence of 2.0 ml of methyl 
orange solution (Table. 5.8, Fig. 5.5). 
 
4.5.6.3. Color Stability. 
. 
  Standard solution of Duloxetine hydrochloride (0.5 ml) was transferred 
into a glass stoppered tube containing 2.0 ml of methyl orange solutions. The 
volume was adjusted to 5.0 ml with Phthalate buffer (pH 3.0) and analysed as 
described under 4.5.4. The absorbance of the colored solution was measured 
at 426.0 nm against reagent blank at interval of (1, 2, 3, 4, 8, 12, 24, 36, and 
48 hours).  
 
 The color intensity remained constant for 48 hours (Table. 5.6, Fig. 5.9).  
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4.5.7. Validation of proposed method. 
 
4.5.7.1. Linearity. 
 
 It is the ability of the method within a given range to obtain best result, 
which is directly proportional to the concentration of analyte in the sample. 
 
 The absorbance value obtained at 426.0 nm of different concentration of 
Duloxetine hydrochloride was used to plot a calibration curve. The linearity 
range for Duloxetine hydrochloride was found to be 2.0 – 12.0 μg/ml and 
correlation coefficient was found to be 0.9988 (Table. 5.3, Fig. 5.6).   
  
4.5.7.2. Accuracy 
 
 The accuracy of the analytical method is closeness of the result obtained 
by that method to the true value. Accuracy may often be expressed as 
percent recovery by the assay of known, added amount of analyte. Accuracy 
is a measure of the exactness of the analytical method. 
 
Accuracy data of Duloxetine hydrochloride 
 
Pre analyzed sample solution (A) = 50 μg/ml 
Standard drug solution (B) = 50 μg/ml 
Sample solutions were prepared from above solutions. 
 
1) 0.2ml of solution A + 0.0ml of solution B 
2) 0.2ml of solution A + 0.2ml of solution B 
3) 0.2ml of solution A + 0.4ml of solution B 
4) 0.2ml of solution A + 0.6ml of solution B 
5) 0.2ml of solution A + 0.8ml of solution B 
 
 The above series of solutions (1 to 5) were transferred in to glass 
stoperred tubes. Methyl orange (2.0 ml) was added and the volumes were 
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adjusted to 5.0 ml with phthalate buffer (pH 3.0) and analysed as described 
under 4.5.4. The absorbance of the colored solutions was measured at 426.0 
nm against reagent blank.    
             
 The % recovery experiment revealed good accuracy. The % recovery of 
Duloxetine hydrochloride was found to be 99.08 % to 101.89 % (Table 5.9). 
 
4.5.7.3. Precision 
 
 Precision is the measure of either the degree of reproducibility or 
repeatability of the analytical method. It is expressed as the standard 
deviation or relative standard deviation (co-efficient of variance). 
 
4.5.7.3.1. Repeatability of measurement of absorbance 
 
 Standard solutions of Duloxetine hydrochloride (0.2, 0.4, 0.6, 0.8, 1.0 
and 1.2 ml) were transferred into a series of glass stoppered tubes, each 
containing 2.0 ml of methyl orange solution. The volumes were adjusted to 5.0 
ml with Phthalate buffer (pH 3.0). The drug – dye ion pair complex were 
extracted similarly as described under 4.5.4. The absorbance of the colored 
solutions was measured at 426.0 nm against reagent blank. The absorbance 
of the same solutions was measured seven times and % CV was calculated 
(Table 5.12).  
  
4.5.7.3.2. Intra day and Inter day precision 
 
 Variation of results within the same day is called intra day variation, and 
variation of results within days is called inter day variation. Intra day precision 
was determined by analyzing drug as per the procedure described in 4.5.4. 
For three time in the same day. The inter day precision was determined by 
analyzing the Duloxetine hydrochloride as per the procedure described in 
4.5.4. daily for three days (Table 5.15). 
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4.5.7.4. Limit of detection (LOD) 
 
           It is the lowest concentration of analyte in a sample that can be 
detected, but not necessarily be quantified under the stated experimental 
condition. 
 Different concentrations of standard drug solution were used and 
minimum detectable limit was found. LOD values was calculated from the 
calibration graph using equation LOD = 3.3 SD / b. (Where, SD = Standard 
Deviation and b = Slop of corresponding calibration curve). The LOD was 
found to be 0.4902 (Table 5.21) 
 
4.5.7.5. Limit of quantification (LOQ) 
 
 It is the lowest concentration of analyte in the sample that can be 
determined with the acceptable precision and accuracy under stated 
experimental condition. LOQ value was calculated from the calibration graph 
using equation LOQ = 10 SD / b (Where, SD = Standard Deviation and b = 
Slop of corresponding calibration curve). The LOQ was found to be 1.4854 
(Table 5.21). 
 
4.5.7.6. Specificity 
 
 It is the ability of the developed analytical method to detect analyte 
quantitatively in the presence of other component, which are expected to be 
present in the sample matrix or other related substances. 
 
4.5.8. Job’s method for determination of Stoichiometry 
 
 Job’s method, also called the method of continuous variation, is a 
simple and effective approach to the determination of chemical reaction at 
stoichiometry. In Job’s continuous method equimolar solutions of drug and 
dye are used. 
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Preparation of working standard drug solution 
 The working standard solution of Duloxetine hydrochloride (50.0 μg/ml) 
was used. Its concentration was equal to 1.498 X 10-7 M/ml. 
 
Preparation of Methyl orange solution: 1.498 × 10-7 M/ml 
 Accurately weighed methyl orange (4.902 mg) was transferred into 100 
ml volumetric flask, dissolved in ethanol (40.0 ml) and diluted to 100 ml with 
distilled water.   
 
Procedure  
 
 Standard solutions of Duloxetine hydrochloride (0.0, 0.2, 0.4, 0.5. 0.6, 
0.8, and 1.0ml) were transferred in a series of glass stoppered tube. The 
volume of each glass stoppered tube was adjusted up to 1.0 ml with methyl 
orange solution to get mole fraction of Duloxetine hydrochloride as 0.0, 0.2, 
0.4, 0.5, 0.6, 0.8, and 1.0. The volumes were adjusted to 5.0 ml with Phthalate 
buffer (pH 3.0) and analysed as described under 4.5.4. 
 
 It was found that Duloxetine hydrochloride form 1:1 complex with 
methyl orange (Table 5.16, Fig. 5.10). 
   
4.5.9. Analysis of marketed formulations 
 
             For tablets: Twenty tablets were accurately weighed and powdered.  
For capsules: Twenty capsules were weighed and removed powder 
from shell. Then shell were weighed and the weight of the powder obtained by 
deducting weight of the shell from weight of capsules.  
 
 A quantity of the powder equivalent to 50.0 mg of Duloxetine 
hydrochloride was transferred into 100 ml volumetric flask containing ethanol 
(10.0 ml) and sonicated for five minutes. Volume was adjusted to 100 ml with 
Phthalate buffer (pH 3.0) and filtered through Whatman filter paper no.42. The 
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solution (10.0 ml) was diluted further to 100 ml with Phthalate buffer (pH 3.0) 
to give a solution having strength of 50.0 μg / ml. 
 Aliquots (0.5 and 0.8 ml) were transferred into glass stoppered 
tubes containing 2.0 ml methyl orange solution. The volume was adjusted to 
5.0 ml with Phthalate buffer (pH 3.0) and analysed as described under 4.5.4. 
The absorbance of the colored solutions was measured at 426.0 nm against 
reagent blank. 
 
 The amount of Duloxetine hydrochloride was determined by 
referring to calibration curve (Table 5.19). 
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4.6. Spectrophotometric determination of Valsartan (Basic dye method)  
 
4.6.1. Apparatus and Instruments 
 
  As described under 4.1.1 
 
4.6.2. Reagents and Materials 
 
  As described under 4.1.2 
 
4.6.3. Preparation of buffer solutions (pH 4.0 – 8.0)   
Various buffer solutions were prepared as per following.  
(IP 1996: A-144, A-145).    
  
Table 4.3. Preparation of buffer solutions (pH 4.0 – 8.0) 
   
pH Types of buffer Preparation 
 
4.0 Acid phthalate 
buffer 
Potassium hydrogen phthalate, 0.2M (50.0 ml) 
+ Hydrochloric acid, 0.2M (0.1 ml), the volume 
was adjusted up to 200 ml with distilled water. 
5.0 Neutralized 
phthalate buffer 
Potassium hydrogen phthalate, 0.2M (50.0 ml) 
+ Sodium hydroxide, 0.2M (22.6 ml), the 
volume was adjusted up to 200 ml with distilled 
water. 
6.0 Phosphate buffer Potassium dihydrogen phosphate, 0.2M (50.0 
ml) + Sodium hydroxide, 0.2M (5.6 ml), the 
volume was adjusted up to 200 ml with distilled 
water. 
6.4 Phosphate buffer Potassium dihydrogen phosphate, 0.2M (50.0 
ml) + Sodium hydroxide, 0.2M (11.6 ml), the 
volume was adjusted up to 200 ml with distilled 
water. 
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6.8 Phosphate buffer Potassium dihydrogen phosphate, 0.2M (50.0 
ml) + Sodium hydroxide, 0.2M (22.4 ml), the 
volume was adjusted up to 200 ml with distilled 
water. 
7.0 Phosphate buffer Potassium dihydrogen phosphate, 0.2M (50.0 
ml) + Sodium hydroxide, 0.2M (29.1 ml), the 
volume was adjusted up to 200 ml with distilled 
water. 
8.0 Phosphate buffer Potassium dihydrogen phosphate, 0.2M (50.0 
ml) + Sodium hydroxide, 0.2M (46.1 ml), the 
volume was adjusted up to 200 ml with distilled 
water. 
 
4.6.4. Preparation of safranin O solution 
 
 Accurately weighed safranin O (50.0 mg) was transferred into 100 ml 
volumetric flask, dissolved in phosphate buffer (pH 6.8) and diluted to 100 ml 
with same solvent to give 0.05 % w/v solution of safranin O. 
 
Washing of safranin O solution 
 
 The above dye solution was washed by 3 X 10 ml of chloroform to 
remove chloroform soluble impurities and minimize absorption value of 
reagent blank. 
 
4.6.5. Preparation of standard solution of Valsartan 
 
 Accurately weighed valsartan (100.0 mg) was transferred into 100 ml 
volumetric flask, dissolved in methanol (10.0 ml) and diluted by distilled water 
up to the mark. The solution (10.0 ml) was diluted further to 100.0 ml with 
distilled water. The final solution contained 100.0 μg/ml of Valsartan. 
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4.6.6 Preparation of standard solution of Hydrochlorothiazide 
 
 Accurately weighed hydrochlorothiazide (100.0 mg) was transferred 
into 100 ml volumetric flask, dissolved in methanol (10.0 ml) and diluted by 
distilled water up to the mark. The solution (10.0 ml) was diluted further to 
100.0 ml with distilled water. The final solution contained 100.0 µg/ml of 
hydrochlorothiazide. 
 
4.6.7 Preparation of standard solution of s- Amlodipine besylate 
 
 Accurately weighed s- Amlodipine besylate (100.0 mg) was transferred 
into 100ml volumetric flask, dissolved in methanol (10.0 ml) and diluted with 
distilled water up to mark. The solution (10.0 ml) was diluted further to 100 ml 
with distilled water. The final solution contained 100.0 µg/ml of s- amlodipine 
besylate. 
 
4.6.8. Determination of wavelength of maximum absorbance of Valsartan 
 
    Standard solution of Valsartan (1.0 ml) was pipetted out into glass-
stoppered tube containing Sefranin O solution (2.5 ml) and mixed thoroughly. 
The volume was adjusted with phosphate buffer (5.0 ml; pH 6.8). Chloroform 
(5.0 ml) was added and mixed well for one minute using cyclomixer. The drug 
– dye ion pair complex was extracted in chloroform. The chloroform layer was 
separated out, dried over anhydrous sodium sulphate (1.0 gm). The 
absorbance of the colored solution was scanned on spectrophotometer in the 
range of 400-800 nm against reagent blank. The blank was prepared similarly 
in which volume of standard solution of valsartan was replaced by an equal 
volume of phosphate buffer (pH 6.8).  
 
 Maximum absorbance was obtained at 518.8 nm. (Fig. 5.17). 
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4.6.9. Calibration curve of Valsartan 
 
 Standard solutions of Valsartan (0.25, 0.50, 0.75, 1.0, 1.25 ml) were 
transferred into a series of glass-stoppered tubes and volumes were adjusted 
to 2.5 ml with phosphate buffer (pH 6.8). Sefranin O solution (2.5 ml) was 
added and mixed thoroughly and analysed as described under 4.6.8. The 
absorbance of the colored solution was measured at 518.8 nm against 
reagent blank.  
 
 The Lambert – Beer’s law was obeyed in the concentration range of 
5.0 – 25.0 μg/ml (Table. 5.31, Fig. 5.18).  
   
4.6.10. Factor affecting the development of color 
 
4.6.10.1. Effect of pH of buffer 
 
  Standard solution of Valsartan (0.5 ml) was transferred in to five 
different glass-stoppered tubes, each containing (2.5 ml) safranin O solution. 
The volumes were adjusted to 5.0 ml with phosphate buffer (pH 4.0, 5.0, 6.0, 
6.4, 6.8, 7.0 and 8.0) and mixed thoroughly and analysed as described under 
4.6.8. 
 
  The absorbance of the colored solutions were measured at 518.8 nm 
against reagent blank. The optimum pH was found to be 6.8 for the reaction 
(Table 5.23, Fig. 5.13).  
  
4.6.10.2 Effect of concentration of safranin O solution 
 
  Standard solution of Valsartan (0.5 ml) was transferred in to a series of 
glass-stoppered tubes, containing (0.5, 1.0, 1.5, 2.0, 2.5, 3.0 and 3.5 ml) 
safranin O solutions. The final volumes were adjusted to 5.0 ml with 
phosphate buffer (pH 6.8) and analysed as as described under 4.6.8. The 
absorbance of the reaction mixtures was measured at 518.8 nm against 
reagent blank.   
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  Maximum absorbance was obtained in presence of 2.5 ml of safranin O 
solution (Table. 5.33, Fig. 5.20). 
 
4.6.10.3. Color Stability. 
 
  Standard solution of Valsartan (0.5 ml) was transferred into a glass 
stoppered tube containing safranin O solution (2.5 ml). The volume was 
adjusted to 5.0 ml with phosphate buffer (pH 6.8) and analysed as described 
under 4.6.8. The absorbance of the colored solution was measured at 518.8 
nm against reagent blank at (1, 2, 3, 4, 8, 12, 24, 36, and 48 hours) time 
interval.  
 
  The color intensity remained constant for 48.0 hours (Table 5.25, Fig. 
5.15). 
 
4.6.11. Validation of proposed method 
 
4.6.11.1. Linearity 
 
  It is the ability of the method within a given range to obtain best result, 
which is directly proportional to the concentration of analyte in the sample. 
 
 The absorbance value obtained at 518.8 nm of different concentration of 
valsartan was used to plot a calibration curve. The linearity range for valsartan 
was found to be 5.0 – 25.0 μg/ml and correlation coefficient was found to be 
0.9994 (Table. 5.22, Fig. 5.12).   
  
4.6.11.2. Accuracy 
 
 The accuracy of the analytical method is closeness of the result obtained 
by that method to the true value. Accuracy may often be expressed as 
percent recovery by the assay of known, added amount of analyte. Accuracy 
is a measure of the exactness of the analytical method. 
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Accuracy data of Valsartan 
  
Pre analyzed sample solution (A) = 100 μg/ml 
Standard drug solution (B) = 100 μg/ml 
Sample solutions were prepared from above solutions. 
 
1) 0.25ml of solution A + 0.0ml of solution B 
2) 0.25ml of solution A + 0.25ml of solution B 
3) 0.25ml of solution A + 0.5ml of solution B 
4) 0.25ml of solution A + 0.75ml of solution B 
5) 0.25ml of solution A + 1.0ml of solution B 
 
 The above series of solutions (1 to 5) were transferred in to glass 
stoperred tubes. Safranin O solution (2.5 ml) was added and the volumes 
were adjusted to 5.0 ml with phosphate buffer (pH 6.8) and analysed as 
described under 4.6.8. The absorbance of the colored solutions was 
measured at 518.8 nm against reagent blank.    
             
 The % recovery experiment revealed good accuracy. The % recovery of 
Valsartan was found to be 99.59 % to 101.35 % (Table 5.26). 
 
4.6.11.3. Precision 
 
 Precision is the measure of either the degree of reproducibility or 
repeatability of the analytical method. It is expressed as the standard 
deviation or relative standard deviation (co-efficient of variance). 
 
4.6.11.3.1. Repeatability of measurement of absorbance 
  
 Standard solutions of Valsartan (0.25, 0.50, 0.75, 1.0, 1.25 ml) were 
transferred into a series of glass-stoppered tubes and volumes were adjusted 
to 2.5 ml with phosphate buffer (pH 6.8). Sefranin O solution (2.5 ml) was 
added into each and analysed as described under 4.6.8. The absorbance of 
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the colored solutions was measured at 518.8 nm against reagent blank. The 
absorbance of the same solutions was measured seven times and % CV was 
calculated (Table 5.27).  
 
4.6.11.3.2. Intra day and Inter day precision 
 
           Variation of results within the same day is called intra day variation, 
and variation of results within days is called inter day variation. Intra day 
precision was determined by analyzing drug as per the procedure described 
in 4.6.8. For three time in the same day. The inter day precision was 
determined by analyzing Valsartan as per the procedure described in 4.6.8. 
daily for three days (Table. 5.28). 
 
4.6.11.4. Limit of detection (LOD) 
 
 It is the lowest concentration of analyte in a sample that can be detected, 
but not necessarily be quantified under the stated experimental condition. 
 
 Different concentrations of standard drug solution were used and 
minimum detectable limit was found. LOD values was calculated from the 
calibration graph using equation LOD = 3.3 SD / b. (Where, SD = Standard 
Deviation and b = Slop of corresponding calibration curve). The LOD was 
found to be 1.0603 (Table. 5.38) 
 
4.6.11.5. Limit of quantification (LOQ) 
  
 It is the lowest concentration of analyte in the sample that can be 
determined with the acceptable precision and accuracy under stated 
experimental condition. LOQ value was calculated from the calibration graph 
using equation LOQ = 10 SD / b (Where, SD = Standard Deviation and b = 
Slop of corresponding calibration curve). The LOQ was found to be 3.2129 
(Table. 5.38). 
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4.6.11.6. Specificity 
 
 It is the ability of the developed analytical method to detect analyte 
quantitatively in the presence of other component, which are expected to be 
present in the sample matrix or other related substances. 
 
4.6.12. Job’s method for determination of Stoichiometry 
 
 Job’s method, also called the method of continuous variation, is a 
simple and effective approach to the determination of chemical reaction at 
stoichiometry. In Job’s continuous method equimolar solutions of drug and 
dye are used. 
 
Preparation of working standard drug solution 
 The working standard solution of Valsartan 100 μg/ml was used. Its 
concentration was equal to 2.296 X 10-7 M/ml. 
 
Preparation of Safranin O solution: 2.296 × 10-7 M/ml 
 Accurately weighed safranin O (83.78 mg) was transferred into 100 ml 
volumetric flask, dissolved in phosphate buffer (pH 6.8) and diluted to 100 ml 
with the same solvent.  
 
Procedure  
 
 Standard solutions Valsartan (0.0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75 
and 2.0 ml) were transferred in a series of glass stoppered tubes. The 
volumes of each glass stoppered tube were adjusted up to 2.0 ml with 
safranin O solution to get mole fraction of Valsartan as 0.0, 0.125, 0.250, 
0.375, 0.500, 0.625, 0.750, 0.875 and 1.0. The volumes were adjusted (5.0 
ml) with phosphate buffer (pH 6.8). The drug – dye ion pair complex were 
extracted similarly as described under 4.6.8. 
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 It was found that Valsartan form 1:1 complex with safranin O (Table 
5.29, Fig. 5.16). 
 
4.6.13. Analysis of marketed formulations 
 
 For Tablets: Twenty tablets were accurately weighed and powered. 
 For Capsules: Twenty Capsules were weighed and powder removed 
from shell. Then shells were weighed and the weights of the powder obtained 
by deducting weight of the shell from weight of capsule. 
 
 A quantity of the powder equivalent to 100.0 mg of Valsartan was 
transferred into 100 ml volumetric flask; methanol (10.0 ml) was added and 
sonicated for 5 minutes. The volume was adjusted up to the mark with distilled 
water to obtain Valsartan concentration 1mg/ml. The solution was filtered 
through whatman filter paper no.42. Solution (10.0 ml) was diluted further to 
100ml with distilled water. The final solution of Valsartan was contained 
100µg/ml. 
 
 The solutions (0.5 and 1.0 ml) were transferred into glass stoppered 
tubes containing safranin O solution (2.5 ml). The volumes were adjusted to 
5.0 ml with phosphate buffer (pH 6.8) and analysed as described under 4.6.8. 
The absorbance of the colored solutions was measured at 518.8 nm against 
reagent blank. 
 
 The amount of Valsartan present in pharmaceutical dosage forms were 
determined by referring to the standard calibration curve of Valsartan (Table. 
5.40, Fig. 5.18)  
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4.7. Analysis of Valsartan in combined dosage forms (One component 
analysis) 
 
4.7.1. Analysis of Valsartan in presence of Hydrochlorothiazide 
 
4.7.1.1. Preparation of standard solution of Hydrochlorothiazide 
As described under 4.6.6. 
  
4.7.1.2. Preparation of standard solution of Valsartan 
As described under 4.6.5. 
 
 4.7.1.3. Interference of Hydrochlorothiazide on absorbance of Valsartan 
– safranin O solution complex 
 
 The standard solutions of Hydrochlorothiazide (0.25, 0.5, 0.75, 1.0 and  
1.25ml) were transferred into series of glass stopper tubes, each containing 
standard solution of Valsartan (0.5 ml). Safranin O solution (2.5 ml) was 
added to each tubes. The final volumes were adjusted to 5.0 ml with 
phosphate buffer (pH 6.8) and analysed as described under 4.6.8. The 
absorbance of the colored solutions were measured at 518.8 nm against 
reagent blank (Table. 5.31). 
 
4.7.1.4. Analysis of marketed formulations Containing Valsartan and 
Hydrochlorothiazide    
 
 For Tablets: Twenty tablets were accurately weighed and powered. 
 For Capsules: Twenty Capsules were weighed and powder removed 
from shell. Then shells were weighed and the weights of the powder obtained 
by deducting weight of the shell from weight of capsule. 
 
 A quantity of the powder equivalent to 100.0 mg of Valsartan was 
transferred into 100 ml volumetric flask; methanol (10.0 ml) was added and 
sonicated for 5 minutes. The volume was adjusted up to the mark with distilled 
water to obtain Valsartan concentration 1mg/ml. The solution was filtered 
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through whatman filter paper no.42. Solution (10.0 ml) was diluted to 100ml 
with distilled water. The final solution of Valsartan was contained 100 µg/ml. 
 
 The solutions (0.5 and 1.0 ml) were transferred into glass stoppered 
tubes containing safranin O solution (2.5 ml). The volumes were adjusted to 
5.0 ml with phosphate buffer (pH 6.8) and analysed as described under 4.6.8. 
The absorbance of the colored solutions was measured at 518.8 nm against 
reagent blank.  
 
 The amount of Valsartan present in pharmaceutical dosage forms were 
determined by referring to the standard calibration curve (Table. 5.33). 
 
 
4.7.2. Analysis of Valsartan in presence of s- Amlodipine besylate 
 
4.7.2.1. Preparation of standard solution of s- Amlodipine besylate 
As described under 4.6.7. 
  
4.7.2.2. Preparation of standard solution of Valsartan 
As described under 4.6.5. 
  
4.7.2.3. Interference of s- Amlodipine besylate on absorbance of 
Valsartan – safranin O dye complex 
 
 The standard solutions of s- Amlodipine besylate (0.25, 0.5, 0.75, 1.0 
and  1.25ml) were transferred into series of glass stopper tubes, each 
containing standard solution of Valsartan (0.5 ml). Safranin O solution (2.5 ml) 
was added to each tubes. The final volumes were adjusted to 5.0 ml with 
phosphate buffer (pH 6.8) and analysed as described under 4.6.8. The 
absorbance of the colored solutions was measured at 518.8 nm against 
reagent blank (Table. 5.32). 
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4.7.2.4. Analysis of marketed formulations containing Valsartan and  
             s- Amlodipine besylate. 
 
 Twenty capsules were weighed and powder removed from shell. Then 
shell were weighed and the weights of the powder obtained by deducting 
weight of the shell from weight of capsule.  
 
 A quantity of the powder equivalent to 100.0 mg of Valsartan was 
transferred into 100 ml volumetric flask; methanol (10.0 ml) was added and 
sonicated for 5 minutes. The volume was adjusted up to the mark with distilled 
water to obtain Valsartan concentration 1.0 mg/ml. The solution was filtered 
through whatman filter paper no.42. Solution (10.0 ml) was diluted further to 
100ml with distilled water. The final solution of Valsartan was contained 100 
µg/ml. 
 
 The solutions (0.5 and 1.0 ml) were transferred into glass stoppered 
tubes containing safranin O solution (2.5 ml). The volumes were adjusted to 
5.0 ml with phosphate buffer (pH 6.8) and analysed as described under 4.6.8. 
The absorbance of the colored solutions was measured at 518.8 nm against 
reagent blank.  
 
 The amount of Valsartan present in pharmaceutical dosage forms were 
determined by referring to the standard calibration curve (Table 5.33). 
 135
 
 
 
 
                                                                                                                                                               
   
   
   
5. 
   
   
RESULTS  
&  
DISCUSSION… 
 
 
 
                                                   
 
 
 
 
 
 
 
 
_____________________________________________Result and Discussion______ 
5. RESULTS AND DISCUSSION 
 
         Selective serotonin reuptake inhibitors are one of the important class 
of antidepressant drugs. This work mainly reports the applicability of acid dye 
technique for the routine analysis of nitrogenous drug molecules. A wide array 
of dyes was used and efforts were made to apply this method to most of the 
antidepressants that are in vogue in the contemporary therapy today. 
 
        The study brought to light certain important aspect of acid dye 
complexation. Literature survey revealed that to increase the sensitivity of the 
method, the ion-pair complex that is formed has to be extracted into organic 
layer, and brought back to aqueous layer (acidic or basic) by shaking the 
organic layer with 0.1 N hydrochloric acid or 0.1 N sodium hydroxide 
depending on the dye initially used for complex formation. The dye used in the 
complex formation is quantitatively extracted with aqueous layer and the 
absorbance of the resultant aqueous solution is measured. However, in actual 
practice, this process is tedious and time consuming due to formation of 
strong emulsions which interferes with extraction.  
 
        This method, by itself, is not a novel one.  Sufficient amount of data is 
available where ion-pair complexing was utilized for the generation of 
chromophores with a number of drug molecules (table 1.1).  In spite of that, 
the study brought certain unfocussed areas of the method.  
 
 The secondary nitrogen containing drugs having capability to form ion 
pair complexes with dyes. This method was so far reported but not been 
explored for applicability in combined dosage form. Therefore it was thought 
of interest to modify the method in which drug was liberated itself in organic 
phase to avoid further extraction step. 
 
        The role of ethanol/methanol employed in the preparation of drug or 
dye solutions has not been discussed anywhere in the literature. After 
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meticulous experimentation, it was conclude that methanol or ethanol does 
not interfere in the intensity of the color.   
        
 As per the theory of acid dye technique, free dye remains insoluble in 
organic phase viz. chloroform, it then extracted in an alkaline aqueous phase 
(Sethi, P.D, 1997). In our modification of the method, the drugs (Fluoxetine 
hydrochloride, Sertraline hydrochloride and Duloxetine hydrochloride) were 
directly forms complexes with methyl orange in 0.1N hydrochloric acid and it 
was found that relatively basic compounds readily form complex with methyl 
orange and was easily extracted in chloroform. 
 
        To obliterate the possibility of interference from chloroform soluble 
fraction of the dye, washing of dye with chloroform was done prior to 
complexation. This gives clear colorless blank and rules out possibility of the 
presence of any uncomplexed chemical in the dye, if any, being extracted with 
chloroform along with the drug-dye complex. 
 
 The affinity/specificity towards buffers, their pH and dyes were also 
different for different drugs undertaken for study.  This phenomenon was 
observed even for compounds of the same pharmacological category.  This is 
because the dye and pH requirements are mainly based on the environment 
of nitrogen and overall acidic /basic nature of the molecule. In our drugs 
(Fluoxetine hydrochloride, Sertraline hydrochloride and Duloxetine 
hydrochloride) methyl orange gives ion pair complex directly with 0.1N 
hydrochloric acid. 
 
 This combination of drug-dye was selected after extensive 
experimentation with different buffers and dyes for all the drugs and the 
optimum combination was selected. 
 
 Mechanism of proposed method 
 
In the proposed method for the estimation like Fluoxetine hydrochloride, 
Sertraline hydrochloride and Duloxetine hydrochloride, (secondary aliphatic 
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nitrogen containing basic drugs) formed ion pair complex with acidic dye 
methyl orange as mentioned below. 
 
The equilibrium for ion-pair formation can be expressed as; 
 
A+ aq.    +    D- aq.                   AD org. 
A+ aq. is the protonated amine in aqueous phase. D- aq. is the anionic pairing 
dye in aqueous phase and AD org. is the final ion-pair complex extractable 
into organic phase.   
 
1. Ion – pair Complex with Fluoxetine Hydrochloride 
 
F3C
O N CH3H
H
H
+
HCl
 
Fluoxetine hydrochloride (cationic drug) 
 
+ 
N
CH3
CH3
N N SO3
 
Methyl orange (anionic dye) 
 
 
 
F3C
O N CH3H
H
H
+
HCl
N
CH3
CH3
N N SO3
 
Fluoxetine hydrochloride – Methyl orange Ion Pair Complex 
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2. Ion – pair Complex with Sertraline Hydrochloride 
 
 
N
CH3H
Cl
Cl
H
HCl
+
 
 
 
N
CH3
CH3
N N SO3
 
        + 
 
 
 
Sertraline hydrochloride            Methyl orange (anionic dye) 
(cationic drug) 
 
 
 
 
N
CH3H
Cl
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N
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Sertraline hydrochloride – methyl orange ion pair complex 
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3. Ion – pair Complex with Duloxetine Hydrochloride 
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N
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+
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   + 
 
Duloxetine hydrochloride           Methyl orange (anionic dye) 
(cationic drug) 
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Duloxetine hydrochloride – methyl orange ion pair complex 
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Factors affecting the development of color 
 
 A chemical reaction is affected by many of experimental parameters. 
Various experimental conditions such as concentration of dye, effect of pH 
and effect of time have been studied and optimized.  
 
Effect of concentration of dye 
 
 Yellow colored chromophore was formed as a result of the reaction 
between the drugs (Fluoxetine hydrochloride, Sertraline hydrochloride and 
Duloxetine hydrochloride) and Methyl orange. The intensity of ion pair 
complex in chloroform was measured. Optimum concentration of dye was 
found to be 2.0 ml of 0.05 % w/v for Fluoxetine hydrochloride, Sertraline 
hydrochloride and Duloxetine hydrochloride (Table 5.5, Fig. 5.8). 
 
Effect of pH of buffer 
 
 Various buffer solutions having pH ranges (1.0 - 8.0) and 0.1N 
hydrochloric acid were used. Maximum absorbance was obtained in presence 
of 0.1N hydrochloric acid (pH 1.0 - 4.0) for fluoxetine hydrochloride while 
maximum absorbance was obtained in presence of 0.1N hydrochloric acid 
(pH 1.0) for sertraline hydrochloride. Duloxetine hydrochloride shown 
maximum absorbance with phthalate buffer (pH 3.0) and acetate buffer (pH 
3.0) (Table 5.4, Fig. 5.7).  
 
Color Stability 
 
 The stability of colored solution was studied at room temperature. The 
drug – dye complex was stabled for more than 48 hours for Fluoxetine 
hydrochloride, Sertraline hydrochloride and Duloxetine hydrochloride (Table 
5.6, Fig. 5.9). 
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Validation of the proposed method 
 
Linearity 
 
 The absorbance values obtained at respective λmax of different 
concentration of drugs were used to plot a calibration curve. The linearity 
range for Fluoxetine hydrochloride, Sertraline hydrochloride and Duloxetine 
hydrochloride was found to be 5.0 – 30.0 μg/ml, 2.0 – 14.0 μg/ml and 2.0 – 
12.0 μg/ml respectively. 
The data with graph along with Standard deviation and % CV given for 
Fluoxetine hydrochloride (Table 5.1, Fig. 5.4), Sertraline hydrochloride (Table 
5.2, Fig. 5.5) and Duloxetine hydrochloride (Table 5.3, Fig. 5.6) respectively. 
  
Accuracy 
 
 The % recovery experiment revealed good accuracy. The average % 
recovery of Fluoxetine hydrochloride, Sertraline hydrochloride and Duloxetine 
hydrochloride were found to be 99.68 – 101.88 %, 98.48 – 101.78 % and 
99.08 – 101.89 % respectively (Table 5.7, 5.8, 5.9). 
 
 
Precision 
 
 The %CV obtained for repeatability of measurements of absorbance for 
Fluoxetine hydrochloride, Sertraline hydrochloride and Duloxetine 
hydrochloride were found to be 0.24 – 0.68 %, 0.19 – 0.53 %, and 0.23 – 0.95 
% respectively (Table 5.10, 5.11, 5.12).  
 
The %CV obtained for intra day precision for Fluoxetine hydrochloride, 
Sertraline hydrochloride and Duloxetine hydrochloride were found to be 0.89 
% – 1.66 %, 0.75 % – 2.04 %, and 0.56 % – 1.24 % respectively (Table 5.13, 
5.14, 5.15). 
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The %CV obtained for inter day precision for Fluoxetine hydrochloride, 
Sertraline hydrochloride and Duloxetine hydrochloride were found to be 1.59 – 
2.78 %, 1.01 – 2.51 %, and 0.98 – 2.54 % respectively (Table 5.13, 5.14, 
5.15).  
 
Limit of detection (LOD) 
 
  Limit of detection for Fluoxetine hydrochloride, Sertraline hydrochloride 
and Duloxetine hydrochloride were found to be 0.98 µg/ml, 0.21 µg/ml and 
0.49 µg/ml respectively (Table 5.20). 
 
Limit of quantification (LOQ) 
 
 Limit of quantitation for Fluoxetine hydrochloride, Sertraline 
hydrochloride and Duloxetine hydrochloride were found to be 2.97 µg/ml, 0.63 
µg/ml and 1.49 µg/ml respectively (Table 5.20). 
 
Validation parameters are summarized in Table 5.20  
 
Optical and regression characteristics are summarized in Table 5.21 
 
Job’s continuous variation method 
 
 Job’s continuous variation was conducted for Fluoxetine hydrochloride, 
Sertraline hydrochloride and Duloxetine hydrochloride which formed 1:1 
complex with methyl orange (Table 5.16, Fig. 5.10). 
 
Analysis of marketed formulations 
 
 The marketed formulation of Fluoxetine hydrochloride, Sertraline 
hydrochloride and Duloxetine hydrochloride were analyzed with the proposed 
method (Table 5.17, 5.18, 5.19). The result obtained are in good agreement 
with labeled value of dosage forms.   
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Table 5.1. Calibration data for Fluoxetine hydrochloride in 0.1N HCl  
      
Concentration of 
Fluoxetine HCl  
(µg/ml) 
Absorbance at 426.0 nm 
Mean ± S.D. 
(n = 5) 
% CV 
5.0 0.211± 0.0032 1.50 
10.0 0.362 ± 0.0045 1.25 
15.0 0.482 ± 0.0029 0.61 
20.0 0.624 ± 0.0050 0.80 
25.0 0.774 ± 0.0019 0.95 
30.0 0.922 ± 0.0035 1.29 
 
 
 
 
 
y = 0.0282x + 0.0692
R2 = 0.9991
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Fig. 5.4. Calibration curve for Fluoxetine hydrochloride at 426.0 nm 
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Table 5.2. Calibration data for Sertraline hydrochloride in 0.1N HCl 
 
Concentration of 
Sertraline HCl  
(µg/ml) 
Absorbance at 425.0 nm 
Mean ± S.D. 
(n = 5) 
% CV 
2.0 0.164 ± 0.0030 1.85 
4.0 0.336 ± 0.0022 0.66 
6.0 0.476 ± 0.0058 1.21 
8.0 0.606 ± 0.0025 0.42 
10.0 0.787 ± 0.0037 0.48 
12.0 0.914 ± 0.0036 0.40 
14.0 1.087 ± 0.0088 0.81 
 
 
 
 
y = 0.0756x + 0.0191
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Fig. 5.5: Calibration curve for Sertraline hydrochloride at 425.0 nm 
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Table 5.3. Calibration data for Duloxetine hydrochloride in Phthalate 
buffer pH 3.0 
 
Concentration of 
Duloxetine HCl  
(µg/ml) 
Absorbance at 426.0 nm 
Mean ± S.D. 
(n = 5) 
% CV 
2.0 0.212 ± 0.0065 1.55 
4.0 0.408 ± 0.0150 1.42 
6.0 0.589 ± 0.0080 1.35 
8.0 0.764 ± 0.0054 0.70 
10.0 0.918 ± 0.0102 1.11 
12.0 1.083 ± 0.0090 0.82 
 
 
 
 
 
y = 0.088x + 0.0497
R2 = 0.9988
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Fig. 5.6: Calibration curve for Duloxetine hydrochloride at 426.0 nm 
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Table 5.4. Effect of pH of buffer solutions.  
 
Absorbance  
 
Concentration 
of drug 
(µg/mL) 
pH of 
buffer 
solution Fluoxetine 
hydrochloride 
Sertraline 
hydrochloride 
Duloxetine 
hydrochloride
5.0 1.0 0.212 0.408 0.166 
5.0 2.0 0.211 0.381 0.205 
5.0 3.0 0.209 0.352 0.511 
5.0 4.0 0.211 0.342 0.509 
5.0 5.0 0.184 0.311 0.455 
5.0 6.0 0.151 0.289 0.312 
5.0 7.0 0.132 0.251 0.296 
5.0 8.0 0.062 0.121 0.148 
5.0 
0.1 N 
HCl 
0.212 0.409 0.155 
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Fig. 5.7. Effect of pH of buffer  
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Table 5.5. Effect of concentration of methyl orange 
 
Absorbance  
 
Concentration 
of drug 
(µg/ml) 
Methyl 
orange 
solution 
(ml) 
Fluoxetine 
hydrochloride 
Sertraline 
hydrochloride 
Duloxetine 
hydrochloride
5.0 0.5 0.060 0.110 0.101 
5.0 1.0 0.110 0.213 0.253 
5.0 1.5 0.192 0.305 0.365 
5.0 2.0 0.211 0.411 0.502 
5.0 2.5 0.210 0.409 0.500 
5.0 3.0 0.208 0.410 0.499 
5.0 3.5 0.209 0.409 0.501 
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Fig. 5.8. Effect of concentration of methyl orange 
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Table 5.6. Effect of time on stability of color complex  
 
Absorbance  
 
Concentration 
of drug 
(µg/ml) 
Time 
(hours) 
Fluoxetine 
hydrochloride 
Sertraline 
hydrochloride 
Duloxetine 
hydrochloride
5.0 0.0 0.212 0.412 0.509 
5.0 1.0 0.211 0.411 0.510 
5.0 2.0 0.210 0.410 0.507 
5.0 6.0 0.213 0.412 0.508 
5.0 12.0 0.211 0.412 0.510 
5.0 18.0 0.210 0.409 0.509 
5.0 24.0 0.209 0.410 0.511 
5.0 36.0 0.211 0.413 0.508 
5.0 48.0 0.212 0.410 0.510 
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Fig. 5.9. Effect of time on stability of color complex 
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Table 5.7. Recovery data for Fluoxetine hydrochloride  
 
Amount of 
sample drug 
taken (µg/mL) 
Amount of 
standard drug 
added (µg/mL) 
Amount of drug 
found (µg/mL) 
Mean ± SD 
% Recovery ± % 
CV (n=5) 
5.0 0.0 5.01 ± 0.013 100.15 ± 0.85 
5.0 5.0 10.07 ± 0.062 101.35 ± 1.22 
5.0 10.0 15.03 ± 0.056 100.61 ± 1.02 
5.0 15.0 19.96 ± 0.051 99.68 ± 1.34 
5.0 20.0 25.12 ± 0.061 100.78 ± 1.14 
5.0 25.0 30.28 ± 0.072 101.88 ± 1.96 
 
 
 
 
 
Table 5.8. Recovery data for Sertraline hydrochloride  
 
Amount of 
sample drug 
taken (µg/ml) 
Amount of 
standard drug 
added (µg/ml) 
Amount of drug 
found (µg/ml) 
Mean ± SD 
% Recovery ± % CV 
(n=5) 
4.0 0.0 3.92 ± 0.023 98.48 ± 1.05 
4.0 2.0 6.07 ± 0.078 100.64 ± 1.45 
4.0 4.0 8.03 ± 0.051 100.13 ± 1.23 
4.0 6.0 9.96 ± 0.065 99.45 ± 1.77 
4.0 8.0 12.12 ± 0.023 101.78 ± 1.28 
4.0 10.0 14.09 ± 0.012 100.78 ± 0.96 
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Table 5.9. Recovery data for Duloxetine hydrochloride 
 
Amount of 
sample drug 
taken (µg/ml) 
Amount of 
standard drug 
added (µg/ml) 
Amount of drug 
found (µg/ml) 
Mean ± SD 
% Recovery ± % CV 
(n=5) 
4.0 0.0 3.95 ± 0.013 99.08 ± 1.09 
4.0 2.0 6.07 ± 0.062 100.72 ± 1.58 
4.0 4.0 8.03 ± 0.056 100.14 ± 1.43 
4.0 6.0 9.96 ± 0.051 99.45 ± 1.83 
4.0 8.0 12.12 ± 0.072 101.89 ± 1.20 
 
 
Table 5.10. Results of repeatability of measurements of absorbance for 
Fluoxetine hydrochloride 
 
Concentration 
(µg/ml) 
Absorbance 
Mean ± SD (n=7) % CV 
5.0 0.211 ± 0.0019 0.68 
10.0 0.362 ± 0.0021 0.36 
15.0 0.481 ± 0.0025 0.24 
20.0 0.614 ± 0.0022 0.42 
25.0 0.772 ± 0.0031 0.38 
30.0 0.918 ± 0.0023 0.59 
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Table 5.11. Results of repeatability of measurements of absorbance for 
Sertraline hydrochloride 
 
Concentration 
(µg/mL) 
Absorbance 
Mean ± SD (n=7) % CV 
2.0 0.165 ± 0.0066 0.53 
4.0 0.339 ± 0.0014 0.19 
6.0 0.480 ± 0.0085 0.28 
8.0 0.605 ± 0.0056 0.47 
10.0 0.793 ± 0.0041 0.37 
12.0 0.916 ± 0.0048 0.52 
14.0 1.081 ± 0.0048 0.41 
 
 
Table 5.12. Results of repeatability of measurements of absorbance for 
Duloxetine hydrochloride 
 
Concentration 
(µg/ml) 
Absorbance 
Mean ± SD (n=7) % CV 
2.0 0.221 ± 0.0043 0.56 
4.0 0.414 ± 0.0081 0.95 
6.0 0.598 ± 0.0035 0.26 
8.0 0.779 ± 0.0065 0.24 
10.0 0.932 ± 0.0048  0.23 
12.0 1.102 ± 0.0029 0.43 
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Table5.13. Precision data for Fluoxetine hydrochloride 
 
Intra day precision Inter day precision 
Concentration 
(µg/ml) Absorbance 
Mean ± SD (n=3) % CV 
Absorbance  
Mean ± SD (n=3) % CV
5.0 0.209 ± 0.0045 1.66 0.211 ± 0.0052 2.18 
10.0 0.359 ± 0.0087 1.02 0.361 ± 0.0092 2.78 
15.0 0.480 ± 0.0109 1.56 0.484 ± 0.0048 2.20 
20.0 0.620 ± 0.0092 1.12 0.614 ± 0.0102 1.62 
25.0 0.773 ± 0.0083 0.89 0.770 ± 0.0073 1.59 
30.0 0.922 ± 0.0065 1.23 0.928 ± 0.0059 2.23 
 
 
Table5.14. Precision data for Sertraline hydrochloride 
 
Intra day precision Inter day precision 
Concentration 
(µg/ml) 
Absorbance 
Mean ± SD (n=3) % CV 
Absorbance  
Mean ± SD (n=3) % CV
2.0 0.160 ± 0.0026 0.93 0.167 ± 0.0106 2.35 
4.0 0.336 ± 0.0068 1.75 0.334 ± 0.0044 1.01 
6.0 0.471 ± 0.0078 1.55 0.471 ± 0.0023 2.46 
8.0 0.606 ± 0.0099 2.04 0.603 ± 0.0075 2.51 
10.0 0.785 ± 0.0053 1.22 0.786 ± 0.0046 1.18 
12.0 0.911 ± 0.0042 0.93 0.918 ± 0.0088 2.05 
14.0 1.087 ± 0.0105 0.75 1.099 ± 0.0091 1.09 
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Table 5.15. Precision data for Duloxetine hydrochloride 
 
Intra day precision Inter day precision 
Concentration 
(µg/ml) 
Absorbance 
Mean ± SD (n=3) % CV 
Absorbance  
Mean ± SD (n=3) % CV
2.0 0.206 ± 0.0048 0.56 0.209 ± 0.0053 1.36 
4.0 0.422 ± 0.0062 1.05 0.387 ± 0.0091 2.04 
6.0 0.579 ± 0.0095 0.99 0.588 ± 0.0108 1.85 
8.0 0.758 ± 0.0120 1.24 0.761 ± 0.0086 0.98 
10.0 0.917 ± 0.0078 0.87 0.912 ± 0.0091 1.50 
12.0 1.110 ± 0.0036 1.21 1.091 ± 0.0097 2.54 
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Table 5.16. Data for Job’s continuous variation method 
 
Absorbance  Mole fraction 
of drug 
Mole fraction of 
methyl orange Fluoxetine 
HCl 
Sertraline 
HCl 
Duloxetine 
HCl 
0.0 1.0 0.000 0.000 0.000 
0.2 0.8 0.064 0.092 0.165 
0.4 0.6 0.208 0.228 0.371 
0.5 0.5 0.215 0.391 0.492 
0.6 0.4 0.207 0.239 0.369 
0.8 0.2 0.049 0.089 0.172 
1.0 0.0 0.000 0.000 0.000 
 
 
 
 
0
0.1
0.2
0.3
0.4
0.5
0 0.2 0.4 0.6 0.8 1
Mole fraction of drug
A
bs
or
ba
nc
e
Fluoxetine HCl
Sertraline HCl
Duloxetine HCl
 
 
Fig. 5.10. Job’s continuous variation method 
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Table 5.17. Analysis of Fluoxetine hydrochloride in dosage forms 
 
Formulation Label claim 
(mg) 
%  found 
Mean ± SD (n = 5) 
 % CV 
Tablet - 1 10.0 99.35 ± 0.104 1.05 
Tablet - 2 20.0 100.70 ± 0.630 0.62 
Capsule - 1 20.0 98.93 ± 0.882 1.25 
Capsule - 2 60.0 101.05 ± 0.451 1.06 
 
 
Table 5.18. Analysis of Sertraline hydrochloride in dosage forms 
 
Formulation Label claim 
(mg) 
%  found 
Mean ± SD (n = 5) 
 % CV 
Tablet - 1 25.0 101.53 ± 0.857 1.44 
Tablet - 2 50.0 98.960 ± 0.632 2.43 
Tablet - 3 100.0 99.16 ± 1.077 1.68 
 
 
Table 5.19. Analysis of Duloxetine hydrochloride in dosage forms 
 
Formulation Label claim 
(mg) 
% found 
Mean ± SD (n = 5) 
 % CV 
Tablet - 1 20.0 99.50 ± 0.225 1.54 
Tablet - 2 40.0 100.67 ± 0.247 1.62 
Capsule - 1 20.0 98.67 ± 0.494 2.25 
Capsule - 2 40.0 102.00 ± 0.816 2.06 
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Table 5.20. Summary of validation parameters  
 
Parameter Fluoxetine HCl Sertraline HCl Duloxetine HCl 
Linearity range 
(μg/ml) 5.0 – 30.0 2.0 – 14.0 2.0 – 12.0 
Limit of detection 
(LOD) (μg/ml) 0.98 0.21 0.49 
Limit of quantification 
(LOQ) (μg/ml) 2.97 0.63 1.49 
Precision (% CV) 
• Repeatability 
• Intraday 
• Interday 
 
0.24 – 0.68 
0.89 – 1.66 
1.59 – 2.78 
 
0.19 – 0.53 
0.75 – 2.04 
1.01 – 2.51 
 
0.23 – 0.95 
0.56 – 1.24 
0.98 – 2.54 
% Recovery 
99.68 – 
101.88 
98.48 – 101.78 99.08 – 101.89 
Specificity Specific Specific Specific 
 
Table 5.21. Optical and regression characteristics  
 
Parameters 
Fluoxetine  
HCl 
Sertraline  
HCl 
Duloxetine 
HCl 
λmax (nm) 426.0 425.0 426.0 
Regression equation 
(Y = mx + c) 
Y = 0.0282x  
+ 0.0692 
Y = 0.0756x 
+ 0.0191 
Y = 0.0880x 
+ 0.0497 
Slope (b) 0.0282 0.0756 0.0880 
Intercept (a) 0.0692 0.0191 0.0497 
Correlation coefficient (r2) 0.9991 0.9985 0.9988 
Sandell’s sensitivity 
(μg/ml/cm2) 
0.0237 0.0094 0.0122 
Molar absorptivity 
(L/mol.cm) 
7.13 x 103 2.69 x 104 3.27 x 104
AT1 Receptors blocker 
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 AT1 receptors blockers are one of the well- known class of 
antihypertensive drugs. Losartan is parent molecule of this class. Losartan 
can be estimated by both acid and basic dye. Losartan posses’ different 
functional moieties such as N alkyl substituted imidazole (basic) and tetrazole 
(acidic) of varied reactivity. Alkyl substituted nitrogen in imidazole reacts with 
acidic dye bromocresol green and tetrazole with basic dye safranine O. 
Therefore it was thought of interest to develop basic dye method for other 
drugs belongs to the same class and having tetrazole moiety in the structure. 
 
 It was found that tetrazole ring system was responsible for the ion-pair 
complex formation. As tetrazole ring system it self contain four nitrogen, but 
ring resonance make it acidic and this property was utilized in development of 
ion pair technique with basic dye. Valsartan contain tetrazole ring system in its 
structure and this method was proven successfully.  
 
Mechanism of proposed method 
 
In the proposed basic dye method for the estimation of Valsartan, which 
containing tetrazole ring system makes ion pair complex with basic dye 
safranin O as mentioned below. 
 
The equilibrium expression for ion-pair formation can be expressed as 
 
A-aq + D+aq      ADorg  
 
 
A-aq = anionic drug in aq. Phase 
 
D+aq = cationic dye in aq. Phase 
 
ADorg = ion-pair complex extractable into organic phase 
 
Ion – pair Complex with Valsartan 
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Factors affecting the development of color: 
 
 A chemical reaction is affected by many of experimental parameters. 
Various experimental conditions such as concentration of dye, effect of time 
for stability of color and effect of pH of buffer have been studied and optimized 
to maximize the sensitivity and reproducibility of the method. 
 
Effect of concentration of dye 
 
 Red colored chromophore was formed as a result of the reaction 
between the drug and Safranin O. The intensity of ion pair complex in 
chloroform was measured. Optimum concentration of dye was found to be 2.5 
ml of 0.05 % w/v (Table 5.24, Fig. 5.14). 
 
Color Stability. 
 
 The stability of colored solution was studied at room temperature and 
shows that drug – dye complex was stable for 48 hours. (Table 5.25, Fig 
5.15).  
 
Effect of pH of buffer 
 
 Initially citrate buffer was used for pH optimization. Then it was 
counterchecked by phosphate buffer USP. Similar results were found through 
both buffers. Citrate buffer and glycine- NaCl buffer ranging from 3 to 9.5 were 
utilized for optimization. Optimum pH, where ion- associated complex showed 
maximum absorbance, was found to be pH 6.8 (Table 5.23, Fig. 5.13). 
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Validation of the proposed method 
 
Linearity 
 
 The absorbance value obtain at the respective λmax of different 
concentration of drug was used to plot a calibration curve. The linearity range 
for valsartan 5 – 25 μg/ml (Table 5.22, Fig. 5.12). 
 
 Accuracy 
 
 The % recovery experiment revealed good accuracy. The average % 
recovery of valsartan was found to be 99.59 - 101.35 % (Table 5.26).  
 
Precision 
 
The %CV obtained for repeatability of measurements of absorbance for 
Valsartan was found to be 0.21 - 0.88 % (Table 5.27).  
 
The %CV obtained for intra day precision for Valsartan was found to be 1.02 - 
1.96 % (Table 5.28). 
 
The %CV obtained for inter day precision for was found to be 1.51 - 2.18 % 
(Table 5.28).   
 
Limit of detection (LOD) 
 
  Limit of detection for valsartan was found to be 0.5 (Table 5.34) 
 
Limit of quantification (LOQ) 
 
 Limit of quantitation for valsartan was found to be 5.0 (Table 5.34) 
 
Validation parameters are summarized in Table 5.34  
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Optical and regression characteristics are summarized in Table 5.35 
 
Job’s continuous variation method 
 
 Job’s continuous variation was conducted for Valsartan which form 1:1 
complex with safranin O dye (Table 5.29, Fig. 5.16).  
 
Analysis of market formulations: 
 
 The market formulation of Valsartan was analyzed with the proposed 
method (Table 5.30).   
 
Analysis of Valsartan in Combined dosage form (One Component 
Analysis) 
 
The basic dye method was used for analysis of the drug in combined 
dosage form.   
 
Hydrochlorothiazide as well as s-amlodipine did not form an ion pair 
complex with the safranin O solution. Hence, combined dosage forms like 
valsartan -  hydrochlorothiazide and valsartan – s-amlodipine were taken into 
analysis. There was absolutely no interference of hydrochlorothiazide, s-
amlodipine or usual excipients in the analysis of the drug under study. 
Hydrochlorothaizide and s-amlodipine were added in increasing order to the 
drug and it was observed that irrespective of the quantities present, 
hydrochlorothiazide and s-amlodipine did not interfere in the analysis. (Table 
no.  5.31, 5.32, 5.33) 
 
All other experimental conditions applied to the bulk drugs and their 
formulations, were found to be suitable for combined dosage forms. The 
results obtained are very convincing.  
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Thus in present study, the basic dye technique was successfully 
employed for analysis of one drug in presence of another non-ion –pair 
forming drug in combined dosage forms.  
 
 
 
Fig. 5.11 A visible Spectrum of Valsartan at 518.8 nm 
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Table 5.22. Calibration data for Valsartan in phosphate buffer pH 6.8 
 
Concentration 
(µg/ml) 
Absorbance 
Mean ± SD (n=5) % CV 
5.0 0.157 ± 0.0057 1.65 
10.0 0.319 ± 0.0067 2.10 
15.0 0.470 ± 0.0069 1.48 
20.0 0.634 ± 0.0058 0.90 
25.0 0.809 ± 0.0075 0.92 
 
 
 
 
y = 0.0324x - 0.0079
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Fig. 5.12. Calibration curve for Valsartan at 518.8 nm 
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Table 5.23. Effect of pH of buffer solutions  
 
Concentration of drug 
(µg/ml) 
pH of buffer 
solution 
Absorbance  
10.0 4.0 0.091 
10.0 5.0 0.132 
10.0 6.0 0.164 
10.0 6.4 0.299 
10.0 6.8 0.32 
10.0 7.0 0.306 
10.0 8.0 0.187 
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 Fig. 5.13. Effect of pH of phosphate buffer  
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Table 5.24. Effect of concentration of safranin O 
 
Concentration of drug 
(µg/ml) 
Safranin O 
solution (ml) 
Absorbance  
10.0 0.5 0.185 
10.0 1.0 0.205 
10.0 1.5 0.235 
10.0 2.0 0.281 
10.0 2.5 0.321 
10.0 3.0 0.318 
10.0 3.5 0.320 
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Fig. 5.14. Effect of concentration of safranin O 
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Table 5.25. Effect of time for stability of color 
 
Concentration of drug 
(µg/ml) 
Time (hours) Absorbance 
10.0 0.0 0.320 
10.0 1.0 0.321 
10.0 2.0 0.318 
10.0 6.0 0.320 
10.0 12.0 0.317 
10.0 18.0 0.319 
10.0 24.0 0.321 
10.0 36.0 0.320 
10.0 48.0 0.318 
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 Fig. 5.15. Effect of time for stability of color 
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Table 5.26. Recovery data for Valsartan in phosphate buffer pH 6.8 
 
Amount of 
sample  taken 
(µg/ml) 
Amount of 
standard  
added (µg/ml) 
Amount  found 
(µg/ml) 
Mean ± SD 
% Recovery ± % CV 
(n=5) 
5.0 0.0 5.01 ± 0.013 100.15 ± 0.85 
5.0 5.0 10.07 ± 0.062 101.35 ± 1.22 
5.0 10.0 14.96 ± 0.051 99.68 ± 1.34 
5.0 15.0 19.99 ± 0.020 99.59 ± 1.37 
5.0 20.0 25.03 ± 0.056 100.61 ± 1.02 
 
 
5.27. Results of repeatability of measurements of absorbance of 
Valsartan at 518.8 nm 
 
Concentration 
(µg/ml) 
Absorbance 
Mean ± SD (n=7) % CV 
5.0 0.158 ± 0.0035 0.61 
10.0 0.321 ± 0.0062 0.32 
15.0 0.472 ± 0.0029 0.21 
20.0 0.633 ± 0.0054 0.40 
25.0 0.811 ± 0.0039 0.88 
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Table 5.28. Precision data for Valsartan in phosphate buffer pH 6.8 
 
Intra day precision Inter day precision 
Concentration 
(µg/ml) Absorbance 
Mean ± SD (n=3) % CV 
Absorbance 
Mean ± SD (n=3) % CV
5.0 0.152 ± 0.0045 1.96 0.161 ± 0.0051 2.18 
10.0 0.299 ± 0.0060 1.02 0.330 ± 0.0070 2.12 
15.0 0.468 ± 0.0085 1.82 0.466 ± 0.0100 2.15 
20.0 0.641 ± 0.0075 1.18 0.651 ± 0.0098 1.51 
25.0 0.788 ± 0.0071 0.90 0.803 ± 0.0103 1.28 
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Table 5.29. Data for Job’s continuous variation method 
 
Mole fraction of 
Valsartan 
Mole fraction of  
safranin O 
Absorbance of 
Valsartan 
0.000 1.000 0.000 
0.125 0.875 0.155 
0.250 0.750 0.210 
0.375 0.625 0.275 
0.500 0.500 0.318 
0.625 0.375 0.261 
0.750 0.250 0.189 
0.875 0.125 0.129 
1.000 0.000 0.000 
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Fig. 5.16. Job’s continuous variation method 
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Table 5.30. Analysis of market formulations of Valsartan  
Formulation Label claim 
(mg) 
% l found 
Mean ± SD (n = 5) 
 % CV 
Tablet - 1 80.0 99.64 ± 0.021 2.28 
Tablet - 2 160.0 100.07 ± 0.038 2.81 
Capsule - 1 40.0 99.91 ± 0.045 1.89 
Capsule - 2 80.0 98.88 ± 0.081 2.06 
 
 
Table5.31. Interference of Hydrochlorothiazide on absorbance of 
Valsartan-safranin O complex 
Concentration of 
Valsartan 
(µg/ml) 
Concentration of 
Hydrochlorothiazide 
(µg/ml) 
Absorbance ± SD 
(n=5) 
 
% CV 
10.0 5.0 0.318 ± 0.0033 1.23 
10.0 10.0 0.319 ± 0.0059 0.92 
10.0 15.0 0.317 ± 0.0068 0.97 
10.0 20.0 0.321 ± 0.0031 1.05 
10.0 25.0 0.319 ± 0.0034 1.53 
 
Table 5.32. Interference of s-Amlodepine besylate on absorbance of 
Valsartan-safranin O complex 
 
Concentration of 
Valsartan 
(µg/ml) 
Concentration of  
s-Amlodepine 
besylate (µg/ml) 
Absorbance ± SD 
(n=5) 
 
% CV 
10.0 5.0 0.320 ± 0.0031 1.73 
10.0 10.0 0.321 ± 0.0024 1.25 
10.0 15.0 0.318 ± 0.0032 0.94 
10.0 20.0 0.319 ± 0.0050 2.05 
10.0 25.0 0.322 ± 0.0039 1.33 
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Table 5.33. Analysis of marketed formulations of Valsartan in 
combination with Hydrochlorothiazide and s-Amlodipine besylate 
individually. 
 
Formulation Label claim 
(mg) 
%  found 
Mean ± SD (n = 5) 
 % CV 
Tablet - 1 
Valsartan 80.0 
Hydrochlorothiazide 12.5 
99.92 ± 0.028 2.18 
Tablet - 2 
Valsartan 80.0 
Hydrochlorothiazide 12.5 
98.04 ± 0.075 2.04 
Capsule - 1 
Valsartan 80.0 
s-Amlodipine besylate 2.5 
100.59 ± 0.071 1.24 
 
 
Table 5.34. Summary of validation parameters of Valsartan 
 
Parameter Valsartan 
Linearity range (μg/ml) 5.0 – 25.0 
Limit of detection (LOD)  
(μg/ml) 0.50 
Limit of quantification (LOQ) 
(μg/ml) 5.00 
Precision (% CV) 
 
• Repeatability 
• Intraday 
• Interday 
 
 
0.21 – 0.88 
0.90 – 1.96 
1.28 – 2.18 
% Recovery 99.59 – 101.35 
Specificity Specific 
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Table 5.35. Optical and regression characteristics of Valsartan 
 
Parameters Results of Valsartan 
λmax (nm) 518.8  
Regression equation  
(Y = mx + c) 
Y= 0.0321x – 0.0079 
Slope (b) 0.0321 
Intercept (a) 0.0079 
Correlation coefficient (r2) 0.9994 
Sandell’s sensitivity (μg/ml/cm2) 0.0314 
Molar absorptivity (L/mol.cm) 1.39 x 104
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6. DISSOLUTION PROFILE STUDY 
 
6.1. Introduction 
 
 Dissolution testing has been emerged as a single most important test 
to ensure quality of the product when carried out appropriately. Knowledge of 
theoretical as well as practical aspects of dissolution testing proved to be very 
important for pharmaceutical scientist engaged in product development and 
quality control. Since the dissolution rate of a drug from its dosage form can 
often become the rate limiting process in the bio-availability, efforts have been 
laid down in the development of reliable in vitro test methods that can mimic 
the in vivo conditions.  
 
Objectives of dissolution test 
 
1. As quality control tool 
2. In the development of new drug products 
3. To assists in the determination of bioavailability and bioequivalence. 
4. For characterizing the biopharmaceutical quality of a product at  
           Different stages of life cycle. 
5. For choosing between different alternative formulation candidates. 
6. As a supportive in the evaluation and interpretation of possible risks. 
 
Official apparatuses 
 
USP App- I 
 
 It can be used for the dissolution testing of capsules. It consists of the 
following: 
 
• A covered vessel made up of glass or other inert transparent material 
• A motor assembly  
• A metallic drive shaft 
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• A cylindrical basket – 40 mesh (USP) 
• A suitable water bath in which vessel can be partially immersed and 
have capacity to maintain specified temp inside the vessel 
 
USP App- II 
 
 It is used for the dissolution testing of tablets. It consists of the 
following: 
 
• Paddle and shaft as a stirring element 
• A small, loose piece of non – reactive material (few turns of wire helix) 
may be attached to dosage units that would otherwise float 
• All others points, (from (1) to (3)) are same as in App 1 
 
USP App- III 
 
 It is used for the dissolution testing of extended release dosage forms. 
The assembly consists of; 
• A set of cylindrical flat bottom glass vessels 
• A set of glass reciprocating cylinders 
• Stainless steel fittings and polypropylene screens to fit tops and 
bottoms of the reciprocating cylinders. 
• A motor and a drive assembly 
• A water bath 
• Distance traveled by the reciprocating cylinder during the upward and 
downward stroke 9.9 – 10.1 cm 
 
USP App- IV 
 
 It is used for dissolution testing of delayed release dosage forms. It 
consists of 
• A reservoir 
• A pump for dissolution medium 
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• A flow through cell 
• A water bath 
• Delivery range of the pump is 240 – 960 ml/hr. Flow rate is 4.8 and 16 
ml/min 
• Bottom cone filled with small glass beads of 1mm diameter of which 
one bead is of about 5 mm positioned at apex to protect the fluid entry tube 
• A tablet holder for positioning of special dosage forms e.g. inlay tablets 
 
USP App- V 
 
 It is used for dissolution testing for transdermal dosage forms. 
• It consists of stainless steel disc assembly in addition to paddle 
apparatus for holding transdermal dosage forms.  
 
 
USP App- VI 
 
 It is used for dissolution testing for transdermal dosage forms. 
• Basket is replaced and a shaft with a stainless steel cylinder stirring 
element and a water bath to maintain specified temp during test. Dosage form 
is spreaded on the cylinder in form of flat film. 
 
USP App- VII 
 
 It is used for dissolution testing of variety of dosage forms such as 
transdermal dosage forms and solid dosage forms. It consists of: 
• A set of reciprocating disc shaped sample holders 
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Testing conditions 
 
(1) Dissolution medium 
 
Composition : Generally water is used as solvent for the dissolution medium 
but pH and surface tension of pure water varies depending upon source of 
water pH may change due to absorption of CO 2  from air. Additions of organic 
solvents are generally avoided. 
 
pH:  It should be in between 1- 6.8. For low pH 0.1 N HCl is used. For high 
pH (4.5 – 8.0 pH) – USP buffers are used. 
 
Volume: USP specifies it in between 50 ml – 1000ml. Generally 900 ml is 
used. For poorly soluble drugs 4000 ml can be used but it is considered as 
modification. 
 
Agitation: It should be in between 50 -100 rpm but should not be more than 
150. In cell flow rate should be 4, 8 or 16 ml/min. 
 
Temperature: It should be 37±0.2 oC for transdermal dosage forms. 
 
Deaeration: It should be done by suitable validated method. 
 
(2) Qualification and validation 
 
  Apparatus suitability test (AST) with calibrators is a further important 
aspect of qualification and validation. The use of USP calibrator tablets 
(disintegrating and non-disintegrating) is recommended. System suitability 
test of USP App-3 has to be performed with both multi particulate and a mono 
particulate standard formulation. AST are recommended to be performed not 
less than twice per year per equipment and after any occasion of equipment 
change, significant repair or movement. 
Validation of dissolution tests for solid dosage forms 
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• Specificity 
• Accuracy  
• Filter bios calculations 
• Precision and ruggedness 
• Geometrical and dimensional accuracy 
 
(3) Dissolution specifications 
 
 They are set to ensure batch to batch consistency with the range, 
which guarantees acceptable biopharmaceutical performances in vivo. For 
immediate and very fast drug releasing dosage form in a single point test at 
least 80% of the drug substance is dissolved in 15 min under reasonable 
justified test conditions. 
 
For controlled release – At least three points are required. 
 1st specification point – To prevent dose dumping it should be set after 
a testing interval of one or two hours or corresponding to a dissolved amount 
20 – 30 % of labeled drug substance. 
 
 2nd specification point – It should define the dissolution pattern and 
thus be around 50 % release of labeled drug substance. 
 
 3rd specification point – It should release quantitative drug release 
generally > 80 % 
 
 The dissolution run in quality control should be extended for the time 
interval at least 80 % of drug substance is dissolved. 
 
Shorter time test intervals can be acceptable in special cases. 
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(4) Factors affecting dissolution time 
 
Factors related to the physicochemical property of drug 
 
• Solid phase characteristics 
• Polymorphism 
• Amorphous / crystal state 
• Free or salt form 
• Complexation, eutectics 
• Partical size 
• Surfactants 
 
Excipients and additives 
 
• Granulating agents and binders 
• Disintegrating agents 
• Lubricants 
• Surfactants 
 
Factors related to dosage forms 
 
• Granule size 
• Drug excipients interactions 
• Compression force 
• Degradation 
• Storage of dosage forms 
 
Factors related to the dissolution testing devices 
 
• Eccentricity of agitating element 
• Vibration 
• Agitation intensity 
• Stirring element alignment 
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• Flow pattern disturbances 
• Sampling probes position and filter 
• Dosage form position 
• Type of device 
 
Factor related to dissolution test parameter 
 
• Temperature 
• Dissolution medium (composition, viscosity, dissolution) 
 
Miscellaneous factors 
 
• Adsorption 
• Sorption 
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6.2 Dissolution study 
 
6.2. 1. Apparatus 
 
• Dissolution test apparatus [Electro lab] 
• Double beam spectrophotometric [shimadzu model UV- 1601] 
• Sartorious monopan balance 
• Digital pH meter (cystronic) 
• Sonicator 
• Glass stoppered tubes 
 
6.2. 2 Reagents and materials 
 
• Dye solution 
• 0.1 N hydrochloric acid 
 
6.2. 3 Preparation of solution (As per 4.1.2) 
           
6.2.4. Dissolution profile study (Fluoxetine hydrochloride, Sertraline 
hydrochloride) 
 
 The dissolution profile study was carried out using dissolution 
apparatus USP – II (Electrolab, India) containing 900 ml of 0.1N hydrochloric 
acid used as a dissolution medium at 37±2 0C at 50 rpm. Carefully transferred 
tablet/capsule of same brand (Fluoxetine hydrochloride, Sertraline 
hydrochloride) into six different baskets. Samples were withdrawn (5.0 ml)  at 
interval of 10, 20, 30, 45, 60 & 90 minutes from each basket and 
simultaneously same amount was replaced by 0.1N hydrochloric acid into 
each basket. 
 
 An aliquot (1.0 ml) was pipetted out in to a glass stoppered tube 
containing methyl orange solution (2.0 ml). The final volume was adjusted to 
5.0 ml with 0.1N hydrochloric acid and analysed as described under 4.3.5 and 
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4.4.5 for fluoxetine hydrochloride and sertraline hydrochloride respectively. 
The absorbance of the colored solution was measured at 426.0 nm and 425.0 
nm for fluoxetine hydrochloride and sertraline hydrochloride respectively 
against reagent blank. The concentrations of drugs (Fluoxetine hydrochloride, 
Sertraline hydrochloride) were determined. The dissolution profile study for 
five different branded tablet/capsule of fluoxetine hydrochloride (Table no. 6.1 
to 6.5 and Fig. 6.1 to 6.6) and sertraline hydrochloride (Table no. 6.6 to 6.10 
and Fig. no. 6.7 to 6.12) were carried out.  
 
6.2.5. Dissolution profile study (Valsartan). 
 
 The dissolution profile study was carried out using dissolution 
apparatus USP – II (Electrolab, India) containing 900 ml of phosphate buffer 
(pH 6.8) used as a dissolution medium at 37±2 0C at 50 rpm. Carefully 
transferred tablet/capsule of same brand of valsartan (single as well as 
combined dosage forms) into six different baskets. Samples were withdrawn 
(5.0 ml) at interval of 5, 10, 15, 20, 25 and 30 minutes from each basket and 
simultaneously same amount was replaced by phosphate buffer into each 
basket. 
 
 
 An aliquot (1.0 ml) was pipetted out in to a glass stoppered tube 
containing safranin O solution (2.5 ml). The final volume was adjusted to 5.0 
ml with phosphate buffer (pH 6.8) and analysed as described under 4.6.8. 
The absorbance of the colored solution was measured at 518.8 nm against 
reagent blank. Five different branded tablets/capsules of Valsartan (single as 
well as combined dosage forms) were taken for dissolution profile study. The 
concentration of Valsartan was determined. (Table no. 6.11 to 6.15, Fig. no. 
6.13 to 6.18) 
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6.2.6 Results and Discussion 
 
 Dissolution test is an important quality control tool for routine analysis. 
Dissolution test for fluoxetine hydrochloride is official in IP, BP and USP and 
they specify Q limit at 80 %, while for sertraline hydrochloride and valsartan 
the dissolution test in not prescribed by any pharmacopeias. 
 
 US-FDA described single point dissolution test for the highly soluble 
and rapidly dissolving drug product with specification of not less than 85 % (Q 
= 80 %) in 60 minutes or less is sufficient as a routine quality. 
 
 The dissolution profile study for fluoxetine hydrochloride and sertraline 
hydrochloride were carried out using 0.1N hydrochloric acid as a dissolution 
medium at 37±2 0C and analysed by proposed acid dye technique. Five 
different branded tablet/capsule were used. It was found that almost 80 % 
dissolution was completed within 30 minutes, in all the analysed dosage 
forms. (Table no. 6.1 to 6.10, Fig. no. 6.1 to 6.12) 
 
 Same way dissolution profile study for valsartan in single as well as 
combined dosage form was carried out using phosphate buffer (pH 6.8) as a 
dissolution medium at 37±2 0C and analysed by proposed basic dye 
technique. It was found that almost 90 to 95 % dissolution was completed 
within 30 minutes, in all the analysed dosage forms (Table no. 6.11 to 6.15, 
Fig. no. 6.13 to 6.18). 
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Table 6.1. Dissolution profile of Afzot tablet (20.0 mg Fluoxetine HCl)  
 
Cumulative % drug release 
Time 
(minute) 1 2 3 4 5 6 
% drug 
release 
mean + SD 
10 61.22 59.91 65.18 63.81 65.72 62.62 63.08 + 3.01 
20 72.81 78.88 74.29 73.92 77.79 76.66 75.72 + 2.26 
30 81.32 86.85 84.43 79.45 78.78 83.56 82.40 + 2.40 
45 86.62 88.33 84.72 89.92 83.59 87.45 86.77 + 2.33 
60 91.41 94.36 93.46 92.96 91.37 94.73 93.05 + 1.43 
90 97.32 98.47 94.59 99.1 97.43 97.76 97.45 + 1.55 
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Fig. 6.1. Dissolution profile of Afzot tablet (20.0 mg Fluoxetine HCl) 
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Table 6.2. Dissolution profile of Exiten tablet (20.0 mg Fluoxetine HCl)  
 
Cumulative % drug release 
Time 
(minute) 1 2 3 4 5 6 
% drug 
release 
mean + SD 
10 56.91 59.61 61.6 64.52 58.62 56.94 59.70 + 2.95 
20 70.82 64.64 69.45 68.64 71.43 72.48 69.58 + 2.78 
30 78.54 79.52 82.72 81.62 77.95 75.92 79.38 + 2.49 
45 88.62 83.83 84.34 84.92 87.39 85.56 85.78 + 1.86 
60 94.56 91.44 96.47 91.91 93.52 94.59 93.75 + 1.87 
90 97.16 98.39 94.52 97.59 99.22 98.23 97.52 + 1.63 
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Fig 6.2. Dissolution profile of Exiten tablet (20.0 mg Fluoxetine HCl)  
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Table 6.3. Dissolution profile of Flunat tablet (20.0 mg Fluoxetine HCl)  
 
Cumulative % drug release 
Time 
(minute) 1 2 3 4 5 6 
% drug 
release 
mean + SD 
10 59.10 52.16 60.92 56.47 57.16 58.84 57.44 ± 3.02  
20 66.24 69.13 62.73 65.42 69.48 64.92 66.32 ± 2.59 
30 79.29 81.92 78.62 83.67 81.91 82.28 81.28 ± 1.93 
45 83.71 89.34 84.46 90.83 91.27 84.32 87.32 ± 3.53 
60 93.62 91.57 97.40 93.76 97.73 93.96 94.67 ± 2.40 
90 99.30 94.43 99.32 97.48 96.24 97.95 97.45 ± 1.88 
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Fig 6.3. Dissolution profile of Flunat tablet (20.0 mg Fluoxetine HCl)  
 
 
 
 
 
 
 189
 __________________________________________Dissolution Profile Study___ 
Table 6.4. Dissolution profile of Flunil capsule (20.0 mg Fluoxetine HCl)  
 
Cumulative % drug release 
Time 
(minute) 1 2 3 4 5 6 
% drug 
release 
mean + SD 
10 62.65 58.12 61.94 59.11 61.52 56.66 60.00 ± 2.39 
20 68.73 71.43 73.83 71.27 77.42 69.25 71.99 ± 3.22 
30 81.28 82.91 79.22 77.38 83.34 78.62 80.46 ± 2.42 
45 85.24 86.88 83.29 91.46 87.92 87.67 87.08 ± 2.76 
60 92.52 91.23 94.39 93.82 89.59 91.48 92.17 ± 1.78 
90 96.48 94.42 96.91 96.83 93.28 99.26 96.20 ± 2.10 
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Fig. 6.4. Dissolution profile of Flunil capsule (20.0 mg Fluoxetine HCl 
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Table 6.5. Dissolution profile of Flutinol capsule (20.0 mg Fluoxetine 
HCl)  
 
Cumulative % drug release 
Time 
(minute) 1 2 3 4 5 6 
% drug 
release 
mean + SD 
10 54.93 59.56 53.82 61.83 58.92 59.58 58.11 ± 3.07  
20 66.75 69.48 64.78 69.54 72.58 67.63 68.46 ± 2.70 
30 82.47 78.91 79.53 76.56 71.79 79.73 78.17 ± 3.65  
45 86.62 84.73 81.49 89.72 85.48 86.71 85.79 ± 2.71 
60 93.82 91.66 88.7 89.81 96.57 92.82 92.23 ± 2.84 
90 98.44 94.52 91.35 98.77 93.53 96.43 95.51 ± 2.91 
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Fig. 6.5. Dissolution profile of Flutinol capsule (20.0 mg Fluoxetine HCl) 
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Fig. 6.6. Overlay of dissolution profile curve (Fluoxetine hydrochloride) 
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Table 6.6. Dissolution profile of Serenata tablet (50.0 mg Sertraline HCl)  
 
Cumulative % drug release 
Time 
(minute) 1 2 3 4 5 6 
% drug 
release 
mean + SD 
10 63.15 61.92 62.55 64.52 59.92 62.47 62.42 ± 1.51 
20 71.72 74.8 75.27 74.78 77.48 78.57 75.44 ± 2.39 
30 82.42 79.35 77.48 81.4 78.34 82.92 80.32 ± 2.25 
45 86.25 85.28 88.61 84.68 87.77 88.81 86.90 ± 1.75 
60 91.6 89.46 92.73 88.2 92.45 93.65 91.35 ± 2.10 
90 95.52 96.56 94.94 96.49 97.23 98.14 96.48 ± 1.15 
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Fig. 6.7. Dissolution profile of Serenata tablet (50.0 mg Sertraline HCl) 
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Table 6.7. Dissolution profile of Serlin tablet (50.0 mg Sertraline HCl)  
 
Cumulative % drug release 
Time 
(minute) 1 2 3 4 5 6 
% drug 
release 
mean + SD 
10 58.10 63.42 59.62 62.44 64.95 61.67 61.70 ± 2.50  
20 77.34 74.47 71.42 79.63 77.10 75.83 75.97 ± 2.81 
30 79.44 82.43 83.95 80.56 78.38 81.43 81.03 ± 2.02 
45 89.90 84.13 87.24 89.73 90.62 91.46 88.85 ± 2.71 
60 95.33 91.16 93.62 92.88 91.86 93.42 93.05 ± 1.46 
90 98.12 94.42 96.63 93.58 95.73 99.15 96.27 ± 2.14 
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Table 6.8. Dissolution profile of Serlin tablet (50.0 mg Sertraline HCl) 
 
 
 
 
 
 194
 __________________________________________Dissolution Profile Study___ 
Table 6.8. Dissolution profile of Inosert tablet (50.0 mg Sertraline HCl)  
 
Cumulative % drug release 
Time 
(minute) 1 2 3 4 5 6 
% drug 
release 
mean + SD 
10 57.43 61.94 63.92 60.23 59.2 63.96 61.11 ± 2.63 
20 73.86 69.58 72.96 77.41 71.62 74.72 73.36 ±2.68 
30 88.47 81.42 84.84 83.52 87.43 83.75 84.91 ± 2.63  
45 91.57 89.44 87.33 92.43 88.48 81.63 88.48 ± 3.86 
60 93.59 92.16 89.17 93.82 94.27 95.47 93.08 ± 2.19 
90 95.48 92.22 96.25 98.62 95.52 98.55 96.11 ± 2.37 
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Fig. 6.9. Dissolution profile of Inosert tablet (50.0 mg Sertraline HCl) 
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Table 6.9. Dissolution profile of Daxid tablet (50.0 mg Sertraline HCl)  
 
Cumulative % drug release 
Time 
(minute) 1 2 3 4 5 6 
% drug 
release 
mean + SD 
10 60.32 63.91 61.94 65.2 61.96 59.57 62.15 ± 2.12 
20 68.42 66.43 73.78 65.82 66.74 76.45 69.61 ± 4.43 
30 74.67 79.73 81.42 75.88 73.72 81.75 77.86 ± 354 
45 77.37 81.62 83.65 82.73 79.52 83.82 81.45 ± 2.55 
60 79.48 88.48 86.48 89.25 81.67 91.42 86.13 ± 4.64 
90 94.57 96.43 97.18 95.66 98.41 95.77 96.34 ± 1.34 
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Table 6.10. Dissolution profile of Daxid tablet (50.0 mg Sertraline HCl) 
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Table 6.10. Dissolution profile of Serdep tablet (50.0 mg Sertraline HCl)  
 
Cumulative % drug release 
Time 
(minute) 1 2 3 4 5 6 
% drug 
release 
mean + SD 
10 58.60 64.72 61.79 59.84 65.42 67.16 62.92 ± 3.37 
20 71.15 79.91 69.56 74.47 78.72 72.83 74.44 ± 4.13 
30 85.82 83.52 84.83 81.53 78.49 79.22 82.24 ± 2.99 
45 81.79 89.67 90.97 88.58 82.77 83.35 86.19 ± 3.99 
60 85.81 92.40 92.42 91.66 94.49 90.18 91.16 ± 2.97 
90 96.27 94.32 97.16 94.69 94.62 97.28 95.72 ± 1.34 
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Fig. 6.11. Dissolution profile of Serdep tablet (50.0 mg Sertraline HCl)  
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 Fig. 6.12. Overlay of dissolution profile curve (Sertraline HCl) 
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Table 6.11. Dissolution profile of Valzar tablet (80.0 mg Valsartan)  
 
Cumulative % drug release 
Time 
(minute) 1 2 3 4 5 6 
% drug 
release 
mean + SD 
5 32.24 42.41 40.11 36.44 33.25 31.14 35.93±4.55 
10 61.23 70.44 71.65 65.04 60.11 62.25 65.12±4.89 
15 88.25 94.07 96.23 93.93 91.24 89.52 92.21±3.05 
20 94.66 98.07 100.32 97.04 95.23 94.45 96.63±2.30 
25 96.44 98.98 101.11 98.37 98.22 98.52 98.61±1.50 
30 97.25 101.58 101.54 99.41 98.52 100.74 99.84±1.75 
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Fig. 6.13. Dissolution profile of Valzar tablet (80.0 mg Valsartan) 
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Table 6.12. Dissolution profile of Valzar H tablet (80.0 mg Valsartan)  
 
Cumulative % drug release 
Time 
(minute) 1 2 3 4 5 6 
% drug 
release 
mean + SD 
5 31.21 38.25 35.85 34.69 41.08 40.55 36.94±3.77 
10 65.24 70.31 68.31 70.92 66.62 68.23 68.27±2.15 
15 91.98 97.23 96.25 100.62 97.54 99.08 97.12±2.95 
20 94.22 97.69 99.08 101.23 98.15 99.85 98.37±2.39 
25 97.98 98.46 100.00 101.08 98.62 100.15 99.38±1.20 
30 99.23 98.62 100.62 101.69 101.08 100.77 100.34±1.17 
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Fig 6.14. Dissolution profile of Valzar H tablet (80.0 mg Valsartan) 
 
 
 
 
 200
 __________________________________________Dissolution Profile Study___ 
Table 6.13. Dissolution profile of Valent H tablet (80.0 mg Valsartan)  
 
Cumulative % drug release 
Time 
(minute) 1 2 3 4 5 6 
% drug 
release 
mean + SD 
5 42.11 48.03 44.25 48.33 48.79 42.42 45.655±3.086 
10 58.64 61.06 64.65 57.22 59.39 55.89 59.475±3.096 
15 88.95 90.61 82.23 92.73 90.91 91.97 89.567±3.818 
20 95.23 96.82 92.36 99.7 96.67 96.5 96.213±2.393 
25 98.33 97.12 97.42 100.24 96.97 98.94 98.170±1.266 
30 98.64 97.72 97.27 100.15 99.09 99.55 98.737±1.093 
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Fig 6.15. Dissolution profile of Valent- H tablet (80.0 mg Valsartan) 
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Table 6.14. Dissolution profile of Starval-80 capsule (80.0 mg Valsartan)  
 
Cumulative % drug release 
Time 
(minute) 1 2 3 4 5 6 
% drug 
release 
mean + SD 
5 32.87 21.82 20 22.42 29.35 20.15 24.43±5.37 
10 60.12 58.79 52.23 51.44 58.59 56.21 56.23±3.639 
15 75.23 67.14 68.23 71.06 74.45 69.09 70.87±3.34 
20 90.23 86.67 86.21 87.42 89.97 96.5 89.50±3.82 
25 99.98 98.48 94.23 96.64 98.87 98.94 97.86±2.08 
30 100.22 98.79 99.39 98.64 99.91 98.48 99.24±0.72 
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Fig 6.16. Dissolution profile of Starval-80 capsule (80.0 mg Valsartan) 
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Table 6.15. Dissolution profile of Valsar-SM capsule (80.0 mg Valsartan)  
 
Cumulative % drug release 
Time 
(minute) 1 2 3 4 5 6 
% drug 
release 
mean + SD 
5 22.24 16.82 17.13 15.12 25.24 16.36 18.82±3.99 
10 64.58 57.87 55.71 57.25 66.78 55.4 59.60±4.85 
15 82.87 80.4 78.55 77.93 84.47 74.84 79.84±3.50 
20 89.2 82.89 88.27 89.97 92.45 84.27 87.84±3.60 
25 98.61 94.87 100.46 100.15 98.46 100 98.76±2.08 
30 100.27 99.69 100.62 100.93 99.14 100.62 100.21±0.64 
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Fig 6.17. Dissolution profile of Valsar-SM capsule (80.0 mg Valsartan) 
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Fig. 6.18. Overlay of dissolution profile curve (Valsartan) 
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7. SUMMARY 
1. The present investigation is study on the utility of ion – pair complex of 
acid dye as well as basic dye with different nitrogen containing 
molecules, which are widely used as an antidepressants and specific 
AT1 receptor antagonists. 
 
2. The proposed methods were validated and found to be very simple, 
accurate, sensitive and cost effective for determination of fluoxetine, 
Sertraline, duloxetine (acid dye method) and valsartan (basic dye 
method) in bulk and dosage forms. 
 
3a. Valsartan was analyzed in combined dosage forms (valsartan + 
hydrochlorthiazide, valsartan + s-amlodipine) by basic dye method. 
Hydrochlorthiazide and s-amlodipine does not form ion – pair complex 
with safranin O solution, and therefore did not interfere in the analysis. 
 
3b. Excipients and other diluents used in the tablets and capsules did not 
interfere in analysis carried out either by acid dye technique or basic 
dye technique. 
 
4. The composition of ion – pair was determined by Job’s continuous 
variation method using equimolar solution. It was found that 1:1 
stoichiometric complex was formed for valsartan with safranin O 
solution. 
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5. The ion pair composition of fluoxetine hydrochloride, sertraline 
hydrochloride and duloxetine hydrochloride were also determined by 
job’s continuous variation method using equimolar solution. It was 
found that 1:1 stochiometric complex was formed for fluoxetine 
hydrochloride, sertraline hydrochloride and duloxetine hydrochloride 
with methyl orange. 
 
6. The proposed methods are equally applicable for dissolution profile 
study for fluoxetine hydrochloride, sertraline hydrochloride (acid dye 
method) in dosage forms and valsartan (basic dye method) in single 
as well as combined dosage forms.  
 
7. In dissolution profile study of fluoxetine hydrochloride and sertraline 
hydrochloride, six marketed formulations were evaluated and all of 
them show more than 85% release in thirty minutes. 
 
8. In dissolution profile study of valsartan, six marketed formulations 
including single and combined dosage forms were evaluated and all of 
them show more than 90% release in thirty minutes. 
 
9. This study suggests that ion – pair complexation method can be 
employed for routine analysis of fluoxetine, sertraline, duloxetine (acid 
dye complexation) and valsartan (basic dye complexation) in dosage 
forms. 
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